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Abstract 
Chromatin is comprised of DNA and a vast network of proteins, which help structure and regulate a cell’s 
genetic material through processes including cell differentiation, regulation of genes, and DNA repair. At the 
core of chromatin structure lays a nucleosome, consisting of DNA wrapped around an octameric protein 
complex made of histones. Histones can undergo post translational modifications (PTMs) which govern 
protein-protein interactions (PPIs) and ultimately control gene activation and suppression. Histone PTMs can 
already be quantitated using existing well defined methods such as liquid chromatography mass 
spectrometry (LC-MS). However with the increasing popularity of techniques such as chromatin 
immunoprecipitation aimed at identifying and understanding the role of PTMs under very specific 
circumstances, ever smaller amounts of histones are being produced and push heavily on the limits of LC-MS 
detection. We were able to reduce the number of cells required for a typical histone PTM LC-MS analysis 
from 106 cells to 105 cells and permitting technical replicates at this level. Chemical cross-linking mass 
spectrometry is another useful tool in characterising PPIs whilst simultaneously providing limited structural 
information, even from native cellular environments and cell lysates making it highly promising for 
chromatin. Much development has been made in this technology, however data analysis for this technique 
can still be difficult and laborious. We proposed to address this by simplifying the complexity of the data by 
altering the functional chemistry of the cross-linker, with limited levels success. Finally, some molecules have 
great therapeutic potential in addressing erroneous chromatin regulations that are implicated in a number of 
cancers. In order for more efficient therapeutics to be developed, it is important to identify how and where 
they bind to proteins. We were able to address this issue for a ligand-protein pair, for a protein known to be 
implicated in cancer and modify histones. 
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 Motivation of the Work 
In this work three analytical mass spectrometry methods have been developed for the study of different 
proteomic aspects of the chromatin environment. Whilst these techniques were developed for chromatin 
proteins, they can be easily adapted to other protein systems with little to no modifications. The techniques 
developed can be summarised as indirect methods for cysteine adduct analysis, the limits of MS detection of 
histone post translational modification (PTM) analysis, and optimising the protein-protein chemical cross-
linking mass spectrometry (CXMS) workflow for simpler data analysis.  
1.1.1. Characterising the Protein ‘Interactome’ to Understand Chromatin Regulation 
It is well known that genetics plays a crucial role in inheritance, evolution and disease. An organism’s genetic 
material (DNA) is under the control of chromatin. Chromatin is comprised of DNA and a vast network of 
protein-protein interactions (PPIs), which help structure and regulate a cell’s genetic material through 
processes including cell differentiation, regulation of genes, and DNA repair (1). At the core of the chromatin 
structure lays a nucleosome, consisting of 147 to 149 base pairs of DNA tightly wrapped around an octameric 
protein complex comprised of proteins known as histones. It is now well established that proteins including 
histones can undergo chemical modifications referred to as PTMs including phosphorylation, methylation, 
acetylation as well as others that are less abundant (2). PTMs can be read and modified to provoke diverse 
consequences in the network of PPIs, which ultimately manipulates cellular processes such as the chromatin-
regulated control of genetic information. As histones have a vast number of confirmed PTM sites with a 
range of possible modifications, millions to trillions of PTM combinations on the same protein are possible. 
The potential for each potential combination of PTMs contributing to a different chromatin regulation state is 
referred to as the ‘histone code hypothesis’ (3). When taking into consideration that each PTM combination 
may culminate into a unique PPI, fully understanding the chromatin environment becomes increasingly 
complex. Another crucial component to PPIs in addition to the recognition and modification of PTMs is 
structure. Proteins are able to interact either stably or transiently with the specific structures they ‘recognise’ 
to actuate their function, which is also important to be studied.  
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1.1.2. Current Technological Limitations 
To date, the elucidation of PPIs and their structural features in chromatin is still challenging, largely due to a 
lack of high-throughout and easy-to-use tools and methods. Traditional techniques utilising antibodies and 
X-ray crystallography, despite their usefulness in identifying protein complex members and protein structure 
(respectively) have major drawbacks and are not always applicable to many protein complexes. Recent 
improvements in techniques such as 3 dimensional-electron microscopy (3D-EM) has permitted great 
progress into studying protein structure for a wide range of protein complexes, but still requires a great deal 
of time and effort (4). The only technique available to date with the potential of simultaneously providing PPI 
and limited structural information in a high-throughput fashion is chemical CXMS, usually via liquid 
chromatography in tandem with mass spectrometry (LC-MS). CXMS also has the potential to be used within 
complex samples such as cell lysates and even within the native cellular environment (5,6), which is important 
as protein systems such as chromatin are regulated by profoundly complex elements including other protein 
complexes, PTMs and DNA modifications. However, CXMS faces the challenge of highly complex LC-MS data 
analysis necessitating further development of analysis software in conjunction with protocol improvements, 
which have resulted in mixed levels of success (7). Improvements in this technology would greatly help to 
provide insights into how specific regulatory elements are able to manipulate chromatin through structural 
alterations including the binding to and modification of PTMs. 
In addition to studying how specific systems are regulated it is also important to understand how they all 
work in concert to keep a cell functioning in response to the various external stimuli. One way to study this is 
to observe and compare the global histone PTM profiles between different cell types and between healthy 
and diseased (in addition to control and treated) cells or tissues. By studying global profiles, specific PTM 
changes may become apparent in response to stimuli, ultimately resulting in improving our understanding 
for the reason or mechanism for such a change. Techniques such as chromatin immunoprecipitation (ChIP) 
sequencing (ChIP-seq) and ChIP-MS are widely used for this purpose and are effective when a large amount 
of tissue is available. However, assessing histone PTMs using the lowest amount of protein possible would 
have significant usefulness when tissue material is difficult to obtain both technically (e.g. pull downs and 
16 
 
rare biological samples) or ethically (e.g. animal tissues) thus having great implications in a range of fields 
including minimising the use of tissue models in academic and pharmaceutical R&D. 
One of the major drivers for studying PPIs, structure and PTM profiles is to ultimately identify new areas for 
therapeutic intervention. However therapeutic treatments themselves also need to be characterised in order 
to improve specificity, potency, efficacy and safety. Studying small molecule-protein interactions for 
therapeutics is carried out using similar techniques as studying structure and PTMs and therefore LC-MS is 
also used to study protein adducts other than PTMs. However adducts can be damaged and even removed 
during sample processing and/or MS ionisation, rendering direct protein or peptide adduct analysis difficult. 
As the luxury of time to use alternative analytical techniques is not always available it may be that indirect 
approaches are more useful and faster to study protein adduct sites. 
1.1.3. Overcoming technique limitations 
Over the years technological advancements in LC-MS has developed it into an extremely useful and powerful 
tool with a broad selection of ionisation and separation techniques that have made it possible to solve a wide 
variety of scientific problems. Improvements in instrument sensitivity coupled with improvements in 
chromatographic robustness and reproducibility permit the detection of even native low abundance PTMs. 
By leveraging this sensitivity and reproducibility to histone PTM analysis we were able to analyse global 
histone PTM profiles from very limited amounts of tissues, which can be greatly beneficial in reducing the 
burden on amount of sample required. 
On occasion however unpredictable chemical changes may occur during sample preparation. These affect the 
mass of the molecules under study making them difficult to find in the data. In this work we show how 
indirect adduct analysis methods can prove effective for a disulphide bound small molecule inhibitor whilst 
still being easier to carry out compared to other techniques. 
Finally it is also important to understand the PPIs and structures involved in regulating chromatin. CXMS has 
accumulated vast interest and experienced significant advancement over the last 15 years. We proposed and 
tested a number of adaptations to the method, composed of a mixture of previously utilised approaches in a 
structured yet still highly modular methodology. 
17 
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 Chromatin 
A haploid human cell contains approximately 2 metres of DNA. In comparison, the average mammalian
nucleus spans a diameter of approximately 5-10 µm (8). However it is a common misconception that a cell 
struggles to “package” this DNA as the total volume of free diploid human DNA is 6.4 μm3 (9) compared to 
the 65 - 524 μm3 nucleus volume. Furthermore it has been noted that chromatin only occupies approximately
15% of the cell nucleus (10). Nevertheless, cells require strict maintenance and control of their genetic
material in an organised structure that is also able to counteract the highly negatively charged DNA.  Cells 
achieve this by wrapping approximately 146-7 base pairs of DNA 1.65 turns around a histone core (11) to 
form a nucleosome structure (Figure 1). The histone core is a positively charged octameric protein complex 
comprised of two subunits of H2A, H2B, H3 and H4. Each subunit has a globular structure with exception of
the N and C terminal tails, which may protrude to allow access to enzymes or contribute to structure
formation.
 
Furthermore, each nucleosome is linked together by strands of linker DNA and histone H1, which can be 
described as “beads on a string” (Figure 2). This results in the thickening of the DNA to form a 10 nm fibre. It 
was previously considered that the 10 nm fibre is further condensed to form a 30 nm fibre, however this 
Figure 1. The Nucleosome Structure. 
The octameric histone core is comprised of two subunits of histone H2A (yellow), H2B (red), H3 (blue) and H4 
(green), and is wrapped by 1.65 turns of DNA(grey) (11).  
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theory is now contested (12–14). Recent research in mouse embryonic stem cells showed that nucleosomes 
do not form highly ordered structures but rather discreet groupings which have been termed as 
“nucleosomal clutches” (15). Actively used genes termed “constitutive” are less tightly packaged and form 
less dense regions.  Larger denser clutches corresponded to inactive chromatin with more H1 histones. 
Facultative genes that are not needed frequently may be packaged into this inactive and dense chromatin 
state. Chromatin’s control of DNA requires it to be dynamic in freeing genes to transcriptional machinery as 
well as repackaging genetic material once it is no longer needed, which introduces the complexity of 
regulation. Chromatin’s structure can be altered in a number of ways; histone residues can modified by PTMs, 
nucleosome locations may be moved along DNA, and histones may be replaced with histone variants and 
DNA can be methylated (16). 
 
Figure 2. Chromatin Structural Organisation. 
The colours represent the different components of nucleosomes; H2A (yellow), H2B (red), H3 (blue) and H4 
(green), H1 (orange) and DNA (black). Multiple nucleosomes are located along a length of DNA resulting in 
a “beads on a string” like appearance. Adjacent nucleosomes are stabilised with histone H1. More active 
constitutive genes are located within low density clutches, whilst facultative and therefore less utilised genes 
are located within higher density clutches. 
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2.1.1. Protein-Protein Interactions (PPIs) in Chromatin Regulation 
Control of all networks such as chromatin is maintained by proteins that function in vastly different ways to 
ensure each process is finely tuned in rate and specificity. Crucial to the control of protein functions are PPIs, 
whereby proteins communicate with each other either by binding transiently or stably to form a protein 
complex in a highly intricate network (also referred to as the interactome). Contrary to the common analogy 
of cells as bags of free floating proteins, cells compartmentalise entire metabolic systems in organelles, 
where proteins are highly organised and stabilised through interacting with other proteins (17). In this regard 
chromatin is no exception, histones and DNA are continually being manipulated and regulated in dynamic 
equilibrium by the surrounding protein environment, which can be considered a mixture of active and 
inactive chromatin. For example, genes can be signalled for silencing through methylation on specific histone 
lysine amino acids, which are added by protein complexes such as polycomb repressor complex 2 (PRC2) and 
G9a-GLP complex. These protein complexes propagate silencing PTMs through euchromatin histone 
methyltransferase 2 (EHMT2/G9a) independently as well as by physically interacting together (18,19). These 
histone PTMs may then be recognised by other proteins such as ubiquitin-like with PHD and ring finger 
domains 1 (UHRF1) that propagate and maintain silencing of the genes by physically recruiting DNA 
methylase 1 (DNMT1) (20), which in turn methylates DNA and transcriptionally silences a specific genomic 
region. Interestingly the reverse interaction of UHRF1 physically associating with G9a to propagate histone 
PTMs has also been speculated (21). G9a can also physically recruit histone linker H1 in addition to creating 
PTM binding sites for Heterochromatin Protein 1 (HP1), ultimately leading to chromatin condensation into a 
dense state (22). By using G9a gene silencing as an example of chromatin complexity, it becomes dauntingly 
apparent how vast the range of PPIs become even for a small subset of chromatin-associating proteins.  
2.1.2. Histone Post-Translational Modifications (PTMs) 
During PPIs, chemical modifications can be added to a protein with the aid of small molecule cofactors such 
as S-adenosyl methionine (SAM) for methylation and adenosine triphosphate (ATP) for phosphorylation. As 
these modifications are added after protein synthesis (i.e. post translation) they are referred to as PTMs.  
PTMs can act as switches which in turn activate, deactivate or alter a protein’s function, encourage or stabilise 
the binding of proteins into a complex and influence subcellular localisation (23). A large number of histone 
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PTMs are docking sites for regulatory proteins that recognise them and so they are effectively “read”. Various 
types of modifications can be found on specific residues on histones. Lysines can be modified through 
acetylation, methylation, ubiquitination, sumoylation, crotonylation, butyrylation, propionylation and ADP-
ribosylation; arginine residues may be modified through methylation, citrullination and ADP-ribosylation; and 
serine and threonine residues may be modified through phosphorylation and glycosylation (24). 
Proteins that “read” PTMs may sometimes only bind if specific PTMs occupy the necessary spatial regions 
thus emulating a form of lock-and-key mechanism leading to a specific set of downstream functions. This 
PTM arrangement selectivity led to the proposition of a “histone code” first proposed by Strahl and Allis in 
2003 (3) (Figure 3). It can be postulated that there are a variety of ways in which PTM combinations can be 
read. A single reader may be effective on multiple PTMs within the same tail (3A). Readers in complex may 
bind two different residues on the same tail forming a cis combination (Figure 4A) or alternatively may bind 
different histone tails forming a trans combination within the same nucleosome (intranucleosomal) (Figure 
4B) or between multiple nucleosomes (internuclesomal) (Figure 4C). Lastly, a much larger multi-subunit 
complex may bind a whole range of different PTMs across the same, or multiple nucleosomes. 
 
Figure 3. Histone Post Translational Modification Readers and Specificity. 
The histone proteins H2A (yellow), H2B (red), H3 (blue) and H4 (green) are wrapped by DNA (black), and have 
protruding histone tails (respective colours) which can be modified by PTMs (represented as the dark orange 
circle, dark green hexagon and dark red rectangle). (a) Reader proteins (purple) may only bind to histones if 
the PTMs meet the required chemical and spatial requirements. (b) Reader proteins will not bind to PTMs 
that are non-specific. 
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PTMs are added or removed by histone modifying enzymes referred to as ‘writers’ or ‘erasers’ (respectively). 
The modifications on histone PTMs can directly interfere with histone core assembly and histone-DNA 
interactions. There are various histone modifying complexes. For example, histone acetyltransferases (HATs) 
and methyltransferases (HMTs) add acetyl and methyl PTMs, respectively, while histone deacetylases (HDACs) 
and demethylases (HDMs) remove them. 
The previously discussed G9a is a HMT capable of exerting catalytic activity independently, or as a 
homodimer and heterodimer with GLP through SET domains interactions and is responsible for H3K9 mono-, 
 
Figure 4. Reading Histone Post Translational Modifications. 
The histone proteins H2A (yellow), H2B (red), H3 (blue) and H4 (green) are wrapped by DNA (black), and have 
protruding histone tails (respective colours) which can be modified by PTMs (represented as the dark orange
circle, dark green hexagon and dark red rectangle). (a) Reader proteins (purple ellipsoid and blue square)
may bind in cis on the same histone tail. (b) Reader proteins can bind in trans across histone tails from the 
same nucleosome. (c) Reader proteins can bind in trans across histone tails on different nucleosomes. (d)
Multi-subunit complexes can bind PTMs on multiple histone tails across different nucleosomes to carry out 
their functions and change the PTM landscape by writing (green triangle) and erasing (red hexagon) PTMs on 
histone tails. 
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di- and tri-methylation which in turn results in gene silencing through a number of mechanisms. Although 
only the heterodimeric G9A–GLP complex is shown to be functional as a H3K9 mono- and 
dimethyltransferase in vivo (25,26). Moreover G9a may also enhance Polycomb Repressor Complex 2 (PRC2) 
perpetuation of the H3K27me3 mark, clearly indicating how interconnected the chromatin system is (18). 
Central to the function and interactions of chromatin is structure, which determines how proteins chemically 
interact with their surroundings through attraction, repulsion, steric hindrance, or spatial orientation of other 
molecules. Protein structure is on a spectrum ranging from highly flexible and intrinsically disordered (e.g. 
histone tails), increasing in structure and rigidity (e.g. more rigid and structured histone cores), towards 
highly rigid, and is mostly determined by amino acid sequence referred to as the primary structure. From the 
primary sequence key amino acid sequence motifs will result in secondary structure formation of alpha 
helices, beta turns and beta sheets. These take part in forming a tertiary structure alongside polar and non-
polar interactions and disulphide bonding. Multiple proteins can all bind together as subunits of a larger 
quaternary structure, e.g. multi-subunit complexes associating with the histone tail (Figure 4D). Protein 
binding may also be affected by PTMs, sometimes as small as methylation, allowing or inhibiting other 
proteins such as readers of histone tails from binding by acting in combination as a lock and key mechanism. 
Proteins may also experience allostery, whereby structural conformation and function is altered through 
protein binding or PTMs (27). Evidence is also emerging that PTMs have physical effects on the structure of 
yeast nucleosomes themselves (28). H3K56 acetylation relaxes the DNA nucleosome interaction close to the 
DNA entry–exit site (29–32). H3K64 acetylation is exclusively enriched at active genes, and nucleosomes fully 
acetylated at H3K64 are less stably bound to each other and to DNA compared to those unmodified at 
H3K64 (33). Nucleosome formation in vitro is drastically reduced when H3T118 is fully phosphorylated (34). 
H4K91 acetylation destabilises histone-histone interactions and therefore nucleosome stability (35). 
DNA Methylation 
DNA methylation is also an important epigenetic component to transcriptional regulation. DNA methylation 
refers to cytosine methylation, almost always observed at cytosine-phosphate-guanine (CpG) nucleotides. 
CpG methylation is added and maintained primarily during DNA replication by DNMT which uses s-adenosyl 
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methionine (SAM) as a methyl donor (36). CpG can cluster into islands where they are defined as regions of 
DNA containing at least 50% C+G nucleotide bases in stretches of more than 200 base pairs, whereby the 
observed/expected frequency of CpG is greater than 0.6 (37). Mammalian genomes have a low abundance of 
CpG dinucleotides (~1%) however around 70% of gene promoters are located in CpG islands (38). Under 
normal circumstances gene promoters are unmethylated, although a small portion (~6%) can be differentially 
methylated specific to tissue type, during cellular differentiation and early development (39). DNA 
methylation is usually associated with gene silencing, as classically represented by the hypermethylation of 
parental alleles whereby one of the two alleles is silenced during gene imprinting for monoallelic expression, 
or X inactivation of the female X chromosome (40–43). Gene silencing by DNA methylation is proposed to 
occur in a number of ways, methylated CpG can recruit methyl CpG binding domain proteins (MBP) (44) 
which in turn recruit histone methylases, acetylases as well as chromatin remodellers to further regulate 
transcriptional regulation of genes (45–48). 
 Importance to Understanding Chromatin 
Our understanding of the function and regulation of chromatin has progressed a great deal from the original 
assumption that it’s only role was to counter balance the negative charge of DNA. Through careful study it is 
now understood that chromatin plays key roles in disease and cellular complexity unaccounted for by genes. 
Whilst there is still much more to uncover about this system, what we already know is already shaping a new 
understanding of how cells function in addition to opening up potential for therapeutic and predictive uses. 
Long before the completion of the human genome project in 2001 it was known that the amount of genetic 
material was not linked to organism complexity. This has been referred to as the C-value paradox describing 
the observation that simpler organisms may contain more nucleic acid material than humans (49). A 
challenge to this paradox presented itself in the discovery of introns, but was once again overturned upon 
completion of genomes for a variety of organisms. A human only required ~ 23,000 genes compared to rice 
(Oryza sativa) containing 42,654 (50). It was now conclusive that gene number is not linked to organism 
complexity. In the background of popular scientific focus, research into studying how cells may be regulated 
via mechanisms other than genetics was already underway and long known as epigenetics (51). 
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Epigenetics is defined as stably heritable phenotypes resulting from changes in a chromosome without 
alterations in the DNA sequence (52). Crucial to epigenetic maintenance is DNA methylation, histone 
modification and RNA interference, carefully maintained by chromatin which regulates access to our genetic 
library in order to keep cells functioning. This regulation is managed by an entire network of proteins which 
when goes awry leads to the development of diseases without any visible errors in the genetic material, for 
example epigenetic misregulation of oncogenes and tumour suppressor genes results in cancer (53) and 
immune and neuronal dysregulation of genes can lead to Alzheimer’s disease (54). For these reasons tools 
that provide a much better understanding of epigenetics and therefore the PPIs, PTMs and protein structures 
involved, is considered highly sought after both for disease understanding and ultimately therapeutic 
intervention. 
One of the most promising aspects of epigenetics as an avenue of therapy is its reversible nature and is 
currently being heavily researched for treatments for a wide range of diseases including cancer, psychiatric, 
neurodegenerative, cardiovascular, viral and autoimmune diseases (55). Epigenetics has already shown 
promise as an avenue of therapeutics as demonstrated by the HDAC inhibitor vorinostat for the treatment of 
cutaneous T cell lymphoma (56). Due to the success of vorinostat and its high level of specificity, many other 
HDAC inhibitors, DNMT inhibitors and combination therapies are also available and undergoing clinical trials, 
with research also exploring HKMTs and HATs as potential treatments (57). Such forms of therapeutics are a 
new and exciting way to treat cancers in a highly specific way, and in order to continue to progress require a 
substantial understanding of epigenetics and the chromatin environment and their role in cancer. 
Stem cell research is becoming more and more promising as a future avenue for regenerative medicine. 
Issues associated with transplantation rejection, shortage of organ donors and slowing down the effects of 
ageing are all areas that may be addressed through stem cell therapies. Two types of stem cell exist, natural 
embryonic stem cells (ESC) and induced pluripotent stem cells (iPSC). iPSC are similar to ESC in that they are 
able to self-renew and differentiate into any cell type (58). They are derived from reverse programming 
differentiated cells back into an ESC like cell during which they undergo large-scale epigenetic 
reprogramming (59). However a variety of epigenetic traits can also affect cellular reprogramming and the 
production of iPSC. Histone variants can facilitate (60) or repress (61) iPSC generation, and histone 
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remodellers such as ASF1A have great importance in somatic remodelling (62). Also aberrant epigenetic 
marks in DNA modifications, histone PTMs and micro RNA can affect the differentiation of iPSC towards that 
of the original cell lineage, a trait that can be removed through prolonged cell culturing (63). In vivo ESC are 
encouraged to differentiate into specific cells types using complex environmental factors including cellular 
microenvironments and chemical signals which are in turn stabilised by epigenetic programming. In vitro 
however this would be too complex and time consuming. By screening the correct combinations of small 
molecules however, the differentiation process can be sped up (64) to produce the tissues of choice. More 
recently, a great deal of interest has been placed in the process of transdifferentiation. It is the direct 
conversion of one cell lineage to another without the need for intermediate generation of iPSC and can 
achieved by forcefully activating a number of specific transcription factors, however the conversion efficiency 
of this is low (65). Fortunately, this process can be made far more efficient with the addition of small 
molecule inhibitors and even reducing the number of transcription factors activated down to two (66). Both 
iPSC and transdifferentiation still require a great degree of work and understanding before they can be more 
effectively utilised for medicinal purposes. It is obvious that epigenetics is a crucial component in being able 
to fully control these technologies. Therefore better techniques into understanding epigenetic 
reprogramming and re-stabilisation are crucial for driving research and understanding of these technologies. 
More and more hard evidence is emerging showing that epigenetic programming is transmissible and able 
to affect future generations in areas such as metabolic syndromes (67–69). This is concerning as without a 
complete reset of epigenetic regulation we are no longer just a product of our genes, but also our parent’s 
and grandparent’s choices. As any direct intervention of embryonic epigenetics would be very unethical, 
research would be limited to studying how epigenetic traits are transmitted. This in itself is still very useful as 
new ways of predicting disease risk may emerge helping to make more accurate socioeconomic planning 
predictions for future medical and economic needs. 
Epigenetic markers can not only unravel understanding of disease mechanisms but can also help identify and 
validate model organisms for diseases such as Alzheimers (54). This can be done by comparing the 
epigenetic PTM profiles between the model cell lines and the tissues they are meant to model. 
Understanding disease mechanism is not always required when predicting disease risk. It has been proposed 
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that studying correlations between epigenetic profiles and disease can be a viable way to predict disease risk, 
much in the same way genetic risk is in use today (70). In addition, epigenetic-wide associations (EWAS) may 
succeed in opening up new research avenues where genetic-wide association studies couldn’t. For example 
recent findings showed differential gene methylation in eosinophils that produce high IgE serum content, 
opening up new therapeutic avenues for asthma, eczema and hayfever (71). 
 Current Challenges in Chromatin Research 
To study novel biological concepts simpler organisms such as yeast are often used as a starting point to help 
develop understanding of key fundamental mechanisms before moving on to more complex organisms. 
Therefore yeast are instrumental in chromatin work owing to their much simpler chromatin systems and low 
histone gene copy numbers making it easier to mutate and study histones in vivo (72,73). Point mutations of 
histones in vivo have allowed scientists to greatly progress the effects of PTMs ranging from protein 
recruitment and structural studies. Yeast do not have the full range of histone PTMs as observed in humans 
(e.g. H3K9 and H3K27 methylation is missing in saccharomyces cerevisiae) nor do they have the full range of 
histone variants (74). Additionally yeast are single celled and therefore do not have facultative genes that 
require chromatin restructuring during cellular differentiation. A lot of the proteins that are associated with 
chromatin in humans were discovered through sequence alignments, which led to the identification of cross 
species homologues. Whilst extrapolating from a simpler species to a more complex one is a good starting 
point, there can be major differences in the numbers of complexes, subunit composition, structures and 
function. For example, the PRC2 complex only has a single PCL subunit in Drosophila whereas there are three 
orthologues of the PCL subunit in mammals termed PCL1 (PHF1), PCL2 (MTF2), and PCL3 (PHF19)11. 
Additionally, assessing putative PTM binding domains of subunits identified through sequence homology 
may lead to an incorrect number of potential association sites. Therefore a lot of earlier research regarding 
protein structure, PTM and PPI carried out in simpler organisms cannot be simply extrapolated to higher 
orgaisms and needs to be treated with caution when studying similar epigenetic systems in human cells. 
In the past large studies into identifying and characterising histone PTM function relied on antibody based 
techniques such as immunofluorescence analysis, western blotting, and chromatin immunoprecipitation 
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(ChIP) (discussed in section 4.3). Whilst very sensitive, antibody techniques are low throughput as they can 
only target one protein or PTM at a time therefore requre a great deal of sample material to generate a full 
screen of histone PTMs, often limiting the type of biological material used to cell cultures. Cell cultures are 
invaluable in preliminary understanding of biological questions and when research is tissue specific a good 
model cell line can provide high quality data. However, cell lines still cannot capture the full array of 
environmental interactions that may occur and influence cellular responses (e.g. immune interactions). 
Therefore live model organisms are still the preferred system for biological research. However due to the 
amount of material often required ethics and cost come into question, thus limiting research to areas of high 
importance, such as drug testing, or high budget research. In addition, model organisms are often small and 
therefore produce smaller amounts of biological material requiring sample pooling thus introducing new 
errors in data analysis such as sample heterogeneity. This has created great need for the development of 
existing and new techniques to adequately describe the PTM environment within chromatin between healthy 
and diseased cells whilst minimising sample amounts. 
 Studying Chromatin Through Proteomics 
Whist chromatin is a mixture comprising of DNA and proteins, a fundamental component of its functions and 
control is maintained by proteins. PPIs regulate and manipulate the structure and function of chromatin 
through physical interactions and PTMs. “Proteomics” is a term referring to the study of proteins (75), and 
therefore encompasses many fields of research, such as structural and functional biology, PPI networks, and 
PTMs using a wide variety of techniques. Therefore, the field of proteomics envelops the study of proteins 
within chromatin. The word “proteomics” is an extension of genomics, the study of genes, and 
transcriptomics, the study of transcription, whilst the “proteome” refers to the entire range of proteins that 
are made and modified by an organism (76). “Proteoform” is a further term that can be used to describe the 
protein products single gene, which may be resultant form genetic variation, RNA splice variants, and PTM 
(77). 
Whilst gene number is constant, it cannot be used to predict the amount and number of proteoforms that a 
cell can express. Even from the amount of mRNA transcribed only a rough estimate can be inferred as to how 
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much will be translated into a protein (78). The reason for such inaccuracy in predicting protein amounts 
results from variable rates of degradation and translational efficiency, in addition to a variety of inhibitory 
mechanisms preventing generation of proteins from mRNA. Adding to this, alternative splicing of mRNA 
leads to the production proteins with different primary sequences, with PTMs further altering their structure 
and function. All of this variability is clearly demonstrated when observing varying types of differentiated cells 
that carry the same genetic information yet vary in their proteome composition and amounts. 
The proteome composition within cells is not fixed. It is a continually changing system subject to protein 
synthesis, degradation and turnover (79–82), with variation also being found in total protein abundance, 
subcellular localisation and tissue distribution (83,84). Proteome profiles also change at different stages of 
the cell cycle (85), in response to external stimuli (86) and during circadian rythyms (87). This complicates 
proteomics a great deal and careful considerations must be made into the importance of implementing limits 
to these variations for specific studies. For example, cells cycle stage can be synchronised using chemicals 
such as lovastatin (88), however it is important to note that such interventions may bring about unpredictable 
changes in the proteome as a result of unnatural intervention. 
At present, many techniques can be used to study the various aspects of proteomics. In particular a highly 
popular and useful technique is mass spectrometry (MS) which is often used for its ability to quickly and 
sensitively identify and analyse protein complexes through exact mass and (partial) sequence data in a high 
throughput manner (89). It is commonly used in tandem with in liquid chromatography (LC) where it is 
referred to as LC-MS. MS techniques such as native mass spectrometry can be used to study protein 
structure (90,91), whist LC-MS can be employed to study proteome profiles (83,84), PTMs (92), and PPIs 
(6,93,94). 
 Introduction to Mass Spectrometry (MS) Analysis in 
Proteomics 
In principle LC-MS follows the following order: chromatographic separation, ionisation, followed by 
molecular ion manipulation and detection by a mass analyser. However, in order to better explain the roles of 
individual components, the order of explanation has been altered. 
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2.5.1. Electrospray Ionisation (ESI) 
Mass spectrometry requires molecules to be ionised (i.e. charged) so that they may be attracted or repelled 
through an electrodynamic field generated by the MS, whereas neutral molecules are not affected. 
Electrodynamic fields are used to focus ions into the MS through a small capillary and subsequently guide 
ions through an increasing vacuum towards a mass detector. Depending on the ionisation source, molecules 
can adopt one to multiple charges via the addition of a charged molecule (e.g. a proton). Each ion therefore 
is a charged mass which can be referred to as a mass-to-charge (m/z) ratio. Depending on the number of 
charges the m/z values can be calculated by the following equation: 
ሺmass	 ൅ 	charge	donor	mass	 ൈ 	number	of	chargesሻ
number	of	charges  
Different molecular ionisation sources exist to suit a user’s needs, however LC-MS often utilises electrospray 
ionisation (ESI) (Figure 5). The development of ESI by the Fenn lab was a crucial step for MS analysis of 
biomolecules as it is a “soft” form of ionisation, i.e. non-destructive on molecules, thus allowing a pre-cursor 
mass to be identified prior to downstream fragmentation (95,96). It is so soft that it is able to preserve the 
structural integrity of protein complexes as well as protein and small molecule interactions, a very important 
feature in native MS (97–99). When using ESI, molecules are generally ionised via the addition of charged 
adducts or protons ranging from one to multiple charging events depending on a number of factors 
including the number of chargeable sites, which in turn is likely to increase with size, and number of 
opposing charges present on the molecule. Ionisation efficiency between molecules also differs and if a 
molecule suffers from poor ionisation there is a risk it will be below the limit of detection in subsequent MS 
analysis. It is also important to note that ionisation is a competitive process. For this reason, sample 
complexity is often reduced via strategies aimed at decreasing the number of different molecular species 
reaching the ionisation source at the same time so that less abundant molecular species are able to be seen. 
Online separation of molecular species is routinely performed using LC, but offline techniques such as 
orthogonal chromatographic separation and fractionation are common also. Alternatively specific enrichment 
for molecules of interest is another strategy to maximise the detection. It is also very important that 
contaminant molecules that are able to dissociate and form a charge (such as salts) need to be removed prior 
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to ionisation. Not only can they suppress analytes of interest from adopting a charge (ion suppression), but 
they can also form adducts with molecules thereby charging them and adding mass to the overall m/z. 
Multiple charging of the molecules is particularly important in MS for a number of reasons. Some mass 
spectrometers have a restricted m/z window and larger peptides and proteins will only be seen if they are 
able to adopt multiple charge states thereby reducing their m/z. In addition having more than one charge 
state also greatly helps in peptide and protein sequence information in downstream MS analysis. The 
miniaturisation of the ESI interface, referred to as nano-electrospray (also referred to as nano-ESI, nanospray 
and nESI), was another crucial step for proteomics (100). Passing smaller amounts of solvent through an 
ionisation source permitted much greater concentrations of analytes and also resulted in much greater 
ionisation efficiencies, and further advancements resulted in the majority of ionised molecules to be analysed 
compared to earlier versions (101). These smaller and more efficient ionisation sources require far less sample 
compared to conventional ESI due to lower amounts of wastage. 
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2.5.2. Liquid Chromatography (LC)  
LC is an important aspect of proteomics as increasingly complex peptide sample matrices, including peptides 
from protein digests, can be separated thus reducing competition at the ionisation source and providing the 
MS time to focus on each new analyte as it appears. This is extremely important when peptides share the 
same m/z because the MS is unable to differentiate the ions, resulting in co-contamination of signals and 
difficulty in downstream analysis. Therefore higher chromatographic resolution is always strived for, as even 
peptides with the same sequence and m/z that vary in PTM or PTM location can also be separated based on 
their differences in interaction with column chemistry (102,103). In proteomics the most common type of 
Figure 5. Overview of Electrospray Ionisation. 
(a) Charge† is applied to the capillary surface, which is then transferred to the solvent that contains solutes. (b) 
Due to the opposite charge attraction from the MS, the charged solution is drawn towards the MS opening
resulting in the formation of a Taylor cone at the end of the capillary tip. (c) At the end of the Taylor cone, 
droplets are formed as they are drawn to the opposite charge within the MS opening. (d) The droplets 
undergo fission into smaller droplets. (e) During the desolvation process the charge transfers onto the solutes
resulting in their uptake into the (f) MS. Some of the neutral molecules are also drawn into the MS as a result
of the strong vacuum within. 
†Charge can be positive or negative. In this example, positive charge was applied to the capillary. 
 
33 
 
chromatographic separation of proteins and peptides is based on hydrophobicity. More specifically, the 
column chemistry encourages hydrophobic molecules to attach with the active chemistry commonly utilising 
hydrocarbon chains tethered to silica beads. This type of chromatography is referred to as reversed phase 
(RP) chromatography. The efficiency of chromatography columns including RP is increasing vastly, with 
commercial columns reportedly able to completely resolve up to 1000s of molecules (104). 
Over the last 10 years great advancements have been made in scaling down HPLC components sizes of 
columns and tubing down to a nano scale, with columns diameters dropping below 0.1mm and flow rates in 
the nL/min range (104,105). This nano-scale LC, referred to as “nano-LC”, has a reduced radial diffusion of 
analytes as a result of smaller tubing and column diameters (105). This produces a more concentrated 
analyte upon entering the MS resulting in a greater signal improving sensitivity and substantially reducing 
sample amounts required. The scaling down of sample required is of great benefit to biology as samples that 
are rare, costly, or difficult to prepare can yield better data from small amounts of material through more 
technical replicates and biological replicates often without the need for sample pooling. In addition advances 
and quality control in commercial columns offer improved reproducibility which reduces the random 
instrumentation noise in technical replicates and in turn provides easier distinction of variation in biological 
replicates. This cleaner background increases the confidence of results when spotting subtle differences 
between treated and untreated samples such as variation in quantity. 
2.5.3. Mass Analysers 
Mass analysers are responsible for accurately detecting the m/z of the ions entering the MS. A range of mass 
analysers are available which can be sub-divided into 2 groups. The first group are scanning and ion beam 
mass analysers such as time of flight (TOF) and quadrupole (Q) separate ions using flight time and m/z 
stability in a radiofrequency (RF), respectively. The second group are trapping mass analysers such as the 
linear ion trap (LIT), Orbitrap and, fourier transfer ion cyclotron resonance (FTICR). These trap ions based on 
radio frequency (RF) fields, and by stopping potentials applied to end electrodes. Hybridisations of the 
various instruments are also possible to widen their functionality. 
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Trapping mass spectrometers are limited in m/z range and commonly between 200-2000 m/z although the 
current maximum is at 20,000 m/z. Due to these restrictive windows, higher mass peptides or proteins 
require higher charge states for the m/z value to be detected therefore making ESI interfaces popular with 
trapping instruments. 
LITs are often heavily used in the field of proteomics because of their ability to generate faster scan rates (the 
rate at which the MS can scan its entire mass range) compared to other mass analysers, resulting in more 
ions being sampled and subsequently fragmented and providing more sample information. In addition a 
faster scan rate permits both targeted and exploratory scans to be carried in the same analysis making the 
data more useful for retrospective analysis of different peptides. Another powerful feature is an ion trap’s 
femtomolar to attomolar sensitivity which pushes the sample amount limits needed for identification of 
peptides and proteins or it can permit multiple technical replicates from a single sample. However, LITs have 
poorer mass accuracy and resolution compared to other mass analysers and therefore cannot distinguish or 
resolve between m/z peaks of similar values as efficiently. This can limit their ability to fully distinguish 
between ions of similar m/z, which may lead to occlusion of m/z peaks of interest by more dominant species. 
FTICR mass analysers are currently the best in mass accuracy and resolving power, this enables better 
distinction of peptides that are similar in m/z ions (106). However, they have much lower scan rates 
compared to LITs. They are also expensive in comparison to other mass analysers. In the year 2000, orbitraps 
were developed (107) and whilst they are not capable of reaching the same mass accuracy and resolution as 
an FTICR they are cheaper and are still one of the best mass analysers available. However, like FTICR they also 
have lower scan rates. Orbitraps can also be coupled to a LIT, generating the faster scan rates and multiple 
MSn fragmentations of the LIT whilst the Orbitrap acquires scans with higher mass accuracy and resolving 
power in parallel resulting in even more powerful MS analysis than any of the mass analysers alone. This 
higher mass accuracy and resolution is extremely important in distinguishing between different molecular 
species that may be similar in m/z. One of the downsides to using an orbitrap is their lower sensitivity to ions 
compared to instruments such as LITs. 
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2.5.4. Peptide and Protein Fragmentation: MS/MS 
Molecular fragmentation is a key component of deriving the identity of proteins, peptides and PTMs in 
proteomics. There are a range of fragmentation methods that can be used to break apart proteins and 
peptides along the peptide backbone within a MS. The most commonly used in proteomics are collision 
induced dissociation (CID), higher-energy collisional dissociation (HCD) and electron transfer dissociation 
(ETD) or electron capture dissociation (ECD). 
CID is a commonly used fragmentation energy for small molecules and peptides. After ions are trapped, an 
inert gas such as helium or argon is introduced and upon adding further energy to the system ions collide 
with the introduced particles resulting in fragmentation. Mass spectrometry of peptides followed by 
subsequent sequencing relies on the predictable and reproducible behaviour of gas phase fragmentation of 
ions as well as the dissociation of the individual amino acids (108). In proteomics, CID is widely used due to 
reproducible dissociation of the peptide bond resulting ion n-terminal and c-termial peptide fragments 
termed b and y product ions respectively (Figure 6) (109,110). Although peptide fragmentation is somewhat 
predictable, understanding of sequence specifc fragmentation has been aided by statistical analysis of large 
proteomic datasets (111), however there still is a lot of work that needs to be conducted in predicting the 
relative abundance of fragment ions as well as characterisation of non-canonical fragmentation (112,113). 
Under CID, PTMs such as phosphorylation (114) and ubiquitinylation (115) are often lost during 
fragmentation as neutral losses make it difficult to localise which residue was originally modified if multiple 
sites are possible (e.g. a phosphopeptide containing multiple serine, threonine or tyrosine residues). 
Fragmenting peptides covalently bound to small molecules via CID can also prove difficult to analyse if the 
small molecules contain lower energy fragmentation pathways. The fragments generated in this way are not 
standard and therefore difficult to predict and explicate. 
Sometimes CID alone is not strong enough a fragmentation method to break stronger covalent bonds such 
as carbon-carbon bonds. This is important when trying to distinguish between residues such as the isomers 
leucine and isoleucine or when it is important to identify the nature of certain PTMs such as glycosylation. 
HCD is a higher energy alternative to CID that is more capable of such fragmentation. 
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ETD and ECD (116,117) are other highly common types of fragmentation peptide sequences and proteins 
(118,119). The difference between ETD and ECD lies in whether electrons are transferred or captured in the 
gas phase, however the dissociative mechanisms are the same whereby a free radical is formed on the 
peptide which results in fragmentation along the peptide backbone between the N-Cα producing c and z 
ions. Larger peptides and proteins require a somewhat even distribution of positively charged residues for 
the proteins sequence to be efficiently obtained. Due to the nature of the fragmentation, positive charges on 
molecules are neutralised by ETD and ECD resulting charge state reduction. For this reason ETD is often 
better suited for fragmenting peptides with a charge greater than 3 in order to produce better c and z ion 
coverage for sequencing, with residue/charge ratio having a greater effect rather than precursor m/z for the 
prodcution of c and z ions (120). Additionally, ETD is well suited for the preservation of PTMs during 
fragmentation (115,121,122). 
 
 
2.5.5. Protein and Peptide Sequencing via MS/MS 
Usually with the help of protein sequence databases such as Mascot (123) or Sequest (124), the peptide 
amino acid sequence can be determined from the fragmentation products through m/z differences equal to 
amino acid losses. From this the peptide sequence can be determined by monitoring the amino acid 
differences in order of loss from either the N-terminus or C-terminus. Sequencing from both the N-terminus 
and C-terminus increases the confidence and therefore validity of results however is not always feasible. In 
Figure 6. Modes of Molecular Fragmentation in Mass Spectrometry. 
Different MS dissociative methods result in variable fragmentation along the peptide backbone. a and x ions
can be generated using a variety of methods including CID and ETD, b and y ions are mostly resultant from 
CID fragmentation and c and z mostly occur from ECD and ETD. 
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order for mass analysers to sequence peptides in this way, it is preferable to have a charge on both ends, or 
as close to the ends of the peptide as possible, as well as a dis. This is not an issue with the N-terminus as it 
readily ionises when using a number of ionisation techniques. However, the C-terminus does not ionise well 
and therefore after loss of the N-terminal charge during fragmentation, the C-terminal fragments lose their 
charge and are unable to reach the detector. 
Peptide sequencing is still not as simple as identifying the amino acids from the mass differences of every 
peak available. b ions are less stable than y ions and can fragment further to make smaller b ions, imonium 
ions and internal ions (125), whilst y ions can also fragment to produce internal ions (126). In addition, neutral 
losses including side chain fragmentation, water loss and deamination, to name a few (127), as well as some 
that are yet to be explained (112,113) also add complexity to a spectra. During fragmentation peptides also 
incur charge losses and therefore produce fragmentation products with different charge states. Furthermore, 
a peptide may have one or more PTMs, thus requiring the consideration that the amino acid mass differences 
may also have additional masses from PTMs. To complicate matters further, isobaric peptides may also co-
fragment contaminating and complicating the fragmentation spectra. 
Establishing the sequence of a peptide or protein directly from the fragmentation spectra is referred to as de 
novo sequencing. However this is a difficult task both manually and computationally due to the sheer number 
of considerations required to be taken into account. Altogether peptide sequencing and validation becomes 
an arduous endeavour with no eminently efficient de novo computer algorithm available at present. Despite 
these difficulties, software such as PepNovo (128) and PEAKS (129) are tools in assisting de novo sequencing. 
To speed up peptide identification, in silico peptide database searching was developed resulting in 
commercial software such as Sequest or Mascot (123,124). With the help of a database containing potential 
protein sequences, a search engine correlates MS data with in silico peptide precursor masses and predicted 
peptide fragmentation spectra (or spectral libraries) within user defined constraints. After the database 
matching has been completed, a statistical comparison referred to as the false discovery rate (FDR) attempts 
to eliminate falsely discovered peptides that may have been assigned randomly. At present there are four 
distinct ways to assess FDR, however three suffer from bias whilst the unbiased approach erroneously forfeits 
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high scoring matches (130). The accuracy of FDR has been a long standing issue in the field and has even 
been likened to the “Achilles heel of proteomics” (131,132). Adding further strain to scoring and the FDR, are 
PTMs which vastly increase the search space required and drastically increasing the ambiguity in 
fragmentation spectral matching. When database searching does not consider PTMs, the searching 
constraints may result in large segments of proteins to be unaccounted for. A recent publication has shown 
that a large portion of “missing” peptides in database searches are a result of PTMs and can be better 
identified by adding in a broader range of modifications (133). This approach however increases the 
computational load and search time, and leads to higher false positive peptide matches. Also, relaxing the 
PTM constraints still does not overcome the complication of unpredictable fragmentation experienced by 
some PTMs and small molecule adducts.  
Finally hybrid approaches also exist. De novo sequencing would be used to identify “short sequence tags”, i.e 
the most likely sequence of 3-5 amino acids, and their likely position in the sequence, these are then 
matched to a database highlighting the most likely candidates before undergoing a more thorough spectral 
matching thus reducing computational load (134). These hybrid databases may prove more useful for PTM 
and chemically modified peptides (135–137). 
 Proteomics Workflows 
It is important to consider the advantages and limitations of the specific components of MS and LC-MS for 
different aspects of proteomics. However, determining how to best analyse the protein samples is just as 
important. Each of the following workflows has its own set of strengths and weaknesses making some more 
suitable for studying specific areas of proteomics. 
2.6.1. Bottom up LC-MS Workflows 
Bottom up proteomics is sometimes referred to as shotgun proteomics in reference to shotgun genomics 
techniques (Figure 7). It a versatile technique that can be used qualitatively and quantitatively to study large 
numbers of proteins (138–140) and PTMs (141,142) or alternatively can be used in a targeted approach to 
study very specific peptides and PTMs (143,144). This wide versatility makes this a commonly used technique. 
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Proteins are extracted from cells and tissues and are enzymatically digested into smaller peptide fragments 
using enzymes (145). Trypsin is frequently used as it cleaves proteins at the C-terminal end of arginine or 
lysine residues (unless followed by a proline), which provides a positive charge at the C-terminus. The 
peptides are then separated by LC, ionised so that they may enter the MS, detected and fragmented (usually 
using CID ro HCD) to produce product ions, and finally are processed usually with the aid of a database 
search engine. Bottom up techniques often have incomplete sequence coverage post data analysis, meaning 
that only a percentage of the protein sequence has been observed through peptide identification. This can 
be caused by a number of aforementioned reasons including ionisation and charging difficulties, peptides 
that are too small or too large (with an inadequate number of charges) to fit within the scan range, PTMs and 
adducts have not been fully considered, and unpredictable fragmentation spectra have been produced. 
Figure 7. Overview of Bottom Up Proteomic LC-MS Workflow. 
(a) Proteins are extracted from cells (b) and are digested using proteolytic enzymes, most commonly trypsin.
(c) Peptides are separated by HPLC to reduce sample complexity. (d) As molecules elute from the HPLC, they 
undergo ionisation so that they may be manipulated by electromagnetic forces and (e) therefore be detected 
inside the MS (i.e. MS1) as a mass to charge (m/z). (f) In data dependant acquisition, the most intense m/z
from the MS1 are selected for fragmentation and subsequent detection (i.e. MS2). (g) The fragments 
produced are analysed by a proteomics search engine in order to identify the peptide. 
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2.6.2. Middle Down LC-MS Workflows 
Middle down is similar to bottom up, but proteolytic digestion aims to generate larger peptide fragments by 
proteolytically targeting less abundant amino acid residues within a protein, for example using Glu-C for 
histone H3 (146), as glutamic acid and aspartic acid residues are not as commonly distributed as lysine or 
arginine. These peptides can then be fragmented using ETD or ECD in subsequent MSn scans, and due to 
their larger size, peptides and fragments greatly benefit from high resolution mass analysers for more 
accurate mass identification (116,117,147) such as FTICR and Orbitrap instruments. The benefits of middle 
down are potentially better sequence coverage and better combinatorial PTM analysis compared to bottom 
up approaches, although the combinatorial PTM information obtained is arguably still not as complete as 
whole protein PTM analysis. Whilst these seem highly attractive benefits, the separation of larger peptides, 
and in particular the more hydrophilic histone peptides, may require non-standard (i.e. reverse phase) 
separation techniques such as weak cation exchange hydrophilic interaction liquid chromatography (WCX-
HILIC) (148). However, even with alternative chromatography isobaric histone PTM peptides can still co-elute 
(103) and if attempting to quantify these peptides, it may be required that unique fragments are first 
generated by MS/MS/MS fragmentation or fragment ion relative ratios (103,149). 
2.6.3. Top Down Workflows 
Top down mass spectrometry (recently reviewed in detail by Toby et al. (150)) attempts to analyse a protein 
in its entirety, either after being denatured or natively. This will give the ultimate information regarding 
protein sequence, as well as all the combinatorial information that comes with any associated PTMs. 
However, endogenous proteins will carry a wide range of PTM combinations and very quickly a protein 
containing the same primary sequence can result in a large number of proteoforms that can significantly 
increase the complexity of a sample. For this reason protein samples often undergo pre-fractionation before 
being analysed either by LC-MS or MS alone. On occasion, pre-fractionation can be extensive, can complicate 
the experimental design and may increase the variability of the data. However it is sometimes considered 
worthwhile to simplify the proteome to increase the number of proteins identified (151). A range of 
separation techniques for top down MS are available. RPLC (152,153) and on-line capillary isoelectric 
focusing (CIEF) mass spectrometry (154) have previously been used, although CIEF can result in a large loss of 
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recovery (155,156). Capillary zone electrophoresis has also been implemented online with top down MS 
(157). Gel-eluted liquid fraction entrapment electrophoresis (GELFrEE) (158,159) is another commonly utilised 
mass separating technique that has facilitated multi dimensional separation of proteomes, resulting in large 
scale top down proteomics almost on par with shotgun proteomic approaches (160–162). However GELFrEE 
requires SDS in order to function and needs to be washed out before it is compatible with ESI which are 
generally manually conducted and increase variability in the data. The various fractions can then be further 
separated and detected in tandem using LC-MS where mass spectra are collected in real time by an FTICR or 
orbitrap instrument. Alternatively the fractions can be directly infused using ESI into a MS.  
Top down MS analysis can be split into three main stages, (a) ionisation, (b) determination of the intact mass 
(i.e. the MS1) and (c) fragmentation of precursor mass (i.e. MS2) that can then be used to sequence the 
precursor. Ionisation is generally achieved using ESI. However, it is important to note that top down ESI MS 
analysis poses many challenges due to the large number of charge states that are adopted, the potential of 
interfering species, and solvent adduction that increases in probability with increasing mass (163). High 
resolution MS is required, particularly for fragment ions in the MS2 as fragmentaion spectra are complicated 
with a number of products and charges states that may all ovelap eachoter. Therefore a resolution of 
>50,000 is necessary. MS1 resolving power however is not needed to determine charge state from isotopic 
cluster, but is helpful. 
Fragmentation is normally achieved using methods such as ETD and ECD and require proteins to have a high 
charge density in order to achieve comprehensive fragmentation and therefore complete protein sequencing 
which may result in long stretches of protein sequences without fragmentation when sites are lacking in 
protonatable sites. As a result, if a protein is modified in a poorly fragmented region it is often difficult to 
identify the modification’s exact location. Specifically with native mass spectrometry,  ETD and ECD often 
preferentially fragment disordered and therefore flexible regions resulting in very few fragmentations within 
the protein centre or structured regions (90,91,164,165). In addition strong salt bridges are resistant to 
ETD/ECD fragmentation (166). However, a recent alternative form of dissociation called ultraviolet 
photodissociation (UVPD) is resulting in better sequence coverage in regions with poor charge densities and 
structure (167,168). Whilst top down is highly useful for some forms of analysis, specialist labs and a large 
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amount of method development is currently required for it to be routinely carried out in a high throughput 
way. 
 Bottom up LC-MS Data Acquisition Methods 
A fundamental aspect to using bottom up LC-MS as an analytical technique is how the MS fragmentation 
data itself is acquired. Ideally, every single unique peptide molecule would be separately fragmented by MS 
so that the identity and amount of each peptide can be elucidated. However, mass analysers are not fast 
enough to sample all ions for fragmentation, in addition isobaric peptide species may co-elute. For these 
reasons a decision has to be made regarding the amount of data that can be sacrificed whilst still meeting 
the proteomic goals of a specific study. 
2.7.1. Data Dependant Acquisition (DDA) 
Data dependant acquisition requires no upfront knowledge of the proteins or peptides in question as 
automatic selection of m/z occurs. This is good for discovery based approaches and can be retrospectively 
analysed for previously unknown proteins and PTMs. However, DDA alone is not often suitable for 
quantitative analysis. This mostly stems from method programming often aimed at sampling as many m/z 
ions as possible, and programmed to select peaks of largest intensity. Depending on the complexity of the 
sample, lower intensity peaks can be ignored from fragmentation resulting in a failure to validate and 
therefore include the peptides species in a quantitation. Quantitating from the intensity of unique fragment 
ions is also unreliable with DDA. Sampling usually occurs at the beginning of chromatographic peaks when it 
is first seen and where intensity is often low. Repeat sampling is normally programmed, but this can also 
occur away from the peak max, possibly resulting in low intensities to be carried forward for fragmentaion. 
This low intensity precursor selection results in ambiguity in the true intensity of unique ions which are 
extremely important for the distinction and quantitation of isobaric peptides. As isobaric peptides have the 
same m/z ions, distinguishing between two species relies heavily on the unique differences in fragmentation 
spectra. Furthermore, when isobaric peptides co-elute, accurate quantitation relies on the percentage 
contribution of unique fragment ions in the spectra so that they may be quantitatively decoupled. In the 
event that homeometric fragments are produced from similar peptides, it may not be possible to attribute 
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quantitative values to a specific peptide, particularly when other defining features such as retention time are 
also absent or unkown. 
2.7.2. Selected Ion Monitoring (SIM) 
SIM uses narrow m/z isolation windows aimed at targets of interest making it highly selective and sensitive 
but requires upfront knowledge of the sample and sometimes a great deal of method preparation. Previously 
obtained peptide fragmentation spectra can be used to isolate the unique fragments specific to that peptide. 
Peptides can then be targeted and routinely fragmented whilst monitoring one (SRM) or more (multiple 
reaction monitoring, MRM) unique fragments specific to the peptide whereby their intensity can be used for 
accurate quantitation. This approach is particularly useful for quantitating isobaric peptides as the percentage 
contribution of the co-eluting isobaric m/z ions can be distinguished. In addition peptides lower in 
abundance and intensity will be benefit from sensitivity improvements. However, increasing the number of 
targeted peptides increases the cycle time used to search for them. This results in reduced sampling of other 
peptides that may be present in the MS acquisition thereby hindering retrospective analysis as well as 
limiting the number of peptides that can be feasibly targeted without information loss. Too many peptides 
widens the restart time for each cycle sometimes risking a failure to even sample a targeted peptide with a 
sharply resolved chromatographic peak. 
2.7.3. Combined Acquisition Methods 
To combat the deficiencies of the two acquisition approaches, methods can adopt a compromise between 
DDA and SRM methods. By specifically including peptide m/z targets on a fragmentation inclusion list, they 
can be selected as and when they appear for multiple fragmentation rounds whilst being monitored for 
unique fragment ions. This reduces the risk of wasting cycle time with fragments not expected to appear. A 
round of non-targeted DDA fragmentations can then be used for later stage re-evaluation of previously 
unknown peptides. 
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2.7.4. Data Independent Acquisition (DIA) 
A recent form of analysis that combines some of the strengths of DDA and SRM/MRM methods is data 
independent acquisition (DIA). With DIA, narrow m/z windows are cycled and fragmented in their entirety, 
resulting in one fragmentation spectra with fragments from all the ions in that m/z window. This is then 
repeated for each consecutive m/z window which then cycles back to the beginning to repeat itself 
throughout the entire run. The narrow m/z windows can allow for better mass resolution, without sacrificing 
too much time. For this method to work rapid and accurate sampling is required. DIA arguably provides the 
largest amount of information for retrospective analysis as all m/z precursor ions are fragmented although 
analysing data in this way can prove to be a major challenge if the fragmentation products of an ion are 
unknown based on the sheer complexity of the spectra. Data searches can be done in an accurate and fast 
manner using peptide fragmentation libraries with the unique fragments identified for each in a similar 
approach used in MRM. Such libraries can be generated in house or obtained from previously published 
larger scale attempts (169,170). However, a lot of work needs to be done to ensure that fragment ions 
observed are annotated and actually unique to a given molecule to prevent false identification and 
quantitation. Whilst this technique can be used for more complex samples, it can be argued that without 
decent sample preparation steps such as purification and prior chromatography the data becomes prone to 
artefacts from other contaminants. Another issue is that lower intensity signals can be outcompeted by the 
more intense signals from other peptides. 
 Middle Down Data Acquisition 
Middle down data acquisition methods are similar to bottom up. The larger peptides generated during the 
middle down workflow are better fragmented with their PTMs using ETD and ECD (171–174). For this reason, 
data can be acquired using DDA based approaches and analysed using traditional search engines such as 
Mascot and Sequest, as well as de novo search engines such as Peaks and PepNovo. In addition, SRM/PRM 
coupled with ETD data acquisition can also be used with middle down data (175). It has been postulated tha 
DIA may be well suited for middle down data (176), specifically for histones as a large degree of middle down 
quantitation is performed using fragement ion intensity (103,172), however the complexity of the spectral 
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analysis would be a great challenge that would require overcoming, with a large part of the complexity 
resulting from isobaric species co-eluting. 
 Top Down Data Acquisition 
Data acquisition for top down proteomics is carried out using DDA, or SRM/PRM based acquisition methods. 
Alternatively it can be done manually during protein infusion. Analysing top down proteoics is a difficult task 
requiring a large degree of manual analysis whereby protein precursor masses and fragmentation spectra are 
compared to known sequence data. This task is often carried out manually, although software is available to 
alleviate this process (177,178). Alternatively data analysis is carried out using express sequence tags and de 
novo proteomics (179). DIA has also been proposed for top down proteomics (180) although it has yet to be 
implemented successfully. 
 Proteomic Method Development 
The following sections aim to introduce three challenges faced whilst working with chromatin systems. A 
proposed solution for each challenge is then briefly made and the corresponding chapter in which the work 
is further discussed is provided. 
2.10.1. Protein-Protein CXMS 
Whilst undergoing significant advancement over the last 15 years protein-protein CXMS is only just 
becoming a more commonly utilised technique. Arguably the key issues associated with CXMS are data-
complexity and probability in fragmenting cross-linked peptides. Whilst a range of software exists to speed 
up the data analysis time, a great deal of manual validation is required in order to confirm validity. 
Furthermore cross-link data needs to be supported with other experiments to confirm its credibility, such as 
cryo-em and other biochemical experiments. In addition to this, the many chemical CXMS advancements 
previously proposed (discussed in section 3.6) to increase the probability of cross-linked peptide 
fragmentation and speed up the data analysis have not been widely adopted due to many challenging 
technical issues they also introduce. Noticeably, the field of cross-linkng have widely reverted to more 
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traditional versions of protein CXMS and instead greater emphasis has been placed on improving the way in 
which data is analysed (7). 
In Chapter 3 of this thesis CXMS as a technique, including the difficulties and technical advancements 
associated with it, are examined in detail. This is followed by our contributions to the field through additions 
in cross-linker multifunctionality, as well as suggestions for optimising CXMS workflows to ease the burden 
on data analysis. 
2.10.2. Pushing the Limits of Detection in Histone PTM Analysis 
Histone PTMs are crucial aspects of epigenetic programming within a cell. Traditional techniques previously 
used to study histone PTMs, such as ChIP (discussed in further detail in section 2.10.2), western blotting and 
immunofluorescence, have been highly important, however are low throughput and plagued by inefficient 
antibodies (181–183). Whilst other techniques will still not be able to replace the use of various antibody 
based methods, LC-MS can be used either standalone, or as a complementary method to ChIP for the 
analysis of histone PTMs. 
In chapter 4 of this thesis we propose a complementary technique that can be utilised in conjunction with 
ChIP-MS in order to examine changes in the global histone PTM profile with a great increase in sensitivity. 
This in turn minimises the sample amounts required as well providing a more comprehensive profile of the 
PTMs available whilst still allowing a high degree of flexibility to include novel PTMs in the global histone 
PTM profile. 
2.10.3. Indirect Analysis of Small Molecule Protein Binding 
Analysing small molecule probes bound to proteins can prove to be difficult for often undescribed reasons. 
Alternative techniques that provide better information regarding small molecule binding locations are often 
time consuming, or difficult to achieve if possible at all. To compensate for this alternative methods are often 
developed to overcome further issues faced in order to obtain some information regarding binding. 
In chapter 5 of this work we were faced with the challenge of the analysis of a small molecule chaetocin and 
binding to its respective protein target G9a. Whilst evidence suggested that chaetocin exerts its inhibition via 
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covalent interaction with G9a, direct analysis provided somewhat difficult and the modified peptide was 
elusive. In order to overcome this difficult we utilised an alternative method with dual chemical labelling to 
indirectly identify the binding region for chaetocin on G9a.  
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 General Introduction: Protein-Protein Chemical Cross-
Linking Mass Spectrometry (CXMS) 
CXMS is a technique that has been around for the last 15 years and has been previously used in a wide 
variety of ways to identify PPIs and protein complex members, as well as deliver low resolution structural 
analysis of proteins and binding domains when in complex (184). CXMS has been used in explorative ways 
with cellular lysates resulting in groups claiming 708 (185) and 2,179 (6) cross-linked unique peptides. In 
addition, specific protein targets have been cross-linked from native cellular environments such as cell lysates 
as demonstrated by the systematic analysis of human protein phosphatase 2A (PP2A) complexes (186). CXMS 
has also been used with structural characterisation as its main target in combination with 3D-EM to define 
restraints within Nup87 (187) and U4/U6.U5 triple small nuclear ribonucleoprotein (188), and in combination 
with X-ray crystallography and 3D-EM to study interactions between the eIF3 complex and the 40S ribosomal 
subunit (189). To date, CXMS is the only technology that can simultaneously achieve both PPI identification 
and structural information making it a highly lucrative proteomics tool. However, CXMS is still a developing 
technology and whilst many technological improvements have been implemented and suggested, there are 
still a great deal of many improvements in the methodology that can be made. 
 Motivation and Importance 
After the completion of the human genome project, larger interest was applied towards completion of the 
human proteome (83,84,190) and just as importantly, the human interactome (191–193). Understanding 
proteins and how their functions and are regulated is extremely important to our understanding of health 
and disease. Traditionally, studying PPIs and structure is done separately though methods such as affinity 
purification and X-ray crystallography, respectively. Whilst some of the traditional techniques are 
unparalleled in sensitivity, resolving power, or ease of use, a large number of these techniques are slow, 
require a degree of trial and error and are not always successful in determining structure or PPIs. Furthermore 
a number of these methods require prior knowledge of at least one of the proteins involved and all fail at 
being able to capture transient PPIs. It is therefore extremely important to provide some more groundwork 
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to help speed up characterisation by studying both PPIs and structure in order to build a more complete map 
of the cellular proteome. 
 Previous Work: Alternative Techniques to Studying 
Protein-Protein Interactions and Protein Structure 
Affinity purification mass spectrometry (AP-MS) 
One of the gold standards for identifying the complexes a protein is involved in is affinity purification mass 
spectrometry (AP-MS) (reviewed by Oeffinger (194)) as recently demonstrated by a large scale approach that 
was used connect 5,400 proteins with 28,500 interactions (93) and 7,668 proteins with 23,744 interactions 
(94). In AP-MS A “bait” protein is used to form a stable complex with other proteins. The bait protein is then 
enriched for, usually using antibodies. If antibodies specific to the protein are unavailable, commonly used 
epitope tags such as FLAG, enhanced green fluorescent protein (eGFP), protein A and haemagglutinin may 
be incorporated into the protein for antibody recovery instead (195). However, there are limitations with 
using AP-MS for high-throughput protein discovery and characterisation scenarios. Protein specific 
antibodies take time to develop and may not always be as selective to a protein as desired, potentially 
resulting in false complex member identifications. As antibodies are very large proteins even epitope tagged 
proteins may undergo distortion effects potentially inducing protein complex dissociation during purification 
stages. Tags in general may also affect folding and protein complex formation. Also, entirely novel protein 
complexes may not be elucidated as at least one of the proteins needs to be known. Furthermore AP-MS 
only works for stable protein complexes and transient PPIs are not identified unless interactions are froxen in 
place with cross-linkers (discussed in section 3.4) (196,197). 
Chromatin immunoprecipitation (ChIP) 
ChIP utilises immunoprecipitation to retrieve protein complexes bound to eachother and their target DNA 
and can be used to target histone PTMs . There are a number of variations of ChIP methods, whereby 
different questions relating to chromatin can be addressed. Native ChIP (NChIP) (198) attempts to retrieve 
stable protein complexes and DNA from native chromatin prepared using micrococcal nuclease digestion or 
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purified mononucleosomes. Alternatively if protein interactions are likely to be transient (e.g. transcription 
factors) or unstable they may be cross-linked before a ChIP pull down (XChIP) either using formaldehyde 
(199) or UV (200), but unfortunately XChIP is sometimes prone to false positives due to the random cross-
linking of proximal proteins. In addition cross-links interfere with epitope sites for antibody pull downs and 
reduce the recovery yield. Proteins retreived from ChIP can then be studied using western blots or MS (ChIP-
MS). DNA that has also been pulled down along with protein complexes can be sequenced after ChIP (ChIP-
seq). 
Yeast two-hybrid system (Y2H) 
Two-hybrid screening (or yeast two-hybrid system) is a technique used to identify PPIs or protein-DNA 
interactions (201). Yeast cells are used to grow plasmids containing the “bait” protein of interest attached to 
a part of a transcription factor known as the binding domain (BD). This is screened against a library of “prey” 
proteins attached to the other part of the transcription factor, the activation domain (AD). If the libraries 
contain suitable binding partners the attached BD and AD work together to bind and activate a reporter 
gene. Proteins may have unnatural folding as a result of being attached to transcription factors. This will lead 
to occlusion issues and potentially false negatives. This process is non-automatable and only one binding 
partner at a time is identified, making this a long winded procedure for wide scale analysis. As the binding 
required for this process needs to be strong, transient PPIs will not be picked up. This technique is also highly 
prone to false positives (202,203).  
Polyacrylamide gel electrophoresis (PAGE).  
Gel separation methods like blue native PAGE (BN-PAGE) and clear native PAGE (CN-PAGE) can separate 
previously uncharacterised protein complexes by charge, size and isoelectric point. Theoretically, no prior 
knowledge of the proteins is required and large protein bands may be excised and analysed using methods 
such as MS for identification. BN-PAGE uses charged dyes such as coomassie blue to bind and separate 
protein complexes whilst CN-PAGE relies on native protein charges for separation, thus reducing the risk of 
dissociation of proteins through the addition of unnatural charges. There are a few downsides with protein 
gel methods. They are labour intensive, non-automatable and further structural analysis would be difficult 
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following on from gel separation. If all proteins were loaded on one gel, bands could contain multiple similar 
weight complexes and will not be pure. Some orthogonal form of separation like ion exchange 
chromatography can conducted beforehand to reduce the risk of this issue. Additionally, the coomassie dye 
in BN-PAGE may induce complexes to dissociate whilst CN-PAGE reduces the risk of dissociation but at the 
cost of lower resolution. Due to the requirement of fairly stable non-covalent bonds, transient PPIs will not be 
detected using this method.  
 
Chromatography 
Other separation techniques may include size exclusion purification, which separates large biomolecules out 
by size. The column is filled with gels or porous particles which allows smaller molecules to travel through 
whilst larger molecules cannot fit though the pores and must travel around. Aqueous solvents may be used 
such as a buffer at physiological pH. This allows proteins and stable protein complexes to maintain their 
structural integrity allowing further structural analysis or experimentation.  
Ion exchange chromatography separates molecules based on their charge. Differently sized proteins or 
complexes will have varying amounts of charge and will adhere less or more strongly with the oppositely 
charged column. Proteins may then be eluted from the column by altering the pH or by altering the ionic 
composition of the solvent, which competitively competes with the proteins causing them to elute. By using 
appropriate physiological buffers the protein structure integrity may be preserved. 
X-ray crystallography and nuclear magnetic resonance (NMR) 
Structural studies are generally carried out through nuclear magnetic resonance (NMR) and X-ray 
crystallography, which can provide full atomised protein and protein complex structures. These methods 
generally require 10–100 mg of protein sample to conduct which can be difficult to produce for proteins 
prone to cellular toxicity and aggregation. NMR is severely limited by protein size and can only successfully 
analyse smaller proteins. X-ray crystallography at present produces the highest resolution imagery of 
proteins. However, in order for X-ray crystallography to work, proteins need to be crystallised first. This is 
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currently achieved through an entirely trial and error approach using a range of non-physiological conditions 
including a range of solvents, making this technique unsuitable for high throughput structural analysis of 
proteins. Crystallising a single protein is difficult in itself and even the slightest changes such as humidity and 
temperature may affect crystal formation. For these reasons the number of protein complexes with multiple 
subunits that have been crystallised is very small. Furthermore, when a single subunit is difficult to crystallise 
research often resorts to truncating the protein down to just the functional domain. When only such 
crystallography data is available, caution is needed as it may not necessarily be a true representation of the 
functional site structure if the rest of the protein is needed for stabilisation. X-ray crystallography is also of 
high interest to pharmaceutical companies for the study of protein-ligand complexes. If a crystallisation 
method is already available for a protein, attempts may be made to crystallise proteins in complex with 
known ligands. This is highly useful when attempting to understand why some ligand-protein interactions are 
so specific or strong. This information may then be used to aid pharmaceuticals to develop ligand analogues 
with better properties whilst maintaining or improving the drug specificity and binding strength. However, 
small molecules may affect the crystallisation efficiency of a protein, and the crystallisation solvents used may 
dissociate the ligands, thus hampering research progress when utilising this approach. It is important to 
remember that ligands crystallised with truncated proteins, or with only one subunit from a larger complex, 
are not necessarily true representations of what happens in vivo and such data must be treated with caution. 
3 Dimensional electron microscopy (3D-EM) 
A technology that has undergone significant advancement in being able to obtain higher resolution 
structural information is 3D-EM and in some instances has been able to rival the resolution of Xray 
crystallography (204–206). Cryo-EM utilises transmission electron microscopy (TEM) to generate a series of 
2D images which are then pieced together using computers and complex algorithms to generate a 3D image. 
Unlike X-ray crystallography however, crystals do not need to be formed and proteins can be analysed 
natively, provided that the sample preparation preserves the complexes and maintains a low signal to noise. 
The major advantage of this is that proteins can be studied alone or in complex, with conformational changes 
more easily observed in the presence of different conditions such as PTMs, pH or small molecules. Moving 
images of proteins can show how they are affected by ligand binding in a step by step fashion. Additionally, 
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the effect of ligand concentration as well as different ligand combinations can all be utilised to study how 
protein function and structure is altered. Cryo-EM will aid greatly in understanding the structure of protein 
interactions for many years to come and still has a great deal of available technological advancements that 
will inevitably enhance this technology. However, with all these benefits 3D-EM still has a number of 
downsides. Aside from the large equipment cost and vast computational power required to generate 3D 
images of a proteins, structures below 200 kDa suffer from low signal to noise ratios, advances in algorithms 
are required to accurately define what is occurring for a range of structures, delicate protein complexes are 
unable to survive sample preparation processes, and at present only some protein preparations are able to 
be observed at such high resolutions (4).  
Protein incorporated photoreactive amino acids 
Photoreactive amino acid substitution in proteins can be used for in vivo cross-linking of protein complexes. 
L-Photo-Leucine and L-Photo-Methionine are some photoreactive amino acids that are substituted for 
leucine and methionine in limiting media and are then indistinguishably incorporated into primary protein 
sequence by endogenous polymerases (207). UV activation of the amino acids will then cross link nearby 
residues which can be both intraprotein and interprotein depending on the positioning of the residue in the 
protein sequence. This technique is limited however to the relative positioning and distribution of methionine 
and leucine residues.  An alternative method that circumvents this issue is available through the introduction 
of exogenous unnatural amino acids that may be introduced through a combination of unique transfer-
RNA:codon pairs permitting the user to insert a photoreactive amino acid into any location within the protein 
sequence (208). Both these techniques can use LC-MS to identify the proteins involved in binding and which 
residues are nearby to eachother. However, due to the random heteroatom insertion of photoreactive groups 
subsequent MS analysis becomes somewhat difficult. 
Limitations in alternative methods for studying PPIs and protein structure 
Traditional techniques into studying PPI such as AP-MS have been important in providing chromatin research 
with a range of protein complexes that may be chosen for study. However it is important to remember that 
these techniques fail to provide information regarding binding orientation and transient interactions that 
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may be crucial to complex functionality. This leaves downstream researchers with a great deal more difficulty 
when studying specific protein complexes which may be missing key information. Capturing transient 
interactions is possible with reversible cross-linkers such as formaldehyde. However, they are prone to a great 
deal of non-specificity, do not provide any structural information, and reduce the number of approaches that 
can be utilised (e.g. interfering with antibody binding epitopes). This lack of information has potentially left 
even classically studied protein complexes with missing functionalities that may still be important.  
When studying protein structure, large amounts of protein is required and is often easier to generate and 
purify from simpler organisms such as E. coli. The disadvantage is that these simpler organisms do not always 
have the chaperones and folding systems that mammalian cells do, so proteins may not be folded properly. 
Human, mammalian or insect cells may be used instead as they fold proteins more efficiently, however they 
are much more difficult to purify from, increasing the risk of protein damage during extraction and 
purification. Even with highly efficient recombinant cell expression systems, generating this amount of 
protein would take many weeks to complete considering typical cell culturing methods may only generate 
less than 10 μg per flask. 
Being able to crystallise a protein individually and in combination with a small ligand is useful for developing 
highly specific small molecule inhibitors, however doesn’t necessarily provide a great deal of functional 
information of how proteins interact with other macromolecules and exert their function. In addition proteins 
in complex may be structurally different than when alone, and a drug being developed for a specific protein 
complex may not work if designed off the incorrect structure of an isolated subunit. In this regard 3D-EM is a 
useful tool in being able to directly observe how proteins are able to move and interact, with the ability to 
generate short media clips of the proteins in action in a range of chemical environments and co-factors. 
However upfront knowledge of all the proteins and macromolecules involved is still required in order for the 
full picture to be completed. Therefore difficulty may arise if PPI knowledge is based on traditional 
techniques as they potentially lack key transient interactions that may be crucial to the function to occur. 
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 Fundamentals of Cross-Linker Design for CXMS 
A method for combining identification of PPIs and limited structural information in a higher-throughput 
manner is chemical protein cross-linking MS (CXMS). Simply put, a cross-linker is a chemical bridge with two 
reactive functional ends that can “freeze” in place PPIs based on proximity and target residue availability. 
Through MS analysis the protein complexes cross-linked together can be identified. Simultaneously, structure 
can be obtained by using the chemical bridge length to provide an approximate measurement of the 
distance between two points. Many groups have attempted to optimise the procedure to a suitable level 
whereby results are more reliable data analysis is less complex (6,185,209). This research has resulted in the 
development of a wide range of cross-linkers that encompass a range of chemistries, spacer arm lengths and 
functionalities to best suit the user’s needs. 
3.4.1. Cross-Linker Functionality 
A cross-link is a bond that links two molecular chains together. A number of molecules that vary widely in 
reactive chemistry are able to achieve this and therefore cross-linking is a term widely used in a range of 
scientific fields. In CXMS a cross-linker is a reactive molecule that is able to freeze in place peptide chains 
based on proximity and target residue availability (depending on the chemistry used). They are often 
composed of at least three main components, a reactive site, followed by a chemical bridge called a “spacer” 
and a second reactive site (Figure 8). Some cross-linkers termed “zero-length” cross-linkers are able to react 
without a noticeable chemical bridge. Additional functionalities may be incorporated into the cross-linker to 
suit a user’s needs, often with the goal of simplifying purification or data analysis. 
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The chemical spacer of a cross-link should be inert to proteins, somewhat flexible so that it may bend and 
attach to adjacent residues and not too bulky so that accessibility to protein grooves and complex binding 
domains is not affected. The spacer is how distance measurements between cross-linked regions can be 
calculated. It is considered that a length of around 8-16 Å is most desirable. Too long a spacer length 
provides too vague a distance between target residues and too short will result in a very limited number of 
cross links. However, whilst spacer lengths are limited in size careful consideration should be used when 
calculating distances between peptide backbones for structural modelling. For example, the commonly used 
commercially available cross-linker spacer found in DSS and BS3 has a relaxed length of 11.4 Å however 
distances between lysine residue Cα atoms should be introduced as a constraint of up to 26–30 Å (210). To 
get a better picture of structure, different length cross-linkers could be used to provide a better definition of 
structure, however would lead to a much larger amount of data to process. Interestingly a spacer’s charge is 
also able to affect the likelihood of cross linking also. A publication by Liu & Goshe reported that a negatively 
charged spacer SuDP formed less cross links in negatively charged regions of BSA, whilst the more non-polar 
SuVP preferred hydrophobic regions (211). On the more relatively neutral haemoglobin however the cross-
linkers seemed to have equal cross-linking of the same residues. 
Figure 8. Structural Representation of Homobi-, Heterobi- and Mutli- Functional Cross-Linkers. 
Cross-linkers are chemical spacers with reactive functional groups. (a) Homobifunctional cross-linkers react 
with the same chemical targets. (b) Heterobifunctional cross-linkers have different chemical targets. (c) 
Multifunctional cross-linkers can be homo- or hetero- bifunctional and incorporate additional functions such 
as enrichment. 
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In addition to careful selection of the spacer arm, choosing whether or not to have identical or different 
reactive chemistries on either side also requires careful consideration. Homobifunctional cross-linkers share 
the same reactive groups on both ends of the cross-linker (Figure 8) and can have a high degree of specificity 
if using amino acid specific reactivity. By utilising amino acid specific cross-linkers, data analysis can be 
facilitated as reactive sites are finite and constraints can be put in place. The caveat to such specificity is fewer 
intra and intermolecular cross-links due to limited target residues within proximity of each other. 
Alternatively, less specific random insertion reactive groups such as photo reactive groups (discussed later in 
section 3.4.2) would significantly increase the number inter and intra-molecular cross-links formed providing 
much more structural information but produce far more complicated data. To mitigate too few or too many 
cross-links, heterobifunctional cross-linkers with different end groups (Figure 8) can be used. For example, by 
combining an amino acid specific reactive group with a photoreactive group more cross-links will be 
achieved with a search space that can be partially pre-defined. In this way, different structural information 
can be obtained and in the event of using a photoreactive chemistry, the data is somewhat simpler to 
deconvolute compared to a homobifunctional photoreactive linker. 
CXMS is normally conducted using a bottom up approach. The way in which cross-linkers react with proteins 
results in a number of cross-linked peptides to be formed after proteolytic digestion (Figure 9). Native-
peptides are unmodified by cross-links and T0 cross-links will only have one reactive group bind a residue 
whilst the other is unable to find a partner and is quenched or hydrolysed. Both reactive ends of a cross-
linker can also react within the same protein (intra) or a separate interacting protein (inter). Exclusively to 
intraprotein cross-links, a cross-linker can form a bridge between two residues that occur on the same 
proteolytically produced peptide forming T1 cross-links. Furthermore both intra- and inter- protein cross 
links can form T2 links that bridge two different proteolytically produced peptides. 
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Depending on the protein and reactive chemistry used, the vast majority of peptides produced will likely be 
native peptides, as a large portion of globular proteins is internal and restricts access to cross-linkers. The 
next most common subset will be T0 which only identify solvent exposed regions. Usually T0 amass the 
largest percentage of cross-link products because only a few proximally located residues will meet the 
distance requirements for T1 and T2 links. As a result, the native peptides and T0 population number will out-
compete the more desired T2 links in both number and intensity of MS signals. Therefore, whilst T0 are 
important in obtaining protein surface topology, they can generally be considered a contaminant of T2. T1 
links are also generally regarded as somewhat of a nuisance as it is expected that residues on the same 
peptide are proximal, however if the peptide is long, T1 links can still prove useful. T2 provide the most 
information but are the most difficult to form as they are based on proximity and accessibility.  As some 
residues are more difficult to access they will result in a lower abundance of cross-links. For this reason T2 
cross-links will normally be on the lower end of abundance compared to other cross-links and native peptide 
species, often making them much harder to detect. Therefore a great deal of emphasis has been placed in 
strategies designed to improve their detection and abundance (see section 3.6). To maximise the abundance 
Figure 9. Type 0, Type 1 and Type 2 Cross-Linked Peptides. 
Following proteolytic digestion, three types of cross-linked peptides (representesd as red and blue lines, 
where blue symbolises a different protein) may be formed. (a) Type 0 only have a single peptide attached 
and identify solvent accessible amino acids on a protein surface and provides no structural information. (b) 
Type 1 occur when a cross-link has formed on the same peptide and provide intramolecular structural 
information. (c) Type 2 are comprised of two different peptides cross-linked together and provide 
intramolecular (two red peptides from the same protein) or intermolecular (red and blue peptides from 
different proteins) protein structural information. 
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of T2 species it is also very important to identify the optimal cross-linker to protein ratio. Too little cross-
linker and the cross-linked peptides will barely be visible above the MS background signal. Too much cross-
linker will result in almost exclusively in T0 as it is a higher probability each lysine will be attacked by a 
different cross-linker based on concentration. To mitigate this, a qualitative assessment can be carried out 
using titrations of protein to cross-linker ratios and running them on a protein gel to assess the degree of 
cross-linking (209). 
3.4.2. Reactive Chemistry: Function 1, 2 
Cross-linker reactive chemistry (Table 1), including the positives and negatives of each chemistry type has 
been previously discussed in great detail by previous reviews (212,213). For that reason only an overview of 
the different chemistries will be discussed, with exception to N-hydroxysuccinimide (NHS). As NHS chemistry 
has been chosen as the reactive chemistry for this project, a little more detail regarding the specific positives 
and negatives will be provided. 
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Different functional chemistry can be used in cross-linkers; attachment sites are denoted by R, R’ and R” 
letters. The structure of each functional group, along with their respective chemical and amino acid targets, 
conditions of use and positives and negatives are described for each. 
  
Table 1. Overview of Cross-linker Functional Chemisty. 
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Primary Amide Cross-linkers  
N-hydroxy succinimide (NHS) is the most commonly used type of cross-linker reactive group as it is residue 
specific and widely commercially available. NHS is a primary amine reactive chemistry however has some side 
reactions. It reacts in the following order of preference: Nα (N-terminal group), Nε (lysine side chain) 
followed by nucleophillic OH groups on the hydroxyl containing amino acids serine, threonine and tyrosine 
(214). NHS cross-linkers are most functional between pH 6.1-pH 9.1 and lysine reactivity correlates with 
increasing pH (213). Due to their charge, Lys residues are usually located on the protein surface however 
upon reaction, charge neutralisation occurs which may disrupt the tertiary and quaternary structures. In the 
presence of histidine, the hydroxyl amino acid serine, threonine and tyrosine, reactivity increases. Tyrosine 
residues located near histidines can exhibit higher cross linking yields than lysines at lower pHs (214). 
Hydrolysis of NHS cross-linkers occurs in approximately 8 hours in water, thus allowing the cross-linker 
adequate time to penetrate cells and cross-link (213). At higher pHs (>8.5) in the presence of NaCl, hydrolysis 
occurs faster (215). To combat the rate of hydrolysis as well as improve the efficiency of cross-linking, N-
succinimidyl carbamate can be utilised instead (216). It has also been found that NHS may undergo 
undesirable reactions with contaminating ammonium ions that can be found in buffer solutions (217). If the 
spacer is too hydrophobic resulting in solubility issues in aqueous buffer, more soluble sulfo-groups may be 
attached to the NHS group itself. 
Imidoesters are another form of amine reactive species that exhibit minimal cross reactivity with other 
nucleophiles such as sulfhydryl groups on cysteine residues and minimal cross reactivity towards other 
nucleophiles. They are highly water soluble and are able to retain the positive lysine charge post reaction 
thus slightly preserving protein structure and solubility. Reaction rate  increases the higher the pH goes over 
10 (218). Below a pH of 10 there is increased risk of side reactions based on the release of reactive alkyl 
alcohol groups (219). The downsides to imidate groups are their high pH requirement, the high likelihood to 
undergo hydrolysis reactions with water reducing the half-life to less than 30 min and modest cross-linking 
efficiency compared to NHS esters (220).  
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Acid Reactive Cross-Linkers 
Dihydrazides are able to cross-link carboxyl groups found on Asp and Glu residues at physiological pH (7-7.5) 
with fastest reaction times between 25-37°C (221). Whilst they have already been in use for other challenging 
problems (222,223), Leitner et al. were reportedly the first to apply them to a protein system (221). The 
previously proposed strategy was to utilise EDC at a pH of up to 5.8 in a 50 mM pyridine HCl buffer (224) 
which may result in structural conformational change and therefore the dihydrazide approach is a preferable 
alternative. 
Sulfhydryl-reactive cross-linkers 
Sulfydryl-reactive cross-links are thiol reactive cross-linkers and therefore preferentially react with reduced 
cysteine residues. As cysteine residues are primarily engaged in disulphide bonding, targeting these residues 
would require denaturation of protein or may induce protein denaturation. For these reasons they are 
unsuitable for structural analysis or cross-linking with the goal of preserving native conformations.  
Maleimides are sulfhydryl reactive between pH 6.5 and pH 7.5. At more basic pHs there is a risk of reactions 
with amines as well as hydrolysis. Halogeno-acetyl functions are not as reactive as maleimides at lower pHs 
however unlike maleimides they preserve their sulfhydryl specificity at higher pHs such as pH 9 and above 
(225). Lastly, thiopridyls are a thiol specific chemical group however require reduction prior to cross-linking. 
Thiol free reducing reagents such as tris(2-carboxyethyl)phosphine (TCEP) could be used instead of the 
classical thiol containing disulphide reducing reagents such as dithiothreitol (DTT) and 2-mercaptoethanol to 
reduce the risk of cross-linker quenching. 
Photoreactive cross-linkers  
Photoreactive functional groups are a lot less specific regarding the cross-linking of proximal residues. 
Depending on the reactive group used, they are able to insert randomly within C-H, C-C and heteroatom-H 
bonds, thus making them highly non-selective for biomolecules or specific residues. As a result the number 
of cross links generated from photoreactive group can be a substantial figure requiring very careful control 
over the concentration of linker used. Upon activation by specific light wavelengths they very quickly react 
with reaction times ranging up to a few seconds. The faster the reaction time, the far less risk there is of non-
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specific cross-linking that may arise from structural distortion of proteins or random cross-linking from 
collisions. The longer the wavelengths of light required the less risk there is in damaging nucleic acids or 
protein structures with high energy wavelengths.  
Reactive carbenes are formed from groups such as diazirenes upon irradiation at 360 nm which may react 
with C-H or heteroatom-H quickly and have half lives in the nanosecond range (226). They are able to self-
quench with water reducing the chance of non-specific cross-linking. However, they have issues with 
intramolecular Wolff rearrangement to form less reactive and longer lived ketenes. In addition some 
carbenes degrade to form diazo-isomers which are long lived electrophiles, highly sensitive to nucleophillic 
attack thereby reducing their efficiency and increasing risk of non-specific cross-links (227). 
Reactive nitrenes are formed from molecules such as aryl azides and are activated at 250 nm whereby they 
become reactive for 100 µs (228). Nitrenes may react with C-H bonds and hetero atom-H bonds and are 
generally more specific than carbenes. In the absence of nearby reactive molecules they will form a more 
stable ketenimine which is less reactive and only reacts with nucleophiles (229). Some nitrenes such as aryl 
azides are not stable at physiological pH and room temperature in the presence of thiol containing chemicals 
(e.g. DTT) often used in proteomics methods (227). Also the short activation wavelengths are potentially 
damaging to biomolecules but reactive groups may be substituted to increase the absorption maximum 
(230).  
Benzophones are activated by longer wavelengths of 350-365 nm. Upon activation, they form diradicals with 
longer reactive times of 80-120 µs whereby they may react with nearby C-H bonds to form C-C bonds. Unlike 
other reactive groups, the diradicals can reform benzophones that may be reactivated again. As a result they 
do not have undesirable internal re-arrangement from instability and do not have to react to become stable 
again thereby reducing non-specific reactions. Continuous application of light will lead to cross-linker 
breakage and reformation of the cross-linker therefore ensuring thus ensuring highly specific cross link 
populations. The downside to benzophones is their size, which restricts access to tight spaces. In addition 
they have also been shown to exhibit methionine specificity (231). 
65 
 
Homobifunctional photoreactive groups are rarely used as they can virtually react everywhere on the protein. 
Following a proteolytic digest, a very large number of product species can be produced, particularly if cross 
links are formed on either side of a proteolytically cleavable residue. This potentially produces a wide range 
of MS signals that in turn will require a large amount of peak sampling. Furthermore, even cross-linked 
peptides with identical m/z can be an entire population of different species comprised of differential residue 
cross-links thus making fragmentation spectra highly complex to analyse. 
 Previous Work: Commonly Utilised CXMS Workflows 
There are a wide range of cross-linkers and cross-linking methodologies available ranging from simple to 
highly complex. The most commonly observed form of CXMS, and arguably the most successful to date is 
one that utilises a the commercial cross-linker DSS or BS3 which are comprised of an alkane chain spacer 
with homobifunctional NHS or Sulfo NHS reactive moieties (respectively) as published by Leitner (209). In this 
approach proteins are firstly cross-linked (Figure 10, 1) and then proteolytically digested (Figure 10, 2). After 
digestion cross-linked peptides are enriched, commonly by peptide size using size exclusion chromatography 
(SEC) (232) or strong cation exchange chromatography (SCX) fractionation (Figure 10, 3) (233,234). All 
separate fractions are then analysed by LC-MS (Figure 10, 4 and 5). Constraints on size and charge in LC-MS 
data dependant acquisition (DDA) of peaks increases the probability of sampling dipeptide cross links for CID 
fragmentation (Figure 10, 6 and 7). Special database searching software such as xQuest/xProphet is then 
used to identify cross-linked peptides based on precursor mass and CID fragmentation, which then should be 
validated manually (Figure 10, 8). 
One of the major benefits of using the workflow proposed by (209) is simplicity of use. Compared to some 
other cross-linking methods no chemical synthesis, expensive reagents or software is required making it 
much more easily accessible to many unspecialised MS labs. However, whilst such a simplistic methodology 
attracts new researchers to experiment with CXMS, the procedure comes with a number of caveats which 
may cause difficulty to unspecialised labs. 
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SEC of cross-linked peptides is possible on T2 peptides as they are the equivalent mass of two peptides with 
the extra addition of a cross-linker. If using primary amine reactive chemistry, trypsin is unable to cleave 
cross-linked lysine residues resulting in a missed cleavage and therefore an even larger T2 molecule. 
Altogether, using this approach would result in T2 to mostly appear in earlier fractions as molecules of their 
size are not as encumbered by the SEC matrix compared to native peptides, T0, and T1, which will fractionate 
later. However, it is important to note that SEC separation is not selective for T2 peptides. Protein digests will 
generate a wide range of peptide lengths, and the native peptides will still contaminate the earlier T2 rich 
fractions. Even though the majority of native peptides will be diluted in the earlier fractions, any remaining 
will still be at a much greater abundance in signal intensity compared to the T2 resulting in some ion 
Figure 10. Overview of a CXMS Workflow. 
A range of CXMS workflows are available for use; this figure represents one example. (a) Proteins are cross-
linked under physiological conditions (b) and proteolytically digested. (c) Cross-linked peptides are enriched 
for and fractionated using SEC or SCX, (d) and subsequently separated by HPLC. (e) Peptides are ionised and 
(f) detected by MS (i.e. MS1). (g) MS1 peaks corresponding to m/z ions are selected for subsequent 
fragmentation and detection (i.e. MS2) using DDA favoured towards cross-linked peptides. (h) Data is 
processed using CXMS specific software to reveal the identity of the more intense α (blue) and less intense 
β (red) cross-linked peptide m/z signals. 
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suppression and fragmentation competition. Lower abundance T2 will still be barely visible within the 
background noise and any T2 found in later fractions will almost suffer the same fate as if they were not 
enriched. 
Alternatively SCX chromatography can be utilised to enrich for T2 peptides cleaved with trypsin. As T2 have a 
minimum of four sites containing primary amine (newly exposed N-termini of peptides and unmodified 
lysines) or guanidino (arginine side chain moieties) groups that are amenable to a positive charge, they are 
more likely to adopt a higher charge state. Native peptides, T0 and T1 links will only have two sites 
containing primary amine or guanidino groups making them more likely to only adopt two positive charges. 
This difference in charge can be separated by SCX chromatography, as multiply charged peptides will bind 
more strongly to SCX columns and elute later, permitting enrichment of T2 in later fractions. SCX requires 
high salt concentrations that may be MS incompatible, although more volatile salts such as ammonium 
acetate can be used to alleviate some of this issue. Furthermore, protease choice is limited to enzymes such 
as trypsin with this technique as multiple chargeable sites need to still be available on the cross-linked 
molecule including the peptide C-terminus. 
To alleviate some of the pitfalls associated with SEC and SCX enrichment, DDA constraints can be used to 
restrict the precursor masses and charges that are permitted for sampling in favour of the larger and more 
charged T2 peptides. As the average amino acid mass is 117 Da, even a small peptide containing only 6 
amino acids would have an approximate mass over 700 Da. As T2 have two peptides including the mass of 
the cross-linker it is safe to say that most will be over 1400 Da. When using trypsin, chargeable C-termini are 
now available thus making a cross linked peptide easily able to obtain a charge of up to +4. A recent 
publication studying 910 unique cross-linked peptides from previous data sets came to the conclusion that a 
mass cut-off of 1300 Da and charge state rejection of +1 and +2 ions provides a 33.3% and 57% reduction in 
native peptides (respectively) whilst minimising T2 loss (Giese et al. 2015). Fragment masses for T2  were also 
found to have a mass greater than 50% of precursor and  charge state of 2+ and above whilst native 
peptides observed the complete opposite of this rule with a small percentage not obeying this rule. However, 
it is important to note that no amount of intelligent DDA can increase the signal intensity of low abundance 
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cross-linked peptides at the lower limit of detection, nor can it decouple co-contaminating m/z ions that may 
be masking T2 peaks. 
After enriching and optimising DDA methods to maximise the detection of T2s, the MS spectra produced 
have to be searched, sequenced and scored for cross-linked peptides. Sequencing T2 brings about a new 
level of complexity as not one, but two peptides are being simultaneously fragmented. Unlike peptide 
sequencing, the precursor mass of each peptide being fragmented is unknown as it is a summation of two 
peptides and the cross linker. Obtaining the precursor mass of each individual peptide is difficult as very 
rarely will the peptide separate from the cross linker itself (235). As a result, peptide sequencing has to be 
done with the consideration that any fragmentation can occur from either peptide as they are physically 
tethered. Without the pre-cursor mass of each peptide, cross-linked peptides have to solely rely on spectral 
matching of fragment data in order to generate any form of score. This can be carried out using specialist 
software such as xQuest (236), Hekate (237) and Kojak (238), each with their own specific uses and strengths 
and weaknesses. Spectral matching has to consider both peptides, and therefore database searching is no 
longer a linear function, but quadratic, requiring more computational time and effort. To alleviate this, 
software such as xQuest pre-indexes likely peptide cross-links and compares the spectra to these. Other 
software such as Hekate interface to SQL databases which can utilise several indexing methods and server 
clustering for faster analysis (237,239). 
Following a search, matched sequences need to go through some form of FDR software to rule out any false 
positive matches assigned statistically randomly, as without this this matches still require a great deal more 
expert manual validation which is very time consuming and highly prone to human error. Algorithms that are 
capable of assessing the FDR for cross-linked data are available for commonly utilised CXMS, such as 
xProphet (240), Percolator (241) and Protein Prospector (242). However, the results of these software vary 
greatly, with different software having stronger efficiencies in different data aspects which can require 
substantial relaxation of FDR percentages in order to achieve an overlap for the majority of cross-links (238). 
Data analysis for cross-linked peptides is particularly difficult for a number of reasons.  In normal proteomics, 
sequencing and FDR is attempting to confirm the existence of a protein, with multiple peptides of the same 
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protein providing a level of redundancy. With CXMS however, sequencing and FDR is attempting assess the 
validity of a structural constraint often solely on the existence of one fragmentation spectra. Technical 
replicates cannot be relied upon either as the same sample may not re-select the same cross-linked peptide 
for fragmentation or the T2 may fragment slightly differently the next time around. Therefore any statistical 
scoring methods are likely to rely on n=1. 
What is very often not mentioned about sequencing cross-linked peptides is the additional complexity of 
fragmentation products that can arise. CID fragmentation results in a number different products owing to the 
non-linearity and large size of a T2 molecules. On top of this there are additional mass losses including water, 
deamidation, side chain cleavages and cross-linker fragments (depending on structure) that can be 
considered. The higher charge states produce fragments in an array of charges. By having all of these peaks 
present sequence matching is made all the more difficult with a far greater chance of incorrect assignments 
and unannotated peaks. To make matters worse, the peptides in T2 do not fragment with equal intensity or 
sequence coverage. It is common to see one peptide fragmenting to produce better sequence coverage than 
the other which has previously been annotated as the α and β for the most and least efficient fragmentation 
(respectively) with on average 78% of the most intense ions matched coming from α peptides (235).  All 
these issues may pose serious challenges to match scoring and FDR analysis potentially resulting in a 
plethora of false positives or worse, spectra being disregarded. 
To improve the data analysis procedures, some groups are actively assessing large data sets and attempting 
to extract key trends and patterns that may be used as constraints to improve data analysis (235), whilst 
other leading CXMS groups have called for a concentrative effort in developing and integrating CXMS 
software (7). However even though cross-linking data analysis has a lot of room for improvement, some 
research groups believe the current data analysis software has reached a suitable level for research of at least 
recombinantly expressed or reconstituted protein complexes (184). 
 Previous Work: Multifunctional Cross-Linkers 
In order to alleviate some of the complexity in data analysis posed by traditional CXMS, many forms of 
supplemental functionality have been proposed including isotopic labelling , enrichable tags,  reporter tags, 
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and cross-linker cleavability (reviewed in (212,213)). These extra functionalities can be summarised as serving 
three main purposes; enrichment of cross-linked peptides for improved MS sampling, improving visibility of 
cross linked peptides within MS data, and providing extra information to make data analysis simpler. It is very 
common for cross linkers to incorporate at least one of these functionalities, as demonstrated by the 
common use of isotopic labelling as previously mentioned in section 3.5. Due to such benefits, a multitude of 
cross-linkers have been previously published that incorporate mixtures of up to all three of these areas of 
functionalities (see section 3.6). Often the major limiting factor preventing the addition of a number of extra 
functionalities is size and chemical properties of the functional groups being introduced. If the functional 
group is too bulky, it may hinder the ability of a cross-linker from accessing binding domains between 
protein complexes and pockets in proteins. Furthermore if the functional groups are non-polar or charged, 
they may experience solubility issues in water or potentially being subject to polarity specific interactions in 
protein domains (reviewed in section 3.4.1). Most previously published cross-linkers with unique functional 
groups have been reviewed before (213) and therefore have only described in detail when deemed 
appropriate. 
3.6.1. Function 3: Enhancing MS Detection 
Isotopic labelling 
The most commonly utilised type of labelling is isotope labelling. By reacting with a 1:1 mixture of heavy and 
light cross-linkers an easy to identify known mass shift can be observed within the MS1 scans. This approach 
has even been inbuilt to a number of cross-linker sequencing software to aid in cross-link identification 
(209,238,242). Commonly this mass shift is introduced via the introduction of deuterium into chemical 
synthesis but it has been shown too many deuterium ions may shift retention time earlier on RP-LC (243,244). 
Alternatively 13C can be utilised as it does not result in such retention time shifts (245). 
Instead of cross-linker isotopic labelling, peptides may be modified with isotopes during or after digestion. 
By carrying out a trypsin digest in H218O solvent, the hydrolysis reaction incorporates heavy oxygen into the 
peptide C-termini (246,247). T2 cross links will incorporate four new 18O molecules compared to every other 
peptide which will only incorporate two. A 1:1 mixture of H216O and H218O digests will result in a +8 Da mass 
71 
 
shift without any apparent shift in retention time shift (248). Alternatively, by utilising the same principle a 
tryptic digest in partial H218O will result in a predictable isotopic distribution that can be identified using 
software without the need of mixing multiple digests (249). 
Also N-terminal isotopic modifications can be utilised in a 1:1 ratio resulting in a 1:2:1 isotopic shift for T2 
peptides (250). However peptides containing unmodified lysine residues will also display the same shift. 
One of the major issues with using isotopic labelling for cross-linked peptides is the distribution of MS signal 
across multiple peaks. If the signals are close to baseline the isotopic shifts may be completely occluded 
making this approach futile. Furthermore, weakening the signals by isotopic distributions may take the 
signals below LOD after fragmentation resulting in very little information to be obtained. 
Signal enhancement 
Some groups are able to improve the intensity of the signal for cross-linked peptides. For example, JMV3378 
(251) contains the UV absorbing tag a-cyanohydroxycinnamic acid (CHCA) which enhances MS signals when 
using MALDI. 
Reporter ions 
Another commonly published functionality is a reporter ion. These are small molecular components that will 
cleave under weak MS fragmentation energies and will produce a very specific m/z in the MS fragmentation 
spectra. The BID cross linker releases a benzyl group with a m/z of 91 during CID (252), whilst CXLs has a 
clickable handle that when utilised with biotin, can be released during CID to produce a reporter ion (253). A 
quick search for this reporter mass in the fragmentation spectra will very quickly indicate which scans have a 
cross-linker present. In order for this to be viable, the mass needs to be unique from all potential amino acid 
fragment mass combinations so that search algorithms can make a confident confirmation. Furthermore it 
needs to be big enough so that the MS scan range is always able to detect it. Integrated cross-linker reporter 
ions pose an issue as they usually need to be over 200 Da to be confidently detected, making the cross-linker 
bulkier and possibly more non-polar, in addition to adding considerable mass to an already large cross-
linked peptide. 
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3.6.2. Function 3: MS Cleavable Cross-Linkers  
Non-cleavable spacers are difficult to sequence for a number of reasons (reviewed in section 3.5). To resolve 
some of the sequencing difficulties cleavable spacers capable of separating the α and β peptides under 
various treatments including chemical, photodissociation, and CID and ETD MS fragmentation were 
proposed. 
Chemical and photo-cleavable cross-linkers are available but are more difficult to use for structural 
determination. Cleavage of the cross-linker away from the MS trap makes it difficult to identify which 
peptides were originally cross-linked together, but can still be achieved by differential mapping, whereby 
intact cross-linked peptide MS runs can be compared to cleaved MS runs to identify which signals where 
originally cross-links. As cross-linked peptides are more difficult to sequence, the better sequenced cleaved 
linear peptides can be used to help. Alternatively this approach is also useful for freezing PPIs in place, 
permitting dissociation and separate downstream individual protein analysis without the need for harsher 
techniques such as boiling as would be required with formaldehyde. 
Asymmetric MS cleavable spacers on the other hand can be used to provide characteristic mass differences 
that indicate the presence of a cross-linked peptide in MS2 scans, as well as provide the individual α and β 
peptide precursor m/z (Figure 11 A). Cross-linkers such as the NHS-BuUrBu-NHS is able to do this and is 
even able to distinguish between the presence of T0, T1 and T2 based on the way they fragment s. If the 
cross-linker spacer has been designed to be highly susceptible to MS cleavage in preference over the peptide 
packbone (Figure 11 B), indivsidual α and β peptides can be taken forward for MSn scans to unambiguously 
provide the individual peptide sequences (Figure 12). 
Soderblom and Goshe proposed a unique approach to crosslinking. They proposed an in source CID (ISCID) 
cleavable linker whereby the MS1 spectra can be compared before and after ISCID fragmentation (254). The 
fragmented peaks from the MS1 were further subjected to MS2 CID fragmentation. A normal database 
search of the peptides was then conducted with Proline+H or SuD+H modifications. Peptides identified with 
the same or very similar retention times were then assessed to see if their combined mass was originally 
observed in the MS1 without the use of ISCID. If a combined precursor mass was found to be present in the 
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first MS1, but absent or reduced in the  ISCID MS1, it can be assumed that the two peptides were most 
probably in a T2. The major issue with this approach is that the most abundant species in the MS1 are most 
likely native peptides. Therefore the chance of a T2 peptide being captured in this approach would be very 
small in during an automated approach therefore requiring multiple sample replicates in addition to a great 
deal of manual assessment and intervention. 
Spacers that are able to cleave under mild CID conditions such as the PIR linker (255), the S-methyl 5,5′-
thiodipentanoylhydroxysuccinimide linker (256) and the DSSO linker (257) are able to separate the α and β 
peptides in the fragmentation spectra with an additional mass of a cross-linker fragment (Figure 11 B). This 
permits the user to visibly see the precursor m/z of each individual peptide separately. The separated 
peptides obtained from fragmentation can be further fragmented in MSn scans to separately sequence each 
peptide almost making this sequencing approach similar to traditional proteomics. However, traditional 
sequencing cannot occur as even though the individual peptide precursor m/z are available in the 
fragmentation spectra, the charge state of these peaks is difficult to extract upfront. The reason for this is 
that molecular isotopes are isolated during MSn scans making charge state difficult to deconvolute in MS2.  
However, it is still extremely useful to confirm if the precursor mass of a peptide is present after a peptide has 
been database matched or de novo sequenced as it provides an extra level of confidence. 
Furthermore it is important to note that when MS cleavable spacers fragment, they do not normally break 
into equal mass fragments. Therefore when α and β peptides separate a minimum of four fragmentation 
products are normally produced. If the spacer cleaved into equal mass fragments the α and β peptides would 
only separate to form two peaks and the signal gain would be improved providing an extremely valuable 
intensity boost for subsequent MS3 fragmentation (Figure 11 C). In addition the fragmentation spectra will 
be simplified, thus requiring less scans to confidently fragment both peptides. Less fragmentation scans per 
potential cross-link allows for a much greater amount of sampling throughout the entire MS run. This idea 
has recently been studied using a proof of concept cross-linker called identical mass linker (IML) developed 
to produce two identical mass fragments on both the α and β peptides which will potentially remediate the 
issue in future (258). 
74 
 
 
Figure 11. Observable MS2 Fragmentation of MS Cleavable Cross-Linkers. 
The individual masses of cross-linked peptides (i.e. α or β peptides) are different, resulting in α and β m/z
peaks to be observed after fragmentation of MS cleavable cross-linkers. The formation of α and β m/z
singlets or doublets depends on the remaining molecular weight of the fragmented cross-linker, identical 
molecular weight spacer fragments result in singlets, whilst asymmetric spacer fragementation yields
doublets. (a) Traditional cleavable cross-linkers also fragment to produce asymmetric molecular weights and 
therefore result in α and β doublet peaks that indicate the presence of a cross-link in the MS2 data. (b) Low 
energy cleavable cross-linkers preferentially cleave at the spacer compared to the peptide backbones
producing more intense α and β doublets for further fragmentation in the MS3. (c) Low energy cleavable 
identical mass linkers only fragment into α and β singlets, but do not divide the signal intensity, increasing 
the number of ions that are further fragmented in the MS3. 
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Figure 12. MS2 of Low Energy Cleavable Cross-Linkers and Downstream MS3 Fragmentation of Individual α 
and β Cross-Linked Peptides. 
Low energy cross-linker spacers preferentially fragment instead of the peptide backbone. This separates the 
cross-linked peptides into α and β product ions that can be selected for individual MS3 fragmentation. The 
b and y ions produced during fragmentation are either from the α or β peptides, and are sequenced 
individually. 
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3.6.3. Function 3: Enrichment of Cross-Linked Peptides 
A number of designs are available specifically for the enrichment of cross-linked peptides. As native peptides 
normally contribute the vast majority of MS signal, removing these drastically reduces sample complexity. In 
turn, cross-linked peptides will ionise more efficiently and have stronger intensities, and with less competing 
signals they will be more likely selected for fragmentation. Removing native peptides also permits cross-
linked peptides to be loaded at higher concentrations on the MS further increasing intensity of all cross-
linked species. By utilising this approach, less abundant cross-linked peptides normally indistinguishable from 
background or normally below the LOD will benefit the most. 
Petrotchenko et al. proposed a CID cleavable isotopically labelled cross linker with an integrated biotin tag 
(259). Enrichment ensures that only biotin containing peptides are present. The isotopic labelling helps 
isolate which signals correspond to cross-linked peptides. Whilst the two CID cleavable sites can help 
distinguish which fragmentation spectra contain T0 or T2 cross links. In order to analyse this data they also 
developed their own software to analyse data specific to their cross linker. 
Biotin is an enticing affinity tag as it has a relatively small size compared to other tags, is cheap to 
incorporate and capture, and due to its very strong binding affinity with avidin it can be washed more 
stringently than other AP systems. By using avidin, only peptides with a biotinyl group such as cross-linked 
peptides will be captured permitting the removal of native peptides. However, there are some caveats with 
the use of an integrated biotin molecule however. Biotin is a large chemical group (~244.3 Da) and has fairly 
limited solubility, which may affect cross-linker solubility and possibly result in precipitation of cross-linked 
proteins thus affecting downstream sample preparation including proteolytic digestion (260). In addition, 
biotin-avidin binding is very strong, and dissociation requires extremely harsh conditions such as boiling in 
detergents (261,262). Even with such conditions recovery is inefficient and most detergents are not MS 
compatible. On bead proteolytic digestion can be utilised to bypass the harsh chemical elution conditions. 
When ustilisingutilising this approach consideration must be made regarding the amount of predicted 
biotinylated material that will be captured so that avidin and enzyme peptide contaminants do not 
outcompete the desired cross-linked peptide signals in intensity. Furthermore, biotinylation can be 
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endogenously ligated to lysine in vivo and therefore contamination may occur from naturally biotinylated 
proteins (263). 
A more common capture approach however is through the integration of an azide or alkyne handle. By using 
Huisgen’s cycloaddition, more commonly referred to as “click chemistry”, an integrated azide or alkyne 
chemical group can be captured by an alkyne or azide containing capture reagent (respectively) (264). 
Through this approach a great deal of extra functionality to suit the user’s needs can be modularly added 
after cross-linking thereby avoiding interference with the cross-linker efficiency. 
Tan et al. built a range of cross-linkers that contain an azide or alkyne moiety but also have inbuilt cleavable 
linkers containing either sodium dithionite, or photocleavable ortho nitrophenyl groups (265). They may also 
containing heavy isotopes to improve data visibility and or PEG3 to improve solubility. Their dithionite 
containing linkers can also be fragmented with HCD to release a reporter ion. The cross-linker spacers 
however are not MS cleavable. 
Kaake et al. recently developed a novel low energy CID cleavable cross-linker that contained a clickable azide 
handle with an inbuilt acid labile dissociation group called azide-A-DSBSO (266). It can be cleaved in 20% 
formic acid, 20% acetonitrile overnight. A further iteration simplified the number of synthesis steps down to 
six and introduced a similar design but with an alkyne handle (alkyne-A-DSBSO) (267). The major benefits of 
this cross linker is that it is cell permeable, retains it’s flexibility and also breaks well under CID in a similar 
fashion to their previously published DSSO. However the synthesis of these cross-linkers is not trivial 
potentially discouraging smaller biology labs from utilising it until it is commercially available. 
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An alternative enrichment approach entirely, is to cross-link directly on a tethered cleavable linker attached 
to a solid support resin (268)(Figure 14). Following the cross-linking reaction, proteins may be digested, 
native peptides washed off, and then cross-linked peptides eluted off the solid support. In the approach 
proposed by Paramelle, a rink-amide (RAM) cleavable linker has been used which cleaves under high 
trifluoroacetic acid (TFA) concentrations. However there are severe limitations with cross linking on beads. 
When the size of some proteins and protein complexes is taken into consideration, e.g. over 100,000 Da, the 
total length of a small lysine chain and RAM linker would only be able to cross-link superficial lysine residues 
on a protein surface resulting in inefficient cross-linking of deeper pockets and binding grooves, a problem 
that becomes worse with increasing protein and complex size. Cross-linker concentrations are limited to resin 
chemical attachment efficiencies and cannot be adjusted easily according to protein amount without 
adjusting the amount of resin used potentially substantially altering the resin volume. In addition this 
approach would not be suitable for in vivo cross-linking of cells. 
Figure 13. Overview of Azide/Alkyne-A-DSBSO Acid Release System 
After click capture, azide or alkyne-A-DSBSO is designed to be released from the capture matrix using 20%
FA and 20% MeCN overnight. The sulfoxide groups are low energy CID cleavable inside the MS permitting
individual MS3 fragmentation of  α and β peptide ions  (266). 
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Figure 14. Overview of Solid-Phase Cross-Linking (SPCL). 
Proteins are added to beads with covalently attached cross-linkers. The captured proteins are then digested 
on bead and non-covalently attached (i.e. native) peptides are then washed off. Cross-linked peptides are 
then eluted from the solid phase using high concentrations (95%) of TFA. The eluent is then analysed by LC-
MS (268). 
80 
 
To circumvent the issues associated with large integrated tags, smaller and less obstructive attachment sites 
for downstream capture handles may be applied instead. 
An alternative approach that permits in solution capture without a solid phase is an approach proposed was 
to integrate a protected sulphur into a 2-acetylsulfanyl-succinic acid bis-succinimidyl ester (SAMS) linker that 
could be exposed after cross-linking by the reagent N-hydroxylamine and captured using alkylation by a 
capture such as the iodo-containing photocleavable chain, succinimidyl 5-(3-iodo-propoxy)-2- nitro-benzyl 
succinic ester (SSIN), covalently attached to a solid resin support (269). The photocleavable group can be 
light dissociated and the cross-linked peptides may then be analysed by MS. With this approach, biological 
contamination is avoided and due to light dissociation any undesired chemicals can be washed off before a 
chemical free elution into any buffer of choice. It is important to note that cysteine containing peptides may 
also be captured in this approach.  
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Figure 15. SAMS-SSIN Capture system. 
After cross-linking with SAMS proteins are digested and the thiol group is exposed using hydroxylamine. The 
digested mixture is then added to beads containing pre-attached SSIN. The beads are washed to remove 
non-thiol containing peptides. Covalently attached peptides are then eluted using 355 nm UV pulses. The 
eluent containing a mixture of T0, T1 and T2 are then analysed by LC-MS (270). 
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Ligation Chemistry 
In addition to the capture methods proposed alternative ligation chemistries may also be used. One of the 
biggest advantages of using ligation chemistry handles on cross-linkers is the large amount of freedom in 
the choice of downstream strategies that can be utilised. These may include cleavable enrichment tags, 
reporter ions, fluorescence groups, absorbance groups, isotopically labelled groups, as well as many more. 
However, there are some limiting factors in ligatable group designs for CXMS. These include anything that 
may affect MS compatibility such as size, ion suppression and solubility issues. 
Ligation chemistry can be approached using a number of approaches (Table 2). Cross-linkers may contain an 
alkyne, azide or activated alkyne, which all can be very small functional groups. Alkynes and azides may be 
captured using Cu(I)-catalyzed azide-alkyne cycloaddition (CuAAC) (271), azides may also be ligated using 
copper free strain-promoted azide-alkyne cycloaddition (SPAAC) (272) with a number of captures such as 4-
dibenzocyclooctynols (DIBO) (273), bicyclo[6.1.0]nonyne (BCN) (274), and Staudinger ligation (275). 
Alternatively strain-promoted alkyne-nitrone cycloaddition (SPANC) is considered a faster than its azide 
alternative (274,276). Activated alkynes may be captured with tetrazines through inverse-demand Diels–Alder 
reactions (277). Aldehydes and ketones can be captured using hydrazides or aminooxy compounds to form a 
hydrazone (278), or oxime (279) group (respectively). Lastly two terminal alkenes can be joined using a 
Grubbs catalyst in a cross-metathesis ligation (280).  
After click capture, if using a solid support resin or protein capture system such as biotin-avidin, the cross-
linker needs to be efficiently released. If elution is not a straightforward procedure, cleavable sites may be 
introduced into the capture ligand. These cleavable sites may then be dissociated using a range of 
chemistries and techniques summarised in Table 3. 
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Reaction Name Ligation Components Ligation Product References 
 
(271) 
 
(272) 
 
(274,276) 
 
(278) 
 
(279) 
 
(280) 
 
(277) 
 
(275) 
Table 2. Biologically Compatible Chemoselective Ligation Reactions. 
Commonly utilised bio-orthogonal chemistry ligation pairs can be used to modifiy biomolecules (e.g. RNA,
proteins, and peptides), or other bio-molecule interacting small molecules (e.g. small molecule ligands) for the
attachment of desired functional groups (e.g. fluorescent labels, and enrichment handles). From left to right: 
the reaction name, the chemical structure of the ligatable pairs (where R and R’ symbols on each chemical
structure denote attachment sites), the ligation products, and references are outlined. 
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Linker Release 
Mechanism 
Products References 
 
(281,282) 
 
(283) 
 
(284) 
 
(285) 
 
(286) 
 
(287) 
 
(288) 
 
(289,290) 
 
(291) 
 
(281) 
 
(292,293) 
 
(294) 
Table 3. Biologically Compatible Cleavable Capture Reagents. 
Commonly ustilised cleavable chemical groups that can be used for the release of functional groups (e.g.
fluorescent labels, and enrichment handles) that may be covalently attached to biomolecules (e.g. RNA,
proteins, and peptides), or other bio-molecule interacting small molecules (e.g. small molecule ligands).  From
left to right; The linker chemical structure (R and R’ symbols on each chemical structure denote attachment
sites), the cleavage conditions, cleavage product structure, and references for each linker. 
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(222) 
 
(295) 
 
(296) 
 
(297) 
 
(298) 
 
 
(299) 
 
(300,301) 
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(303,304) 
 
(305) 
 
(306) 
Table 3. Biologically Compatible Cleavable Capture Reagents. (Continued) 
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 Technical Challenges and Opportunities 
CXMS has the potential to pick up novel PPI information in throughputs better than those of AP-MS, whilst 
simultaneously providing sites of interaction, orientation of protein complexes, as well as capturing transient 
interactions and is easier to perform compared to to incorporating photoreactive amino acids. Even though 
structural information obtained from cross-linking approaches are very limited when compared to X-ray 
crystallography and 3D-EM, CXMS have the ability to be utilised in native cellular environments such as cell 
lysates, providing a unique role for this technique. However, analysis of cell lysate cross-linknig data is still a 
major challenge as shown by the small number of cross-linked proteins compared to the protein background 
of the cell (6,185). CXMS is also still challenged by false positive peptide identifications owing to the difficulty 
in co-sequencing of peptides, requiring different and more complex sequencing strategies compared to 
traditional peptide sequencing/identification software. In addition to this, it can be argued that without T2 
specific enrichment techniques, a number of lower abundance T2 can be very easily missed from DDA 
fragmentation selection, provide poor fragmentation spectra as a result of a lack of ion abundance, or fail to 
overcome an instrument’s limit of detection. This may be a crucial issue if only few T2 are able to prove the 
existence of proximal sites between two proteins. Therefore CXMS still requires a great deal of method 
development to be able to derive more information regarding cellular interactions than is currently reported 
and still requires a specialist’s eye to ensure data validity. 
Modelling structure from cross-linking data 
The end goal of cross-linking data, in addition to identifying PPI partners, is to generate quick 3D  structures 
for proteins that do not have alternative data already available. Whilst CXMS structural information cannot 
rival that of X-ray crystallography and 3D-EM, identified cross-links can be used in conjunction with 
molecular modelling as constraints to provide better predictive models. A number of software exist (307–310) 
however they do not always necessarily take into consideration maximal distance constraints and cross-links 
that do not agree with the model. A recent software which is able to to also take this factors into 
consideration when using cross-linkers as constraints is XL-MOD (311). As CXMS methods improve, along 
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with the software capability of analysing the data, so will there be an improvement in the modelling data 
owing to a much lesser degree of false positive cross-links and improved detection of lower abundance T2.  
 Proposed Methodology 
Whilst much progress has been made in the field of cross-linking, it still is not a technology that is easily 
accessible. There is still a great deal of room for development and even though efforts have been made to 
make the technology simpler and easier to access to the wider scientific community, data analysis is still a 
highly complex task that requires specialist software and understanding followed by careful validation. As a 
result this research field is still limited to an experienced cluster of research groups and advertising it as a 
ready to use technology may only result in distrust in the field. The cross-linking community as a whole are 
working in a great deal of many ways to try and alleviate the issues in CXMS ranging from developing better 
software, to developing new cross-linker reagents and workflows to improve the quality of data. 
We believe there are three key areas that need to be taken into consideration when conducting any form of 
CXMS, so that it can become a more easily accessible technology: 
1. Cross-Linked peptides need to be specifically enriched so that native peptides are unable to compete or 
interfere. 
2. From the remaining cross-linked peptide pool the T0 need to be differentially enriched from the T2s as 
they also provide a great deal of competition. 
3. The cross-linker should be highly sensitive to MS fragmentation so that each peptide is able to be 
fragmented further separately thus reducing ambiguity in sequencing. 
NHS reactive chemistry 
The original goal of this project was to use already available CXMS methods to study chromatin complexes 
that had no structural information previously identified. Wide selections of unique and interesting cross-
linkers have been previously published and some made commercially available. It was expected that data 
analysis would be far simpler to conduct to begin with if the cross-linker was homobifunctional and residue 
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specific. As NHS primary amine reactive chemistry was well studied and widely utilised it was considered the 
best approach. Furthermore, histones tails are key in interacting with protein complexes and are highly 
abundant in lysine residues considering their short lengths. Even though histone tails can carry a wide PTM 
variety therefore making them inert to NHS, the likelihood of every single lysine residue carrying a PTM at 
any given interaction seemed low. Fortuitously histone H3 tails also carry a number of threonine and serine 
residues which may also be targeted using NHS chemistry.  
MS CID cleavable spacers 
Commercially available irreversible cross-linkers such as DSS and BS3 were already accessible with published 
enrichment strategies and analysis software (reviewed in section 3.5). This approach seemed the most 
simplistic to adopt, but further reading brought to light many limitations with detection and sequencing of 
T2 species. The ability to separately sequence peptides from reversible cross-linkers seemed a much more 
promising avenue. At this stage commercially available MS cleavable cross-linker spacers such as DSSO were 
limited, and in house synthesis of previously published cross-linkers was required for the specifically desired 
functionalities. As SuDP had already been tested by a number of publications, it appeared to be a promising 
candidate owing to the easy synthesis, a CID cleavable spacer, including the simply alterable chemistry to 
improve/remove polarity, charge, in addition to other functions by changing the amino acid composition 
(211,254,312). Whilst SuDP was reported as an in source cleavable linker, it was presumed that it would also 
be a preferable cleavage pathway in low energy MS2 CID. 
A large amount of work with SuDP then followed, initially using general transcription factor 2 E (GTF2E) and 
involving a number of different approaches. GTF2E was first cross-linked and separated using SDS PAGE, 
followed by in gel digestion and nanoLC-MS/MS (note normal MS2 fragmentation was used at this stage). 
Public accessible cross-linker software were not designed for low resolution instruments such as a LIT 
instruments, and therefore was processed using a normal Sequest search to identify T0 and native peptides 
and to observe any nanoLC chromatographic and fragmentation patterns that may have been used to our 
advantage for a manual data search and de novo sequencing. Failing this, we were at least able to exclude 
non T2 spectra, however the results showed no indication of cross-linking. As it had been previously noted 
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that T2 peptides have difficulty from escaping acrylamide gels (212,313), the same process was utilised with 
in solution digestion instead, but still did not yield results. 
Owing to small amounts of GTF2E material we were provided, it was decided to optimise the method using 
human serum albumin (HSA) instead due to ease of availability, cost and a published crystal structure. Again 
the same in solution digestion approach was attempted, this time manually searching for T2 masses expected 
to be observed based on the previously published crystallography data, however this also did not prove 
successful. It was presumed that the failure in T2 detection was due to the low abundances of T2 species. A 
priori RP C18 chromatographic separation of in solution digested untreated and cross-linked HSA was 
fractionated and systematically infused followed by manual searching for expected cross-linked T2. After this 
failed, peaks that differed between the control and treated were also targeted for fragmentation and manual 
assessment. 
Introducing optional enrichment of cross-linked peptides 
During this process it had become increasingly apparent that finding T2 amongst T0 and native peptides was 
a very difficult task and would require the use of an enrichment strategy. It has even been reported that 
enrichment strategies may increase the number of observed cross-links by up to 97% from the total number 
of total peptides detected (265). By enriching cross-linked peptides, the MS samples could be analysed by 
LC-MS at a higher concentration, improving signal to noise particularly benefiting low abundant species. As 
the full cross-linking procedure had not been finalised at this stage, a modular approach provided the best 
scope for later refinement. Click chemistry permits a very large degree of freedom in choosing the most 
desirable capture system as the click counterpart can be added to biotin, or even incorporated into peptide 
sequences for highly specific antibody enrichment such as HA or FLAG. By incorporating an azide, the choice 
of click chemistry utilised could have been either CuAAC or, in the event copper interfered with later stage 
processes, SPAAC (reviewed in 3.6.3). However, the azide could be damaged in the presence of reducing 
agents such as DTT or TCEP (314) and it was important at this stage to keep these options available as a large 
number of biological procedures require reducing agents for redox equilibration and preservation of 
disulphide bridges and protein structure. Therefore an alkyne handle was selected, limiting our ligation 
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chemistry to CuAAC but widening our scope for structure preserving buffers during cross-linking. This was 
first attempted using a variation of SuDP whereby an alkyne chain was introduced before the aspartic acid to 
produce SuG(alkyne)DP. This was first trialled without the use of the enrichment group using the same HSA 
procedures that were used with SuDP, and resulted in similar difficulty in observing T2 cross-links, but 
produced the same offline chromatographic traces as SuDP for both HSA control and cross-linked tryptically 
digested peptides as detected by 215 nm absorbance. However, upon closer inspection of the fragmentation 
of SuG(alkyne)DP by itself it was apparent that the number of fragments that were being produced were 
going to result in too many fragments and therefore the design was discarded. 
Another previously reported CID cleavable cross-linker was Petrotchenko’s 
CyanurBiotinDimercaptoPropionylSuccinimide (CBDPS) which also had a relatively simple synthesis with a 
small number of synthesis steps (259). This spacer was reported as an MS2 cleavable indicator for the 
presence of a cross-link (later understood to mean production of MS2 spectra similar to Figure 11, A, and as 
reviewed in section 3.6.1). However, the spectra shown in the publication showed promising MS2 cleavage. 
This combined with other small molecule work in our group with thioether containing compounds showed 
ease of cleavability under CID and it was presumed that this in conjunction with the rigidity of the central ring 
the thioether might be encouraged to preferentially fragment at this site permitting the desired low energy 
MS2 fragmentation and subsequent MS3 fragmentation of separated peptides (Figure 11, B). The original 
CBDPS (Figure 16, A) had an incorporated biotin moiety, however this was deemed too large a handle to 
work with (reviewed in 3.6.3). As the synthesis was straightforward it was expected the biotin can be easily 
substituted for an alkyne handle, in this case for propargylamine, to make CPDPS instead which was 
successful. 
91 
 
 
This time the cross-linker was immediately tested using a control peptide system. Whilst CID had proven 
disappointing as a preferred fragmentation pathway, ETD proved to be a much better alternative at 
permitting MS2 cleavage of intact peptides followed by MS3 CID fragmentation of individual peptides. It was 
decided to change tact, with an alternative protein capable of forming protein complexes. The new protein 
chosen was bovine catalase, a tetramer with a crystal structure available and a very good distribution of 
proximal lysine residues. However, finding T2 in catalase using a nanolLC-MS/ETD-MS/CID-MS procedure 
without enrichment still posed an issue. 
 
 
Figure 16. CBDPS and CPDPS. 
(a) CyanurBiotinDimercaptoPropionylSuccinimide (CBDPS) as initially described by Petrotchenko et al 2012
(259) and (b) CyanurPropargylDimercaptoPropionylSuccinimide (CPDPS) produced by our lab. The avidin 
enrichable biotin handle on CBDPS was considered too bulky and restrictive in its application and was
therefore exchanged in CPDPS for a propargyl group instead. The propargyl group can be ligated to an azide 
attached to a desired funtional group by utilising using Cu(I)-catalyzed azide-alkyne cycloaddition (CuAAC). 
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Capture and release 
Throughout testing of SuDP, SuG(alkyne)DP and CPDPS, capture of our enrichment group appeared to be 
necessary. As the avidin-biotin capture pair is widely utilised as a means of purification and is also relatively 
inexpensive it was chosen as the preliminary capture system to be utilised. It was already known that 
releasing biotin from avidin was extremely difficult. To compensate for the poor recovery of samples in harsh 
chemical conditions a number of cleavable linker strategies have been developed over recent years (315). 
Owing to the chemical free cleavable nature of photocleavable o-nitrobenzyl ether derivatives, a proposed 
peptide synthesisable linker, Biotin-PEG3-Photolabile-Pentanoic Azide (BPeg3PA) (Figure 17, A), was 
designed and synthesised but failed to dissociate at a wavelength of 366 nm. 
A 95% TFA cleavable linker, Gly-Lys(Biotin)-Rink amide-Pentanoic azide (GKBRA) (Figure 17, B), was therefore 
proposed, but the range of avidin beads available on the market were unsuitable for use. An alternative 
unbound avidin capture system utilising molecular weight cut off filters (MWCO) was developed however 
again the method was unsuitable. 
By this stage in the project cleavable linkers were becoming commercially available. Biotin-PEG3-Diol-Azide 
was purchased and tested with a protein click reaction kit. Click chemistry with CPDPS alone appeared to 
work, followed by dissociation from avidin. However when it was attempted to cross-link control peptides, 
click, bind and dissociate, appeared to work but the data did not make sense as highly clean (from click 
reagents) control peptides had eluted, however did not contain a triazole moiety. At this stage my PhD 
funding had run out and I was no longer able to continue lab work and further explain the reasoning behind 
this bizarre result. 
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A. Biotin-PEG3-Photolabile-Pentanoic Azide 
 
B. Gly-Lys(Biotin)-Rink amide-Pentanoicazide 
 
C. Biotin-PEG3-Diol-Azide 
  
Figure 17. Cleavable Biotin Click Captures Synthesised. 
Proposed avidin enrichable reagents that can be ligated using CuAAC and released off of and avidin capture 
matrix using previously reported release mechanisms. (a) Biotin-PEG3-Photolabile-Pentanoic Azide can be 
cleaved using 366 nm light. (b)  Gly-Lys(Biotin)-Rink amide-Pentanoicazide is cleavable using 95% TFA. (c) 
Biotin-PEG3-Diol-Azide can be cleaved using 10 mM sodium periodate. 
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T0 removal 
In a simple control peptide cross-linking experiment the T0 formed cannot outcompete T2 links in terms of 
intensity or signal number. However in order to provide the best chance for the T2 to be fragmented, T0 can 
be removed before the enrichment stage. When using primary amine reactive chemistry a rather simple 
solution presented itself. As NHS esters takes up to 8 hours to become fully hydrolysed in water, they are 
often forcefully quenched using molecules containing primary amines such as ammonium bicarbonate, 
glycine or tris so that non-specific reactions would not be able to occur in downstream processing. Instead, 
by quenching with a biotin containing a primary amine such as lys-biotin or other similar available 
compounds, the vast majority of normally problematic dead end is theoretically removable by utilising avidin 
containing magnetic beads (see section 3.12 and Figure 32). This approach was able to remove the vast 
majority of T0 links, whilst it cannot completely eradicate T0s as during the 30 minute reaction time some 
cross-linkers had hydrolysed, lowering their intensity to a level equal or below T2 peptides will give T2 links a 
far greater chance of being selected for fragmentation. In future analysis of specifically the dead end residues 
can be achieved by using a cleavable biotin lysine quenching group. 
A proposed workflow to improve and maximise T2 detection in cross-linked data 
The overall goal of the work was to maximise the chance of detecting T2 cross-links and fragment them 
independently of each other to improve the confidence in peptide identification. To best achieve this we 
propose the following T2 specific enrichment workflow (Figure 18). Following cross-linking (Figure 18, step 1), 
unreacted cross links should be quenched using an amine containing capturable handle (Figure 18, step 2). 
Proteins should be digested, ideally using something that can generate C-terminal charges such as trypsin 
(Figure 18, step 3). Competition from native peptides should be substantially reduced and intensity of T2 
peptides should be increased, both of which can be done more practically through enrichment strategies 
compared to labelling techniques. T0 are also important for identifying solvent exposed regions, however 
their intensity and number will outcompete T2 for MS sampling. By capturing T0 orthogonally to T2 (Figure 
18, steps 4, 5 and 6), T2 links will have best chance of being sampled and maximising the amount of cross-
linking information obtained. However, it is just as important to separately analyse cross-linked peptides to 
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maximise confidence in peptide identifications. This can be achieved by using a DDA search targeting higher 
charge state peptides with a larger precursor mass >1300 Da, followed by preferential cross-linker 
fragmentation in the MS2, and lastly individual fragmentation of the cross-linked peptides (Figure 18, step 6). 
Figure 18. Proposed T2 Enrichment and Fragmentation Workflow. 
(a) A recombinant or purified protein complex (red green and blue circles) is treated with a low energy MS 
cleavable cross-linker with an integrated enrichment handle (purple triangle). (b) The cross-linker is quenched 
using an amine containing capturable quench group (orange star). (c) After proteins are denatured and
proteolytically cleaved, (d) the majority of T0 cross links can be removed using the quench capture (orange 
circle). (e) The alkyne handle on the cross-linker can be enriched with a capture material of choice (purple 
circle) provided it contains the corresponding group, and unmodified peptides can then be washed away. (f)
The T2 peptides are eluted and the preferential MS cleavable nature of the cross-linker preserves the 
peptides so that they can be individually fragmented in the MS3 (T0 may also be eluted for surface residue 
identification). (g) Individually fragmented peptides are sequenced and the PPI interactions are elucidated. 
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 Materials and Methods 
Fmoc-amino acids and solid phase support resins were all from Merck Millipore unless otherwise stated. All 
HPLC and LC-MS grade solvents and respective additives were purchased from Fisher Scientific. The control 
peptides, FmocRGAAKAAAR and FmocRVAAKAALR, were purchased from Eurogentec. Pyridine, piperidine, 
dimethylformamide (DMF), trifluoroacetic anhydride (TFAA) and dimethyl sulfoxide (DMSO) were all 
purchased from Sigma as anhydrous. All other chemicals and reagents were purchased from Sigma, UK at the 
highest grade/purity unless otherwise stated. GTF2E fractions was provided at by Gary Leroy from the Garcia 
lab. 
3.9.1. Synthesis 
General peptide synthesis 
All reactions were carried out at room temperature (~20-22 °C) using solid phase peptide synthesis in a 25 
mL SPPS glass vessel with a medium frit (Chemglass). All steps were gently mixed using a rotator. Synthesis 
was initiated on the application described solid-phase support containing a pre-attached amino acid residue 
with base sensitive Fmoc N-terminal protection adjusted to 110 µmol. To initially activate, resin was swollen 
in 20 mL dimethylformamide (DMF) for 1 hour. The Fmoc deprotection steps were carried out using 10 mL 
20% piperidine in DMF for 10 mins. The solvent was discarded and washed twice using DMF. The 
deprotection and wash steps were repeated another two times. During the deprotection steps, a separate 
glass vial was used to activate 5 equivalents (Eq) (550 µmol) of the amino acid to be used for the next 
elongation step along with 5 Eq Hydroxybenzotriazole (HOBt) (550 µmol) and 5.5 Eq of N,N-
diisopropylcarbodiimide (DIC) (605 µmol) for 20 mins in minimal amounts of DMF for complete solubility and 
made up to a volume of 2 mL in chloroform (CHL). The activated amino acid solution was then added to the 
SPPS reaction vessel and left to react under argon for 90 mins. The resin was then washed three times in 20 
mL DMF. The Fmoc deprotection, washing and activations steps would be repeated depending on the 
number of amino acids needed for elongation. 
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To release of the resin three washes of 20 mL DMF were used to remove any unreacted material followed by 
two 20 mL washes of CHL. Resin cleavage of acid sensitive Novasyn TGT resins was conducted using five 5 
mL washes of 1% TFA in CHL followed by 3 more washes using CHL alone. NovaTag resins were cleaved 
using 95% TFA in CHL instead. After resin cleavage eluents were pooled, reduced in volume using rotary 
evaporation, extracted using five 2 mL washes of H2O, dried to completion and using rotary evaporation and 
stored at -20 °C. 
SuDP and SuG(alkyne)DP peptide synthesis 
SuXnP synthesis was carried out as reported by (254,313). For the synthesis of SuDP and SuG(alkyne)DP, 
Novasyn TGT was purchased with pre-attached proline. Fmoc-Asp(OtBu)-OH followed by Fmoc-Pro-OH was 
used for elongation of SuDP. Fmoc-propargyl-Gly-OH followed by Fmoc-Asp(OtBu)-OH and Fmoc-Pro-OH 
was used for elongation of SuG(alkyne)DP. 
SuXnP N-terminal expansion to COOH 
The newly exposed N-terminus of D(OtBu)P and G(alkyne)D(OtBu)P was expanded into a carboxylic acid by 
reacting it with 100 mg (1 mmol, 9 Eq) of succinic anhydride for 1 hour in 2 mL DMF. Three washes of 20 mL 
DMF were used to remove any unreacted material followed by two 20 mL washes of CHL. Peptides were then 
cleaved from the resin as described above. The purity of these products was assessed using HPLC at 215 nm 
(Figure 20). The SuXnP water fractions were separated into three fractions and dried to completion and stored 
at -20 °C. 
SuXnP esterification and Asp (OtBu) deprotection 
Before each cross-linking reaction, each fraction corresponding to 33% of each SuD(OtBu)P and 
SuG(alkyne)D(OtBu)P batch would be esterified overnight and deprotected on the day of use in order to 
minimise the amount of hydrolysis taking place. 3 Equivalents of di(N-succinimidyl)oxalate (110 μmol) would 
be added to each SuD(OtBu)P and SuG(alkyne)D(OtBu)P fraction, and solubilised in anhydrous MeCN and left 
to react under argon overnight. 1 mL CHL would be added and the organic layer washed 3 times with 5% 
sodium hydrogen carbonate (NaHCO3) in H2O. The CHL layer was dried under argon then deprotected in 
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95% TFA, 5% H2O. To the solution, 1 mL CHL was added and washed three times with 3 mL in H2O. The CHL 
layer was dried and the and NHS-SuDP-NHS or NHS-SuG(alkyne)DP-NHS was then weighed and immediately 
dissolved into anhydrous DMSO at the required concentration and used. Unused esterified products were 
discarded. 
CPDPS synthesis 
To 184 mg (1 mmol) of cynauric chloride, 700 µL of acetone (ACN) and 700 µL of water was added and 
stirred on a magnetic hotplate stirrer. 240 mg (2 Eq, 2 mmol) of methyl-3-mercaptopropionate was added 
dropwise to the mixture on ice. Sodium carbonate (Na2CO3) was added until the solution was pH 8, the 
reaction temperature was adjusted to 35-40 ˚C and was left stirring for 1 hour with periodic checking of the 
pH which was re-adjusted to pH 8 when necessary. The remaining ACN was removed via a rotary evaporator. 
The desried product 1 (Figure 19) was shaken with chloroform (CHL) and then the organic fraction was 
washed three times using brine water. The CHL layer was dried and the remaining pale yellow oil was 
reconstituted into 700 µL of ACN and 700 µL of water. While mixing on a hotplate stirrer 55 mg (1 mmol, 1 
Eq) of propargylamine was added and the pH adjusted to 8. The reaction temperature was raised to 35-40 ˚C 
and left to react for 1 hour with periodic adjustment of the pH to 8. After the reaction, any remaining ACN 
was evaporated using a rotary evaporator. 5 mL CHL was added to the remaining water and the mixture was 
shaken vigorously. The CHL layer was washed three times using brine water and then dried down using a 
rotary evaporator leaving behind compound 2, a yellow/orange oil of ~70% purity. The oil was dissolved in 5 
mL tetrahydrofuran (THF) and on ice 1 mL of 2 M NaOH was added and left stirring overnight at room 
temperature to deprotect the carboxyl groups. The remaining THF was removed using rotary evaporation 
and the basic mixture was washed three times with 10 mL dichloromethane (DCM) which was able to remove 
the majority of contaminants. The basic solution was acidified below pH 3 using 6 M HCl on ice to form a 
cream coloured precipitate which was filtered and washed twice with ice cold 1 m HCl. The precipitate was 
then re-solubilised through the filter using ACN and then dried to form an off white coloured solid using a 
rotary evaporator to yield compound 3 with ~96% purity as assessed by HPLC at 215 nm (Figure 25). Failing 
precipitation, the acidified product was extracted with using ten 10 mL CHL washes and dried under rotary 
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evaporation to leave behind a product with ~90% purity. Upon completion of drying, batches were flushed 
with argon to prevent condensation during storage at -20 °C. 
CPDPS esterification 
On the day of a cross-linking experiment, 10.3 mg (30 µmol) of dicarboxyllic CPDPS (compound 3), 17.3 mg 
(150 µmol, 5 Eq) of NHS was added and both were fully solubilised in 150 µL anhydrous DMF. To this 
solution, 24.8 µL (180 µmol, 6 Eq) of trifluoroacetic anhydride (TFAA) and 14.6 µL (180 µmol, 6 Eq) of pyridine 
would be added on ice. The solution would then be flushed with argon and shaken vigorously for 1 hour at 
Figure 19.  Schematic synthesis scheme for CPDPS synthesis. 
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room temperature. To the reaction mixture, 1 mL CHL was added and the organic layer was then washed 
three times using 10 mL 5% NaHCO3. The chloroform would then be evaporated to leave behind a dark 
yellow resin (compound 4). This would then be weighed and immediately immediately solubilised in 
anhydrous DMSO and immediately added to the solution requiring cross-linking. Any unused solubilised 
diesterified CPDPS would be discarded. 
Biotin-PEG3-Photolabile-Pentanoic Azide synthesis 
Biotin-PEG3-Photolabile-Pentanoic Azide was synthesised using the above peptide synthesis method with 
exception to the first ligation step which was conducted using DIPEA (5 Eq) and HATU (2.5 Eq) instead of DIC 
and HOBt. NovaTag resin was purchased with pre-attached Biotin PEG 3. Fmoc-Photolabile Linker (Santa Cruz 
Biotech) followed by (S)-Fmoc-2-amino-5-azido-pentanoic acid (PolyPeptide group) Fmoc-Pro-OH was used 
for elongation of SuDP. Cleavage from the NovaTag resin was performed as described previously. 
Gly-Lys(Biotin)-Rink amide-Pentanoic azide synthesis 
Owing to the acid sensitive nature of the Rink Amide linker, Novasyn TGT resin pre-loaded with Glycine was 
used. Fmoc-Rink amide linker (Sigma) was added followed by (S)-Fmoc-2-amino-5-azido-pentanoic acid. 
Cleavage from the NovaSyn TGT resin was performed as described previously. 
LC-MS product identification checks 
All synthesised products were examined for identity using LC-MS. Products were chromatographically 
resolved on an Ultimate 3000 RS-LC-nano System (Dionex), first loaded onto an Acclaim PepMap RSLC 
Nano-Trap Column, C18 stationary phase, 5 µm particle size, 100 Å pore size, 100 μm internal diameter, 20 
mm length (Thermo Fisher) using a loading buffer comprised of 0.1% TFA, 0.5% acetonitrile (MeCN) and 
95.4% H2O running at 3 µL/min, switching after 3 mins onto an Acclaim PepMap100, C18 stationary phase, 2 
μm particle size, 100 Å pore size, 75 μm internal diameter x 150 mm length column (Thermo Fisher). The LC 
gradient conditions comprised of a flow rate of 0.3 μL/min and a gradient starting at 1% B (5% H2O, 95% 
MeCN, and 0.1% formic acid (FA)) and 99% A (0.1% FA and 100% H2O) and increased to 50% B over 20 min 
followed by an increase to 95% B over 5 mins. Real-time tandem mass spectra were acquired on an LTQ 
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Velos Pro linear ion trap (Thermo Scientific) with a 30 min acquisition time. Peptides were analysed using a 
50–1800 m/z scan range and CID fragmentation using normalised collision energy (NCE) of 35. Tandem mass 
spectra were collected using data-dependent acquisitions for the top 7 intense peaks, with a dynamic 
exclusion list (repeat count of 2, repeat duration of 10 seconds, exclusion list size 100, and exclusion duration 
of 30 seconds). Fragmentation spectra were manually examined to confirm the identity of the synthesised 
products. 
LC purity checks and fractionation 
After confirming the synthesised product identities using LC-MS, compounds were suspended into 200 µL of 
LC loading buffer comprised of 97.5% H2O, 0.5% MeCN and 2% TFA (v/v/v). Peptides were 
chromatographically resolved on an UltiMate 3000 HPLC (Dionex) with a Ascentis Express fused core, C18 
stationary phase, 2.7 µm particle size 4.6 mm internal diameter x 100 mm length column (Sigma). The LC 
gradient conditions comprised of a flow rate of 0.5 mL/min and a gradient starting at 0.5% B (3% H2O, 95% 
MeCN, and 2% TFA) and 99% A (97.5% H2O, 0.5% MeCN and 2% TFA) and increased to 95% B over 20 min. 
Peptides were detected using a 215 nm wavelength and fractions were collected every 1 minute. Fractions 
would be dried using vacuum centrifugation and stored at -20 °C until they were ready for further use. 
3.9.2. GTF2E Cross-Linking 
GTF2E cross-linking 
General transcription factor IIE (GTF2E) subunit 1 (GTF2E1) and subunit 2 (GTF2E2) were purified in 
physiological conditions by a collaborative lab. GTF2E was supplied in a 50 mM Tris buffer, 150 mM NaCl 
buffer at pH 7.5. Due to incompatibility of Tris with cross-linking experiments, it was dialysed into 100 mM 
sodium phosphate buffer, 25 mM NaCl pH 7.5 at 4°C overnight. The number of linkable sites on GTF2E 
including lys, tyr, thr and ser was calculated to be 175:1 protein complex. To prevent excessive formation of 
T0, a ratio of ~1:1 target amino acid to NHS was desired. Therefore NHS-SuDP-NHS was dissolved in 
anhydrous DMSO at a concentration of 20 mM and 1.12 µL was added to 40 µg of GTF2E (~0.48 nmol) for a 
final concentration of 424 µM NHS-SuDP-NHS in a reaction volume of 100 µL. The reaction was allowed to 
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proceed on a shaker for 30 mins and quenched by adding 1 µL of 2 M Tris-HCl for a final concentration of 20 
mM. The quenching of cross-linker was left shaking for a further 15 mins. 
GTF2E in gel digestion 
20 µg of cross-linked GTF2E was run on a 15% SDS protein gel stained with coomassie to assess the outcome 
of the cross-linking reaction. The bands, for GTF2E that had an apparent molecular weight of 68 kD 
corresponding to cross-linked homodimeric GTF2E2, 90 kD representing heterodimeric GTF2E1 cross-linked 
to GTF2E2, and 112 kD corresponding to homodimeric cross-linked GTF2E1 were then excised, reduced with 
10 mM DTT in 100 mM ammonium bicarbonate pH 8. The newly exposed disulphides were protected with 55 
mM iodoacetamide in 50 mM bicarbonate pH 8. The proteins were proteolytically cleaved using trypsin 
(Promega, UK) at a concentration of 12 ng/µL at 37 °C overnight in ammonium bicarbonate pH 8 and the 
next day extracted from the gel and desalted using tips packed with C18 solid phase extraction (3M Empore, 
UK). Samples were dried and stored at -80°C awaiting MS analysis. 
GTF2E in solution digestion 
Cross-linked GTF2E was reduced using 5 mM DTT in 100 mM ammonium bicarbonate pH 8 for 1 hour at 51 
°C. The cysteine residues were alkylated in the dark at room temperature using 14 mM iodoacetamide in 50 
mM ammonium bicarbonate. The proteins were proteolytically cleaved using trypsin (Promega, UK) at a 1:50 
trypsin to protein ratio at 37 °C for 8 hours in ammonium bicarbonate and desalted using tips packed with 
C18 solid phase extraction (3M Empore, UK). Samples were dried and stored at -80 °C awaiting MS analysis. 
GTF2E LC-MS analysis 
In gel digestion samples and in solution digestion samples were reconstituted into an MS loading buffer 
containing 99.4% H2O, 0.5% MeCN and 0.1% TFA (v/v/v). Peptides were chromatographically resolved on an 
Ultimate 3000 RS-LC-nano System (Dionex), first loaded onto an Acclaim PepMap RSLC Nano-Trap Column, 
C18 stationary phase, 5 µm particle size, 100 Å pore size, 100 μm internal diameter, 20 mm length (Thermo 
Fisher) using a loading buffer comprised of 0.1% TFA, 0.5% MeCN and 95.4% H2O running at 3 µL/min, 
switching after 3 mins onto an Acclaim PepMap100, C18 stationary phase, 2 μm particle size, 100 Å pore size, 
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75 μm internal diameter x 150 mm length column (Thermo Fisher). The LC gradient conditions comprised of 
a flow rate of 0.3 μL/min and a gradient starting at 1% B (5% H2O, 95% MeCN, and 0.1% FA and 99% A (0.1% 
FA and 100% H2O) and increased to 50% B over 60 min followed by an increase to 95% B over 10 mins. Real-
time tandem mass spectra were acquired on an LTQ Velos Pro linear ion trap (Thermo Scientific) with an 80 
min acquisition time. Peptides were analysed using a 340–1800 m/z scan range and CID NCE of 35. Tandem 
mass spectra were collected using data-dependent acquisitions for the top 7 intense peaks, with a dynamic 
exclusion list (repeat count of 2, repeat duration of 10 seconds, exclusion list size 100, and exclusion duration 
of 30 seconds). 
GTF2E LC-MS data analysis 
Initial peptide identification from the LC-MS/MS data was performed using a Sequest search in Proteome 
discoverer 1.3 (Thermo Fisher) against the Uniprot database with GTF2E appended. Reverse decoy false 
discovery rate values of 0.01/0.05 were used (strict/relaxed), allowing for 4 missed cleavages and a 2 Da 
precursor mass tolerance. Dynamic side chain modifications included in the search were targeted to N-
terminus and lysyl residues of +97.1 Da (P), +197.1 Da (SuD) and +312.1 (SuDP). We manually assessed the 
accuracy of the tandem MS identifications reported by Sequest. Manual data analysis then took place 
searching for peptides with a charge equal or greater than 3+ that had been fragmented and contained two 
102 Da mass shift corresponding to the presence of both SuD and P on fragments from each peptide. 
Following this, the corresponding peptide masses would then be summed to see if the original precursor 
mass could be met. De-novo sequencing then ensued if the conditions were met. 
3.9.3. HSA Cross-Linking Analysis 
HSA cross-linking 
Two vials of 500 µg of lyophilised HSA were resuspended in 50 mM Hepes and 200 mM NaCl at a 
concentration of 1 mg/mL with the intention of having one control and one cross-linked sample. The number 
of linkable sites on HSA including lys, tyr, thr and ser was calculated to be 136:1 protein complex. To prevent 
excessive formation of T0, a ratio of ~1:1 target amino acid to NHS was desired. Therefore NHS-SuDP-NHS 
was dissolved in anhydrous DMSO at a concentration of 100 mM and 4.9 µL was added to one vial 
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containing 500 µg of HSA (~7.21 nmol) for a final concentration of 980 µM NHS-SuDP-NHS in a reaction 
volume of 500 µL. The control vial however had 4.9 µL of blank DMSO. Both were placed on a shaker and the 
reaction was allowed to proceed for 30 mins and quenched by adding 1 µL of 2 M Tris-HCl for a final 
concentration of 20 mM. The quenching of cross-linker was left shaking over a further 15 mins. Both vials 
underwent a CHL methanol precipitation, predominantly to remove excess cross-linker from the treated vial. 
Samples were dried in a vacuum centrifuge and reconstituted in 100 mM ammonium bicarbonate. 
Cross-linked HSA in solution digest 
Both control and cross-linked HSA were dried using vacuum centrifugation and reconstituted in 8 M urea in 
100 mM ammonium bicarbonate pH 8. Samples were reduced using 5 mM DTT in 100 mM ammonium 
bicarbonate for 1 hour at 51 °C. The cysteines were alkylated in the dark at room temperature using 14 mM 
iodoacetamide in 50 mM ammonium bicarbonate. The volume was increased to 400 µL to reduce the 
concentration of urea to 1 M. The proteins were proteolytically cleaved using trypsin (Promega, UK) at a 1:50 
trypsin to protein ratio at 37 °C for 8 hours in ammonium bicarbonate and desalted using tips packed with 
C18 solid phase extraction (3M Empore, UK). Samples were dried on a vacuum centrifuge and stored at -80 
°C awaiting LC fractionation. 
Cross-linked HSA LC fractionation 
Dried control and cross-Linked HSA peptides were resuspended into 200 µL of LC loading buffer comprised 
of 97.5% H2O, 0.5% MeCN and 2% TFA (v/v/v). Peptides were chromatographically resolved on an UltiMate 
3000 HPLC (Dionex) with a Vydac TP, C18 stationary phase, 3 μm particle size, 300 Å pore size, 4.6 mm 
internal diameter x 250 mm length column (Grace). The LC gradient conditions comprised of a flow rate of 
0.5 mL/min and a gradient starting at 0.5% B (3% H2O, 95% MeCN, and 2% TFA) and 99% A (97.5% H2O, 0.5% 
MeCN and 2% TFA) and increased to 95% B over 60 min. Peptides were detected using a 215 nm wavelength 
and fractions were collected every 3 mins. The fractions were dried using vacuum centrifugation and stored 
at -80 °C until they were ready for MS analysis. 
MS analysis of SuDP cross-linked HSA fractions 
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Corresponding control and cross-linked HSA fractions were resuspended into 97.5% H2O, 0.5% MeCN and 
0.1% FA (v/v/v) and separately infused at a flow rate of 0.3 µL a minute onto a LTQ Velos Pro linear ion trap 
(Thermo Scientific) using a 150-2000 m/z scan range. Peaks with a charge state equal or greater than 3+ that 
were present in the cross-linked sample but not the control were manually fragmented with CID energies 
ranging from 15-35 NCE CID. Manual data analysis then took place searching for peptides with a charge 
equal or greater than 3+ that had been fragmented and contained two 102 Da mass shift corresponding to 
the presence of both SuD and P on fragments from each peptide. Following this, the corresponding peptide 
masses would then be summed to see if the original precursor mass could be met. De-novo sequencing then 
ensued if the conditions were met. 
Free avidin enrichment of alkyne containing cross-linkers 
Click capture of alkyne containing cross-linked peptides was performed using the click-it protein reaction 
buffer kit (Themofisher) using a total 4 nmol of in house made Biotin-RAM-Azide capture. Lyophilised free 
avidin with a binding capacity of ~41-61 nmol biotin/mg of avidin was dissolved at a concentrating of 1 
mg/mL into 10 mM PBS buffer pH 7.5. To the click reaction 100 µL of 1 mg/mL avidin was added and shaken 
gently for 10 mins at room temperature. The solution was then loaded onto 10,000 Da molecular weight cut 
off filters (MWCO) (Merck Millipore) and spun. The solution was washed with 500 µL PBS buffer for another 8 
times. The MWCO filter was spun until the volume was reduced down to ~50 µl and then transferred to a 
sample tube and dried under vacuum centrifugation. To the dry sample 50 µL of neat TFA was added and left 
to cleave for 1 hour. The spin columns were reportedly compatible with ≤30% TFA and therefore the sample 
was diluted with H2O to a final volume of 200 µL and loaded onto the MWCO filters, spun and the filtrate was 
collected. Another two washes were used and the filtrates collected. The filtrates were then desalted using 
C18 SPE packed tips. The eluents from these were pooled and dried using vacuum centrifugation and stored 
at -80 °C ready for LC-MS analysis. 
Bead bound avidin enrichment of alkyne containing cross-linkers 
Click capture of alkyne containing cross-linked peptides was performed using the click-it protein reaction 
buffer kit (Themofisher) using a total 4 nmol of in house made Biotin-Photocleaveable-Azide capture or 
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Biotin-Diol-Azide (Jena Bioscience). Streptavidin magnetic beads (ThermoFisher) with a binding capacity of 
2.5 nmol biotin/mg of beads come at a concentration of 10 mg/mL. 160 µL of mixed streptavidin magnetic 
beads were washed with twice with 500 µL PBS then added to the click reaction buffer and left to react on a 
shaker for 10 mins at room temperature, and in the dark for Biotin-Photocleaveable-Azide. The beads were 
washed 8 times with 500 µL PBS buffer. Beads bound with Biotin-Photocleaveable-Azide were irradiated 
using a 366 nm lamp for 1 hour on ice with frequent mixing. Biotin-Diol-Azide was cleaved using 10 mM 
sodium periodate (NaIO4) for 20 mins at room temperature. Eluted fractions were desalted using C18 SPE 
packed tips, dried using vacuum centrifugation and stored at -80 °C ready for LC-MS analysis. 
Lys-Biotin quench and T0 removal 
Lys-Biotin was solubilised in water to a final concentration of 100 M in H2O. After 30 mins of cross-linking, 
lys-biotin was added at 25:1 Molar excess to cross-linker. When proteins were being used, excess cross-linker 
was removed by loading the solution onto Vivaspin 500 columns with a 10,000 MWCO (GE Healthcare) and 
wahsed three times uisng 500 µL PBS washes. The solution was then removed from the MWCO filter and 
proteolytically cleaved with trypsin as described above. Magnetic avidin beads would be added with the 
amount adjusted to the concentration of cross-linker used assumed as entirely T0 linked. The biotin would be 
permitted to bind over 10 mins at room temperature on a shaker. The beads were washed three times using 
100 µL of 0.25X PBS, each time collecting the filtrate. The filtrate would then be reduced in volume to 100 µL 
and reacted with azide capture using the click it protein reaction buffer kit, and further processed as reported 
above. 
3.9.4. Control Peptides FmocRGAAKAAAR and FmocRVAAKAALR Cross-Linking 
Control peptides were cross-linked using a 2:1 ratio of peptide (1 mM) to cross-linker (0.5 mM) in 100 µL 50 
mM Hepes and 200 mM NaCl for 30 mins at room temperature using mild shaking and quenched using a 25 
mM Lys-Biotin quench. Samples were desalted using C18 SPE packed tips, dried using vacuum centrifugation 
and stored at -80 °C ready for LC-MS analysis. 
Control Peptides LC-MS Analysis 
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Corss-linked control peptides were reconstituted into an MS loading buffer containing 99.4% H2O, 0.5% 
MeCN and 0.1% TFA (v/v/v). Peptides were chromatographically resolved on an Ultimate 3000 RS-LC-nano 
System (Dionex), first loaded onto an Acclaim PepMap RSLC Nano-Trap Column, C18 stationary phase, 5 µm 
particle size, 100 Å pore size, 100 μm internal diameter, 20 mm length (Thermo Fisher) using a loading buffer 
comprised of 0.1% TFA, 0.5% MeCN and 95.4% H2O running at 3 µL/min, switching after 3 mins onto an 
Acclaim PepMap100, C18 stationary phase, 2 μm particle size, 100 Å pore size, 75 μm internal diameter x 150 
mm length column (Thermo Fisher). The LC gradient conditions comprised of a flow rate of 0.3 μL/min and a 
gradient starting at 1% B (5% H2O, 95% MeCN, and 0.1% FA and 99% A (0.1% FA and 100% H2O) and 
increased to 50% B over 60 min followed by an increase to 95% B over 10 mins. Real-time tandem mass 
spectra were acquired on an LTQ Velos Pro linear ion trap (Thermo Scientific) with an 80 min acquisition time. 
Peptides were analysed using a 340–1800 m/z scan range and CID fragmentation NCE of 35 as well as a 
second scan using ETD with an activation time of 100 ms and no supplemental activation. Tandem mass 
spectra were collected using data-dependent acquisitions for the top 7 intense peaks, with a dynamic 
exclusion list (repeat count of 2, repeat duration of 10 seconds, exclusion list size 100, and exclusion duration 
of 30 seconds). 
 Results and Discussion: Cross-linker Synthesis and MS 
characterisation 
3.10.1. Amino Acid Based Cross-Linkers 
SuDP synthesis 
Due to simplicity of synthesis and alteration in functionality, it was decided that the first cleavable linkers to 
use were those previously published as SuDP, SuVP and SuGDP, abbreviated as SuXP by the Goshe lab 
(211,254,312). The solid phase peptide synthesis (SPPS) synthesis approach proposed by Soderblom worked 
well and resulted in a relatively pure product (Figure 20). The disuccinimidyl oxalate esterification approach 
used by Soderblom to produce NHS-SuXP-NHS resulted in low yields of NHS-SuD(OtBu)P-NHS (56.97% 
SuD(OtBu)P, 8.39% SuD(OtBu)P-Pyridine, 23.18% NHS-SuD(OtBu)P, 6.67% SuD(OtBu)P-NHS, 4.79% NHS-
SuD(OtBu)P-NHS) compared to Soderblom’s reported values of  28%, 55% and 17% respectively (Figure 21). 
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Similar yields were also observed for DIC and EDC active ester formation with even poorer yields experienced 
when using DCC. The purification of diesterified products using HPLC as used by Soderblom seemed counter 
intuitive as hydrolysis will be continuously occurring during fractionation and the water removal process. 
Liquid-liquid extraction of the product in CHL and 5% aqueous sodium bicarbonate (w/w) proved sufficient 
for purification as the diesterified SuDP as it better dissolved into the organic phase compared to the 
unesterified and monoesterified contaminants. 
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Figure 20. HPLC Trace of SuD(OtBu)P Post SPPS Resin Cleavage. 
SuD(OtBu)P Purity Post SPPS Resin Cleavage using 95% TFA as analysed by HPLC at a Wavelength of 215 nm. 
The SuD(OtBu)P peak was fraction collected and identification was confirmed using LC-MS. 
SuD(OtBu)P 
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Figure 21. HPLC Trace of SuDP DIC Esterification Products . 
Un- (57%), mono- (30%) and di- (5%) esterified SuDP after overnight esterification with di(N-
succinimidyl)oxalate as analysed by HPLC at a wavelength of 215 nm. All peaks were collected separately and 
their identities checked using LC-MS. 
 
Figure 22. HPLC Trace of NHS-SuDP-NHS OtBu Deprotection Products. 
Diesterified SuDP after OtBu deprotection in 95% TFA as analysed by HPLC at a wavelength of 215nm. All 
peaks were collected separately and their identities checked using LC-MS. 
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In order to protect the aspartic acid residue on SuDP during esterification, SuDP is synthesised with an acid 
labile t-butyl group during SPPS which is inert to the mild acidic cleavage conditions of the Nova Tag resin. 
However, following on from NHS-SuDP-NHS purification, this protective group requires deprotection in acid 
and water conditions and yet a further round of clean-up steps to remove any newly formed unesterified and 
monoesterified products. Liquid-liquid extraction of the product in CHL and H2O resulted in sufficient purity. 
The finished product characterised by LC-MS also produced fragments that were in keeping with the desired 
final product (Figure 23). 
Figure 23. MS CID Fragmentation Products of SuDP. 
The major fragmentation product of SuDP using CID at 35 NCE corresponds to the retention of the proton 
on the fragmented Proline residue. 
 
SuG(alkyne)DP 
SuG(alkyne)DP was a simple adjustment to make which incorporated the desired alkyne handle (reviewed in 
3.8). However, even during the MS checks to ensure successful synthesis too many fragmentation products 
began to appear. Unlike SuDP which had one major fragmentation product (Figure 23), or the later discussed 
numerous but unconcerning fragmentation products of CPDPS, SuG(alkyne)DP produced a number of 
cleavage products from different parts of the spacer. Should this occur when peptides are attached, the 
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number of MS2 cleavage products would be overwhelming when also taking into consideration different 
charge states. This would inevitably significantly dilute the MS2 peak signals thus resulting in poor signal 
intensities for further MS3 fragmentation, in addition to making it much more difficult to ensure that DDA of 
both peptides in a T2 will occur. 
3.10.2. CyanuricPropargylDiPropionylSuccinimide (CPDPS) 
CBDPS (Figure 16) was another reported CID cleavable linker containing thioethers adjacent to a rigid ring 
which should encourage fragmentation at this site. However, a permanent biotin handle on the linker was not 
considered ideal and therefore it was decided a click chemistry group such as an alkyne was a better 
alternative. Such a chemical is not commercially available and had to be synthesised in house. In the 
publication by Petrotchenko et al. the addition of hydrazidobiotin with cyanuric chloride in an equimolar 
reaction mixture did not result in considerable formation of the di- and tribiotin products (259). We therefore 
attempted two equivalents of 3-mercaptopropionic acid to one equivalent cyanuric chloride but found that 
the chemistry resulted in a spectrum of products to be formed when analysed by LC-MS. Switching to the 
protected methyl 3-mercaptopropionate instead worked well, we also found that this approach did not result 
in considerable amounts of the mono- and di- methy 3-propionate products to be formed (Figure 24). 
Following some clean-up steps the desired product resulted in a 96% pure (as analysed by LC at 215 nm) 
product to be formed (Figure 25). Due to the low yields of DIC chemistry, alternative esterification reactions 
were considered. In situ formation using trifluoroacetic anhydride (TFAA) and NHS (Leonard & Brunckova 
2011) resulted in a very efficient conversion and became the esterification method of choice. 
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Figure 24. HPLC Trace of Dimethyl CPDPS Products. 
Dimethy CPDPS Post CHCl3 extraction as analysed by HPLC at a wavelength of 215 nm. Pekas were 
confirmed using LC-MS. 
Figure 25. HPLC Trace of Dicarboxylic CPDPS Purity Post Acetone Extraction. 
Dicarboxylic CPDPS purity post deprotection of the carboxyl groups using 2 M NaOH and extraction by 
acetone as analysed by HPLC at a wavelength of 215 nm. Products were conformed using LC-MS 
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 Results and Discussion: Application of Cross-Linkers to 
Model Systems 
3.11.1. Amino Acid Based Cross-Linkers 
SuDP Cross-Linking: GTF2E 
Based on the simplicity of synthesis, the in-source CID cleavable SuDP was chosen as the first cross-linker to 
be utilised. It was presumed that the ISCID approach proposed by the Goshe lab still left a lot of ambiguity as 
to which peptides where initially paired, particularly when data analysis was of a whole protein compared to 
control peptides. It was therefore decided to attempt in-trap CID cleavage of the spacer at a lower CID 
energy instead, with the eventual goal of further fragmenting MS2 peaks into the MS3 for individual peptide 
identification. As SuDP had already been tested by a number of publications (211,254,312), it was decided to 
directly attempt to use this cross-linker to obtain structural information for the GTF2E protein complex. 
The GTF2E complex was provided by collaborators who had carefully fractionated a large amount of pure 
complex from human cell lysates under physiological conditions and would therefore be properly folded.  
GTF2E complex is known to form homo and hetero dimers between their p34 (gene GTF2E2 accession 
P29084) and p56 (gene GTF2E1 accession P29083) monomers which can further combine to form a 
heterotetramer (Figure 26) making it an ideal subject to study T2 links. No crystal structure is available, 
however it had a decent number and distribution of cross-linkable residues across it’s sequence making it a 
potentially ideal protein of study. After cross-linking and boiling in the denaturing conditions of laemmli 
buffer, dissociation of the tetramer and dimers into the constitutive monomers (Figure 27 left lane) was 
observed for the untreated control complex, however was not able to dissociate the covalent SuDP cross-
links between the dimers and tetramer (Figure 27 right lane) thus showing that synthesised NHS-SuDP-NHS 
was able to effectively cross-link as expected. 
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Figure 26. Diagrammatic Representation of GTF2E Tetramer and Dimers. 
P56 and p34 can form homodimers and a hetero dimer. They can also form a heterotetramer consisting of
two P56 and two P34 subunits. 
Figure 27. SDS-PAGE Gel of Control and Cross-Linked GTF2E. 
Non-cross-linked TF2E (left lane) and has resolved to form separate p56 and p34 monomers on the gel. After
cross-linking with SuDP (right lane) the bands have resolved according to respective homo and hetero
dimers apparent molecular weights. 
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Following an in gel digest and careful MS data analysis it became apparent that T2 would be notoriously hard 
to find. In our initial experiments we decided to see how simple it would be to observe and identify cross-
linked peptides by utilising a similar approach to irreversible cross-linkers whereby both peptides are 
simultaneously fragmented in the MS2. At the time, cross-linking software was designed primarily for high 
resolution Orbitrap and FTICR instruments and not for LIT data. As an alternative we had decided to use 
Sequest to help us characterise some of the data. Aware that database peptide identification software such 
as Sequest was not designed for the identification of two cross-linked peptides, it was thought that searching 
for SuD and P fragments as chemical modifications could provide a good starting point in highlighting the 
spectra containing T0 cross-linker modifications and native peptides so that they may be excluded from 
analysis. A number of T0 peaks were found containing a range of modifications including SuD, P and SuDP 
modifications. Whilst a number of spectra were discounted from manual analyses, manual interpretation of 
the data in search for T2 links however was extremely slow and difficult and led to no T2 identifications. It 
was presumed that extracting T2s from a protein gel potentially significantly lowered the abundance of T2 as 
they may become trapped in the acrylamide mesh preventing them from being able to effectively escape, an 
issue previously noted, potentially resulting in losses of up to 80% of cross-links (212). It was therefore noted 
that any further analysis would require in solution peptide digests to retain maximal cross-linked peptides. 
Unfortunately numerous unsuccessful attempts were made into identifying T2 peptides from in solution 
digests. 
Work with SuDP highlighted a very important need for cross-linked peptide enrichment to improve the 
chances of detection. T2 are naturally lower in abundance compared to native and T0 peptides. The lack of 
any cross-linker specific enrichment procedures such as SCX or SEC made DDA based approaches extremely 
unlikely to select T2 peaks for fragmentation.  
SuDP and SuG(alkyne)DP Cross-Linking: HSA 
To retrospectively identify potential T2 for further functionality assessment of SuDP and the newly 
synthesised SuG(alkyne)DP, HSA was chosen for study owing to its published crystal structure. Primary 
amines in close proximity to each other (using a maximal distance of 26 Å between Cα of lysine residues) 
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were identified using the PyMol (Version 1.8 Schrödinger, LLC) distance measurement tool with ligand free 
HSA crystallography data obtained from the Research Collaboratory for Structural Bioinformatics Protein 
Data Bank (entry 4K2C)(316). The expected combined precursor masses for peptides that satisfied the 26 Å 
criteria (containing a missed cleavage at the predicted cross-linked lysine residue and aslo including the 
additional mass of SuDP) were calculated. Control HSA and SuDP/SuG(alkyne)DP treated HSA samples were 
both in solution digested and separately injected on the LC-MS. Predicted precursor m/z of cross-linked 
peptides across a number of charge states were manually examined in the SuDP treated data. Alarmingly all 
the predicted m/z ions that were absent in similar retention time regions from the control HSA sample had 
very low intensities, some nearly indistinguishable from baseline compared to other MS signals and were 
never selected for DDA analysis. Even after the most intense peaks were added to an inclusion list, the 
majority of intensities were still not sufficient for DDA fragmentation selection, and when some were 
successfully selected their intensities were too low for meaningful fragmentation spectra. 
To increase the chances of an adequate fragmentation of a T2 peptide, HPLC fractionation of digested 
control HSA and SuDP/SuG(alkyne)DP treated HSA were detected using 215 nm absorbance and compared 
to identify fractions containing absorbance intensity differences (Figure 28 shows SuDP only, however 
SuG(alkyneDP) was identical). Fractions that had the most differences (33 mins – 48 mins) were then 
sequentially infused directly onto the MS. In order to confirm the presence of T2, an attempt was made to 
exploit the preferential cleavability of SuDP (and theoretically SuG(alkyne)DP) on a list of peaks that were 
present in the treated sample but absent in the control. This approach was taken in addition to searching for 
our predicted T2 masses to widen our chances of also including cross-links from further missed cleavages or 
unexpected cross-link products. To do this all highly charged (+3 or more) unique m/z ions from the SuDP 
treated sample were individually fragmented with a range of CID energies to identify the optimal CID energy 
required for SuDP cleavage whilst maintaining peptide backbone integrity. However no fragments were 
preferentially formed at lower CID intensities and all fragments grew equally in intensity as the CID energy 
values were increased, thus not highlighting any obvious T2 candidates. 
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The offline fractionation and manual analysis of each individual unique peak with a range of CID energies still 
resulted in inconclusive evidence as to whether cross-linked peptides were being found at all, or whether 
SuDP truly cleaves under lower energies of CID. Later in depth SuG(alkyne)DP analysis showed that it 
fragmented far too much in a number of different places making it unsuitable for further MS3 peak picking 
and fragmentation. After more careful further reading and a little experience, it is now apparent that some 
published cross-linkers are explicitly described as low energy cleavable whereas others are simply published 
as cleavable thus indicating that some cleavage mechanisms may not necessarily be the most favourable 
compared to peptide backbones. However, at the time this distinction still had not become too clear. 
Nevertheless we questioned the effective cleavability of cross-linked SuDP and decided to use an alternative 
chemistry. 
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Figure 28. HPLC Trace of Trypsin Cleaved Control and SuDP cross-linked HSA Peptides. 
Control and SuDP cross-linked HSA were reduced using DTT, alkylated with iodoacetamide, digested using 
trypsin and analysed by HPLC at a wavelength of 215 nm. Control HSA peptides are represented in blue and 
SuDP cross-linked HSA peptides are in red. The gridlines indicate 3 minute fractionation boundaries. The 
major peak differences can be observed towards the beginning of the chromatogram where the control 
hydrophilic peptides are visibly reduced in the treated samples. In addition towards the end of the 
chromatogram there are more SuDP treated peptides. This can be attributed to the more hydrophobic nature 
of the larger cross-linked peptides. 
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3.11.2. CyanuricPropargylDiPropionylSuccinimide (CPDPS) 
Control peptides FmocRGAAKAAAR and FmocRVAAKAALR rationale 
During the course of experimentation with SuDP and SuG(alkyne)DP it had become increasingly apparent 
that protein cross-linking data analysis was not simple to conduct. Using purified proteins and protein 
complexes had made analysis very complex and time consuming and therefore a number of control peptides 
were experimented with. After a number of iterations it was deemed that the control peptides 
FmocRGAAKAAAR (referred to as RG) and FmocRVAAKAALR (referred to as RV) would be best for 
experimentation and testing of cross-linker functionality including MS cleavage, click capture and chemical 
release. As NHS chemistry was to be used, a suitable lysine containing control peptide was needed for 
experimental analysis before moving on to more complex proteins. The control peptides were designed to be 
alanine rich to encourage lipophilic interactions so that T2 cross links were more likely to form. The Fmoc on 
the N-terminus prevented the formation of T1 links between the N-terminus and the lysine residue. To 
compensate for the N-terminal neutralisation, an arginine residue was selected owing to its ability to 
protonate. The C-terminal residues were also selected to be arginine to mimic tryptic peptides. The control 
peptides also had different molecular weights and different sequences on both sides of the lysine residue so 
that should any peptide backbone fragmentation occur around the lysine, they would be easily identified. 
 
CPDPS control: cross-linking and CID cleavage 
CPDPS cross-linking analysis with the control peptides RG and RV control peptides resulted in an expected 
number of products including RG-T0, RV-T0, RG-T2-RG, RV-T2-RV and the desired RG-T2-RV. Upon further 
analysis into MS2 CID fragmentation with RG-T2-RV it was found that fragmentation at lower CID energies 
(20-25 NCE CID) did not fully fragment the precursor ions. CID energies were varied up to 35 NCE CID (Figure 
29), at which energy the precursor fragment disappeared, however at all CID energies all peaks were growing 
increasingly more abundant at an even rate. Losses corresponding to the Fmoc group were discounted as 
normal peptides would not have them present, however even without these, losses equating to the terminal 
arginine residues were much more intense than CPDPS cleavage at the thioether. In addition there was a 
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significant amount of peptide backbone fragmentation. CID cleavage products produced in the MS2 were 
once again not from the spacer. Attempts were made to deprotect the fmoc group in solution using 
piperidine and DMF however multiple attempts and extraction methods used to remove the piperidine were 
unsuccessful. 
An attempt to use ETD to fragment our spacer did however finally succeed in producing separate peptide 
ions with the highest peak intensities (Figure 30.). Unfortunately charge state reduction induced during ETD 
meant that the most intense fragment species were only singly charged which in turn did not produce 
adequate peptide fragment ions in the MS3, although the fragments ions that were formed were 
outcompeted by losses from the Fmoc group. When the lower intensity +2 ions were targeted by specifically 
ignoring peak picking of the +1 ions, the signal intensity was too weak to obtain meaningful MS3 data. As a 
test, the +2 charged peaks on from T0 links, were the most intense, and produced good fragmentation 
spectra (Figure 31). 
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Figure 29. Annotated MS2 CID Fragmentation of CPDPS cross-linked Control RG and RV T2 Peptides. 
Control RG and RV peptides were cross-linked using CPDPS and analysed by LC-MS. The +4 charge state for 
LC resolved FmocRGAAKAAAR cross-linked to FmocRVAAKAALR was fragmented using 35 NCE. Both images 
(a and b) correspond to the same MS2 spectra where the RG (a) and the RV (b) peptides are annotated
respectively. The peptide backbone fragmentation indicates that CPDPS spacer does not contain a preferred
cleavage site when using CID. 
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Figure 30. MS2 ETD Fragmentation of CPDPS cross-linked Control RG and RV T2 Peptides. 
Control RG (red line) and RV (blue line) peptides were cross-linked using CPDPS (rhombus with purple 
triangle)   and analysed by LC-MS. The +4 charge state for LC resolved FmocRGAAKAAAR cross-linked to 
FmocRVAAKAALR was fragmented using ETD. The most intense fragment ions are CPDPS spacer
fragmentations as opposed to peptide backbone fragments. 
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Figure 31. Annotated MS3 CID Fragmentation of RG and RV Peptides Post T0 MS2 ETD Cleavage of CPDPS 
Spacer. 
Control RG and RV peptides were cross-linked using CPDPS and analysed by LC-MS. The +3 charge states for 
LC resolved FmocRGAAKAAAR (A) and FmocRVAAKAALR (B) T0 peaks were first MS2 fragmented using ETD
to cleave the CPDPS spacer. The top most intense product ions for each RG and RV corresponded to the
peptide with a cleaved CPDPS spacer, and were taken forward separatelt for MS3 fragmentation using 35 
NCE to produce the above spectra for RG (a) and RV (b) peptides.  
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Capturing alkynated cross-linked peptides 
Early attempts into capturing cross-linked products were carried out with click chemistry using biotin-
pentanoic azide. Due to the very strong binding affinity of biotin and avidin, elution of bound biotin occurs in 
very harsh conditions such as boiling and use of detergents. Attempts at dissociation however, did not 
provide adequate release for any detection of captured material. Cleavable linkers that are able to cleave 
under MS friendly or bio-orthogonal approaches would provide a highly useful alternative in releasing 
captured peptides. Once eluted, the cross-linked peptides would then need to be separated from the avidin 
capture system. Two approaches were proposed, the use of bead bound avidin and free avidin. Avidin 
attached to a solid bead such as agarose or magnetic beads can be removed from the elution wash by 
filtration, magnetism or centrifugation. Free avidin can be also be employed and removed after elution via 
the use of molecular weight cut off (MWCO) filters. 
Capturing with azido-photocleavable-biotin 
When work initially begun, cleavable click reagents were not commercially available. A clickable 
photocleavable capture group would permit dissociation at a wavelength of 366 nm without any addition of 
chemicals or risk of damage to peptides from shorter wavelengths and would have been an ideal method of 
dissociation. A photocleavable cross-linker was successfully synthesised in house using SPPS (Figure 17, A). 
However the photocleavage conditions used did not yield sufficient cleavage of the molecule either alone or 
on control peptide systems over a range of different times. The most likely cause for this is that the light 
source utilised was not powerful enough even to penetrate the purposefully thin solvent layer or through the 
agarose beads that were being utilised. This approach was therefore not thought suitable for our needs 
Capturing with azido-rinkamide-biotin 
Due to the inefficient dissociation of azido-photocleavable-biotin, rink amide linker was synthesised (Figure 
17, B). Attempts to dissociate the capture molecule alone resulted in dissociation of the rink moiety. Due to 
the extremely harsh nature of dissociation (95% TFA) the modular approach we desired was somewhat 
restricted to the use of free avidin and the use of MWCO filters as the agarose or magnetic bead bound 
avidin was not compatible with the dissociation reagents. However, after neutralisation the remaining solvent 
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was extremely viscous requiring a large volume for sufficient dilution of viscosity. With smaller MWCO filters 
a large amount of time was required for filtration and repetitive re-loading of the solvent onto the columns. 
Switching to MWCO with much larger capacities was unsuitable as it would have inevitably lead to significant 
loss of the very small concentration of eluted peptides. The SPE C18 based approach was best in terms of 
efficiency of speed and reducing the amount of neutralisation and dilution efficiency. SPE disks can easily 
tolerate 5% TFA and therefore only required dilution as opposed to neutralisation substantially reducing the 
viscosity and volume of dilution. Bu upon analysis, unsatisfactory amount of clicked product was released. 
The underlying reason is unknown but may have been as a result of inefficient binding by the free avidin 
used or as a result of a poor dissociation efficiency of the rink amide liker. 
Capturing with azido-diol-biotin 
Azido-diol-biotin by itself was tested according to user instructions and was found to dissociate in 10 mM 
sodium periodate (Figure 17, C). RV and RG control peptides were then cross-linked, clicked using a CuAAC 
chemistry kit, captured using magnetic bound avidin and washed rigorously. Following cleavage with sodium 
periodate clean cross-linked peptides were detected with very little remaining click reagent contaminants. 
However, the masses observed were exactly the same as non-click captured cross-linked peptides possibly. 
This may have been a result of non-specific binding and subsequent elution although it was unlikely. LC-MS 
analysis of periodate cleaved CPDPS linker alone from mag beads did not yield m/z ions that were 
explainable. Continued work with periodate cleavage from the DiMaggio group showed that the periodate 
cleavage does occur, however protein groups are heavily modified by the periodate contradicting the initial 
publication of sodium periodate/diol  system use as a biologically compatible cleavable linker (317). 
 Results and Discussion: Removal of T0  
A major cross-linking product that was observed both in protein and control peptide cross-linking was T0. As 
not all NHS would have been completely hydrolysed before 30mins we took advantage of the amine specific 
reactivity and quenched with a capturable biotin-lysine molecule. Chromatographic comparison before and 
after T0 avidin removal (Figure 32), shows a large change in the sample composition. LC-MS analysis of the 
sample had a marked reduction in the intensity of T0 peptides observed, although they were still present. As 
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some of the NHS had already hydrolysed by 30 mins complete removal of T0 linkers was not possible 
although their reduction in abundance would still permit much better sampling of T2 via DDA analysis as 
their relative intensity to T0 was much more improved. 
 Conclusions and Future Work 
Owing to the large number of publications that were already available it was assumed that cross-linking was 
a ready to use technology that could be immediately applied to study the interactions involved with 
chromatin. Work with GTF2E and HSA clearly highlighted the chance of finding cross-links in data without 
any enrichment was highly unlikely. Further characterisation of some cross-linkers described as cleavable 
showed that whilst the spacers can cleave, they do not occur preferentially and do not permit clean peptide 
separation for further MS3 fragmentation. A better distinction needs to be made from other cross-linkers 
that do in fact contain a preferential site of cleavage in their spacer, permitting very efficient separation of 
peptides and separate MS3 analysis. Furthermore, we were unable to replicate the cleavage of previously 
reported biologically orthogonal cleavable linkers. Lack of clear information regarding the specific equipment 
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Figure 32. LC Fractionation Pre T0 removal and Post T0 removal. 
FmocRGAAKAAAR and FmocRVAAKAALR control peptides were cross-linked with CPDPS and quenched 
using Fmoc-Lys-Biotin resulting in T0 linkers to contain a biotin handle. The chromatogram compares the 
cross-linked control peptide mixture before T0 enrichment (Red) and the remaining peptides after 
neutravidin enrichment of the biotin handles (Blue). 
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needed for their use, and misleading information regarding their ability to function without affecting the 
biology have proved time consuming and still have not highlighted a useful candidate for an efficient 
cleavage mechanism for use with the proposed cross-linking workflow. T0 removal through biotin 
enrichment simplifies the complexity of the data although T0 are still visible but reduced in intensity. Overall 
we were unable to achieve successful completion of the proposed method as the capture reagents chosen 
were not effective with our desired procedures. 
3.13.1. Future Direction 
Even after a large number of on bead washes CuAAC click chemistry reagents are still visible in samples after 
release from beads. In addition a number of experiments conducted led to the questioning of the efficiency 
of CuAAC chemistry. Alternative ligation such as thiol based ligation chemistry in a similar approach to (269) 
would be very easy to use, already this is exemplified by the alkylation reaction involving iodoacetamide used 
by virtually all proteomics labs. Dissociation from the beads on the other hand may prove a difficult task.  A 
previously published 10% formic acid cleavable capture performed better than a number of other linkers and 
may prove to be efficient, however the synthesis requires toxic reagents and specialist chemistry equipment 
which may be difficult to achieve in a biology orientated lab (281). 
Later stage work with CPDPS began attempting to methylate the thioethers to attach a permanent positive 
charge, in a similar approach to (256), with the intention of counteracting some of the ETD charge state 
reduction. Interestingly however, other members in the DiMaggio group have synthesised analogues with 
methylated thioethers, when fragmenting these compounds with CID, the cleavage is almost exclusively 
located at this bond, possibly entirely removing the need for ETD altogether. Heavy labelling the cross-linker 
in this way may also prove to be a cheaper alternative to include isotopic lables. 
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Previoulsy published preliminary work with low energy cleavable identical mass linkers appears very 
promising. Albeit very complicated, if it were possible to attach a dissociable group on an identical mass 
linker  that leaves behind a small group it would be extremely promising for the field as a whole. 
More recently, a large vendor has made a much greater push to integrate and market the low energy 
cleavable linker DSSO into their toolkit and recommend a method recently utilised (6). Although in this 
publication, they  did not use the MS3 functionality, provided correct software support is put in place cross-
linking as a whole may benefit substantially compared to previous software approaches. Whilst SEC and SCX 
are still utilised for the recommended method, it may not be long before an optimised T2 enrichment 
protocol will be easily accessible to the wider community. 
  
 
  
Figure 33. Methylated CPDPS. 
This is a proposed variation of CPDPS whereby one of the thioether groups has been further methylated to 
result in a positive charge to be adopted by the sulphur. The purpose of this methylated thioether group
would be to direct ETD cleavage at this location in addition to negating the peptide charge reduction that 
occurs during ETD. 
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 General Introduction: Histone Modifications and 
Chromatin Regulation 
The core of a nucleosome is made up of four histone families arranged into dimers (H2A-H2B and H3-H4) 
with highly specific partnerships. Each histone monomer has a multitude of known isoforms with exception 
to H4. The canonical histones are cell replication dependent and expressed in the cell cycle S-Phase and are 
incorporated into chromatin during DNA replication, whilst histone “variants” are not replication dependant 
and can be expressed throughout the cell cycle (318). The various histone isoforms are deposited into 
chromatin by chaperones which bind to histones in chaperone recognition. Of all the histone families, H3 
arguably has the largest amount of research conducted to date. 
H3 isoforms only differ from each other by one to a handful of amino acid substitutions, which occur in only 
13 different locations (319). Most of the substitutions occur in structured regions but three substitution sites 
are located in the unstructured H3 tail. Histone H3 isoforms have the largest number of known PTM sites that 
can carry a wide range of modifications and can therefore harbour the most potential combinations (Figure 
34). In addition, H3 has the largest number of discovered readers, writers and erasers that have been 
annotated to specific PTMs and combinations. Because of this larger deposit of information, a large amount 
of interest is placed in further researching histone H3 PTMs and readers, writers and erasers that bind to 
them, their roles in disease and ultimately their use as potential therapeutic targets. A recent comprehensive 
list containing known histone PTMs from all histone families has been previously reviewed in detail (320). 
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 Motivation and Importance 
A large amount of research has been carried out to uncover global cell histone PTM profiles, the 
circumstances in which they are read and written as well as how they work in combination in health and 
disease. For example G9a from the G9a/GLP complex dimethylates Histone 3 Lysine 9 (H3K9) resulting in 
transcriptional silencing and if expression of G9a is deregulated it can result in various types of cancer and 
poor prognosis (321,322). PTMs in histones are highly dynamic and their frequency patterns are different in 
various circumstances such as between cell types (323), cell cycle stages (324) and infections by pathogens 
(325). By comparing global PTM profiles between control and treated samples and identifying PTM sites of 
greatest change, key mechanisms to disease deregulation can be uncovered. The cause for such a change in 
PTM frequency can then be studied further to identify novel targets for therapeutics. At present the gold 
standard for studying changes in PTM profiles in health and disease is ChIP-seq. This technique however 
requires large amounts of sample material if the aim of the study is to observe global changes in PTM profile, 
in addition to the many other problems previously discussed in section 4.3. 
 
Figure 34. Example Nucleosome With Commonly Observed Histone Tail PTMs. 
A single nucleosome with commonly observed PTMs on histone tails including acetylation (ac) and 
methylation (me). Histone H3 has the largest number of known PTM sites and modification combinations. 
Each site can only occupy one type of modification, with exception to methylation (me) which can be 
either mono- di- or tri- methylated. The overlapping ac and me PTMs on the H3 tail indicate one or the 
other are commonly observed as theses PTMs cannot be found together at the same location. 
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 Previous Work: Immunoprecipitation for Histone PTM Analysis 
The use of antibodies for detecting histone modifications in techniques such as ChIP-seq, immunostaining 
and immunoblotting analysis has been important for characterising the function of PTMs in chromatin 
(326,327). When studying histone modifications with ChIP-seq, techniques suffer from a large degree of noise 
and bias resulting in considerable variability. A large source of ChIP-seq issues stem from method complexity. 
Increasingly complex methods accumulate variability through larger numbers of biases and noise (328,329) a 
lot of which stems from the use of antibodies. This variability is considerable, even when the same assay is 
used between different labs (330,331). Data centres such as Encode have struggled to develop effective 
algorithms to correct bias from different techniques. Additionally the noise in data obtained from various 
sources is so substantial that it requires development of special statistical tools to measure consistent signals 
between replicates (332). Noise and bias aside, finding an effective way to compare data can also be a 
struggle. Adequate control data might not be available (333–336), antibodies used may be differently 
sourced, or flagged as non-specific for specific histone PTMs (181–183), and as each specific histone PTM 
requires a separate antibody a lot of material is needed for analysis of multiple PTMs. Also adjacent 
modifications can prevent PTM specific antibodies from binding in an occurrence called epitope occlusion 
(337). In addition, all combinatorial information has been lost, opening data interpretation to substantial 
errors based on the statistical comparative methods used. Altogether these issues make detecting subtle 
changes and relationships in PTM profiles extremely difficult to isolate and require a lot of caution when a 
PTM response is found. Therefore when studying the relationship between multiple histone PTMs it is much 
more desirable to use a more comprehensive technique that includes multiple PTMs within the same analysis 
from a ChIP pull down. This is commonly achieved using LC-MS proteomics. 
4.3.1. CRISPR to Study Histone PTMs, Protein Interactors and Functions 
A recently popular technique is clustered regularly interspaced short palindromic repeats (CRISPR) and 
employs a Cas9 protein and RNA pair that can be used to target specific genes of interest so that they may 
be turned off or on, or edited at will (338–342). More specifically to histones, CRISPR can be used to study 
the function of specific epigenetic marks by attaching a histone PTM altering enzyme to the Cas9 protein 
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(343). By attaching a histone PTM writer or eraser protein to Cas9 and target promoter or enhancer regions, 
specific histone modifications may be added or removed at specific gene loci. This permits the functional 
study of very specific histone PTMs and their effects on gene activation and silencing. Additionally, Cas9 can 
also be used to specifically target gene loci for the pull down of associated proteins in a technique referred 
to as enChIP (344). By adapting the method it may be possible to pull down nucleosomes specific to a gene 
locus to study specific histone PTMs nearby to a gene under various circumstances. This rapidy developing 
method can be utilised in conjunction with ChIP-seq and global histone PTM profile studies in order to help 
realise the function of PTMs. 
 Previous Work: MS Proteomics for Histone PTM Analysis 
LC-MS based proteomics is arguably one of the most sensitive and easiest forms of analysis to obtain histone 
PTM information owing to the well-defined and optimised protocols for histone extraction and purification. 
LC-MS techniques can be used on their own without the need for antibodies, tags or chemical capture 
techniques thus eradicating caveats associated with these approaches. Specifically for histone PTMs, bottom 
up and middle down approaches are ready available with comparable accuracies in stoichiometry and 
abundance (146). Middle down approaches conserve PTM combinatorial information to a much larger 
degree than bottom up approaches, however bottom up is still highly useful in comparing global histone 
profiles between cells and cell types (323) as well as isolating dynamic modifications that may arise from 
various treatment circumstances such as viral infection (325). To make matters simpler “one pot” methods are 
available (102) without the need for the previously required histone orthogonal separation techniques such 
as offline fractionation. Both bottom up and middle down techniques can be carried out in high throughput 
with low amounts of required sample (172,323). 
4.4.1. Fundamental Challenges in MS Analysis of Histone PTMs 
The analysis of histone post-translational modifications (reviewed in section 2.2) via LC-MS requires 
specialised workflows. In contrast to standard proteomic studies, in which peptides generally have at most a 
couple of PTMs (e.g. 1 or 2 phosphorylations). Histone peptides frequently exist in a number of distinct 
proteoforms (reviewed in chapter 2.4). This abnormally high frequency of PTMs renders many existing data 
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analysis pipelines for peptide identification ineffective for the analysis of these hypermodified proteins for 
several reasons: 1. the increased number of possible PTMs leads to an exponential explosion in the search 
space and a reduced confidence in peak matches; 2. different modified states of the same sequence share a 
significant number of fragment ions, so fragmentation data is partially redundant; 3. histone PTMs are 
present over a wide dynamic range depending on their function (e.g. H3K27ac is found at enhancers whereas 
H3K27me3 is present in significantly more abundant heterochromatic regions). 
Another problem specific to the analysis of modified histone peptides is chromatographic resolution of 
modified forms of the same sequence. For instance, unmodified, mono-, di- or tri-methylated lysine residues 
all carry a positive charge and thus are very hydrophilic; therefore, in reversed phase chromatography, they 
will tend to interact less with the stationary phase and limit resolving power between these modified states.   
While they individually can be resolved by their distinct masses, co-elution of these lysine isoforms results in 
competition at the ionisation source and more than one site of lysine methylation on the same peptide can 
result in co-eluting, isobaric precursors that produce mixed MS/MS.    
Lastly, a final issue to be considered when using tryptic digestion is the large number of lysine and arginine 
residues that generate a large medley of peptides as a result of trypsin being blocked by dimethylation, 
trimethylation and acetylation.  As a result, depending on the modification present, numerous peptides can 
be generated that contain the same lysine residue (e.g. H3K9) but in different modified states; making 
routine detection of the modified forms significantly more difficult. 
All of these issues severely impact the ease of quantitation of the various modified forms as normally the 
quantitation of label free peptides is represented as a fraction constructed from the integrated AUC for a 
specific histone PTM peptide from the entire sum of integrations for all modified forms (345). 
4.4.2. Methods for Improving Proteoform Identification and Quantitation 
In order to combat such complexity a common approach utilised to reduce the number of modified histone 
peptides in a single LC-MS analysis, and therefore limit isobaric co-elution and ionisation competition, is to 
use offline chromatographic fractionation. This can either be used to separate intact histone families or 
tryptically digested histone peptides. However with this approach new problems are introduced such as 
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sample loss, cost, reduction in throughput, and inaccurate quantification of peptides due to separate sample 
handling and elution across multiple fractions. This approach also does not solve poor retention of 
hydrophilic peptides on RP LC-MS. Furthermore when fractionating intact histones it is important to note 
that an assumption is made that all the various proteoforms within a single histone family have similar 
chromatographic properties, which is shown in our group to not be the case (as later discussed in section 
4.9). 
An alternative approach that can be used to avoid fractionation whilst reducing modified histone peptide 
hydrophilicity, co-elution and tryptic peptide number, is through derivatisation of unmodified and 
monomethylated lysines with a propionyl group. This is commonly achieved using propionic anhydride (117) 
or NHS propionate (346,347), consequently blocking trypsin cleavage after lysine and generating populations 
of homogenous length arginine-terminal peptides effectively mimicking an Arg-C digest, whilst avoiding the 
poor efficiency and lower-specificity. A second round of propionylation can be used after tryptic digestion to 
block all newly formed peptide N-termini. Since propionylation ‘cancels’ the electrostatic charge on the lysine 
residue (analogous to an acetylation), chromatographic resolution of the modified forms of the same histone 
peptide is more readily achieved as the separation is driven primarily through the peptide hydrophobicity. It 
also reduces the number of charge states that each peptide is able to adopt so that the distribution of m/z 
ions is limited to a smaller number of charge states (102) improving ion intensity and detection of low 
abundance species over baseline. Furthermore, modified histone peptides experiencing bias as a result of 
ionisation efficiency can also be accommodated for through the use of correction factors obtained by 
comparing synthetic and endogenous PTM peptides  and this method is also compatible with propionylation 
(348). 
Derivatisation using isotopic labels followed by sample mixing also can be used for ease of detection and 
absolute quantitation of modified histone peptides. This can be achieved in cell through techniques such as 
SILAC (349) or through 15N rich media (350,351). Or they can be introduced via chemical derivatisation during 
sample processing stages through approaches such as H10/D10 propionylation, tandem mass tag multiplex 
(TMT labelling)(352) and isobaric tags for relative and absolute quantification (iTRAQ)(353). Isotopically 
treated and untreated samples can be multiplexed in the same sample however isobaric co-eluting species 
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affect identification efficiency and quantitation (354–356) and further work is required for correction 
(149,357). Using iTRAQ before and after trypsin digest was also reported to not resolve the issues with 
histone peptide hydrophilicity that propionylation solves, however this data has not been published (351). 
Another possibility to address the many challenges with modified histone peptides has recently developed in 
the form of DIA based approaches (reviewed in section 2.7) owing to its comprehensive fragmentation of all 
m/z ions, effectively permitting better quantitation of all known modified histone peptides through unique 
ion transitions in the MS/MS data, as well as permitting revisiting the data for previously unknown 
modifications (176,358). Furthermore it has been previously stated that whilst DIA based approaches are not 
as sensitive as SRM based approaches, [1] data on an inclusion list cannot be revisited for new peptides, and 
[2] SRM methods are not possible due to the requirements for an extremely long list of transitions (358). 
Whist the first statement is somewhat accurate, the work proposed by our group indicates that long 
transition lists are not required for the analysis of histone PTMs, thus retaining valuable MS sensitivity 
without sacrificing fragmentation of the desired modified histone peptides and resolution as a result of time 
constraints. 
 Technical Challenges and Opportunities 
By combining the localisation of histone PTMs, PPIs and gene loci of ChIP, with the powerful identification, 
sensitivity and quantitative ability of LC-MS in an integrated ChIP-MS approach, it becomes far easier to 
target in-vivo gene regulation in a contextual fashion. ChIP-MS facilitates the mapping and understanding of 
the roles of various histone PTM combinations by also identifying the surrounding PPIs that read and write 
them in addition to the specific contexts and gene loci at which they appear. ChIP-MS can be used in a 
variety of ways, such as by studying co-occurrence of histone marks by quantitating histone PTMs from 
precipitated material (359), or by identifying specific histone modifications at which proteins localise to, in 
addition to identifying novel binding proteins to histone PTMs (360). With the interest drawn to ChIP-MS, a 
great deal of exciting new research is occurring (reviewed by (361)). However an important aspect that also 
needs to be considered is that with extremely targeted and specific enrichment techniques material can 
become increasingly lower in abundance requiring much larger amount of starting amounts and enrichment. 
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Therefore to cope with reduced sample amounts whilst mitigating increases in cost, time and potentially 
ethical concern when animal models are involved, the sensitivity and detection of histone PTMs needs to be 
improved. 
Additionally, the aforementioned bottom up LC-MS workflow for histone PTM analysis using propionylation 
requires microgram quantities of histone starting material. When studying holistic and bulk-phase chromatin, 
on the order of 106 cells is sufficient for this purpose. However, when characterising the subset of chromatin 
pulled-down via ChIP of a chromatin-binding protein or histone PTM, which can often be present in less than 
10% of the genome, then either the number of cells will need to be scaled-up accordingly (e.g. by a factor of 
10), or improvements will be required in the sensitivity of the MS method itself.  A similar problem is faced 
when working with tissue models, where starting material is inherently limited and there is sometimes an 
ethical responsibility to reduce the number of animals required.  The work presented in this chapter aims to 
develop a more sensitive MS method for the analysis of histone PTMs to address these challenges. 
 Proposed Methodology 
The proposed methodology for increased sensitivity in histone H3 PTM quantitation is inspired by the 
selective ion monitoring (SIM) approach used in triple quadrupole mass spectrometers, which is arguably the 
most sensitive method for MS-based quantitation.  In the SIM approach, the quadrupoles selectively filter a 
m/z value that proceeds to the electron multiplier detection system, thus resulting in signal detection that is 
exclusive to an ion of that m/z.  The quadruple can sequentially analyse a number of m/z values in this 
fashion; these are referred to as “transitions”. Linear ion traps also have the ability to selectively fill the trap 
with ions of a particular m/z value (or within some range around a given m/z), however the ions are not sent 
directly to the electron multiplier detectors, but instead the trap is filled to a prescribed automatic gain 
control (AGC) value and then the ions are scanned out. None-the-less, such a SIM approach using linear ion 
trap mass spectrometers offer important advantages: 1) there is a significant improvement in sensitivity of 
ion detection, including the ability to detect ions below the baseline of detection in full scan mode; 2) for 
small m/z windows, the scan rate of the ion trap can be reduced (referred to herein as a “zoom scan”) to 
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improve the resolution and mass accuracy of the m/z peak, and can achieve baseline resolution for z=3+ 
charge states.  
Implementing a SIM approach for hypermodified proteins can be challenging, due to the long list of 
transitions required (358). For example, when looking at the number of PTMs on histone H3 in Figure 34, it is 
immediately apparent that there will be a large number of proteoforms to selectively monitor. Hypothetically 
the number of possibly observed proteoforms for histone H3 using the bottom up approach is on the order 
of hundreds, but in practice only 31 proteoforms are generally observed to be the most abundant. 
Nonetheless, many of these proteoforms exist in multiple charge states and this requires on the order of 70 
required transitions to measure each ion independently, which is not feasible over the chromatographic 
elution profiles for these peptides. 
The approach presented in this chapter proposes to leverage the injection waveform filtering technology of 
the linear ion trap to reduce the number of programmed transitions per cycle by combining SIM scans over 
multiple ions with similar chromatographic profiles. Of paramount importance to this approach is retention 
time reproducibility, which has recently become available thanks to advancements in nanoLC 
instrumentation. 
SIM Transition Programming Based on Robust Proteoform Elution Profiles 
To design a minimal set of transitions for quantitation of the most abundant histone H3 proteoforms, we first 
need to characterise their chromatographic profiles in terms of retention time robustness and nearest 
neighbour m/z values.  Histone standards were created for this purpose by acid extracting histones from 
HEK293 cells and offline UHPLC fractionation was used to separate the histones by variants.  The fraction 
containing the purified histone H3 standard was then prepared for bottom up analysis and several nanoLC-
MS/MS experiments were conducted to sample the variation in the retention times for 31 modified H3 
peptides (considering mono-, di-, tri-methylation and acetylation of lysines) over multiple charge states.  
Interestingly, the variation in the observed retention times for the modified histone peptides over all runs was 
relatively small, as shown in Figure 35, where each symbol corresponds to a different proteoform. 
  
138 
 
 
 
  
Figure 35. Plotted Elution Times of Common Histone PTM peptides. 
Each plotted circle represents a single histone PTM peptide species, with the exception of coloured 
circles where the same colour represents the same histone PTM peptide at multiple charge states. The 
error bars indicate the standard deviation. Vertical dashed lines represent the segment time 
boundaries and are numbered at the top of the graph. Black solid boxes represent the m/z scan 
ranges for easch zoom scan window and show how the various histone PTM peptides are organised in 
each zoom scan. To achieve the optimal zoom scan windows and time segments, retention times and 
m/z for histone PTM peptide standards were recorded and inserted into a MILP algorithim 
represented graphically in this image. 
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Using this database of retention times, a mixed integer linear optimisation scheduling algorithm was 
implemented to assign which m/z values to selectively scan for in a given time segment. That is, instead of 
only using standard full scans (m/z = 250-1800) throughout the LC-MS experiment, the mass spectrometer is 
instructed to focus measurements on pre-specified m/z ranges (scan width max of 15 m/z) for distinct time 
segments. The resulting time segments are illustrated by the 6 different colours in Figure 35, where each 
peptide has been colour-coded according to the time segment to which it was assigned. Within each time 
segment, the mass spectrometer executes targeted zoom scan events (with a maximum of 6 targeted events 
per segment) that selectively measures the m/z range only around the histone peptides of interest nearly 
doubling the resolution (Figure 36) thus permitting better distinction of charge states and identification of 
possible contaminants from co-eluting species.  These targeted scan events ranges are provided in Table 4 
under the column headers “m/z Lower bound” and “m/z Upper bound” and illustrated in Figure 35 using 
boxes.  
This substantially improves the signal-to-noise observed for each of the 31 modified histone H3 proteoforms, 
as the mass spectrometer effectively samples only these signals. It should be noted again that this approach 
is different than SIM as implemented on a quadrupole mass spectrometer, as our method sometimes clusters 
neighbouring m/z’s into a single scan event to reduce the number of required transmissions (as shown in the 
boxes containing multiple symbols in Figure 35, and multiple m/z ions for some scan events in Table 4), and 
also executes full range MS scans, data dependent (using an inclusion list of m/z values corresponding to the 
proteoforms) and targeted MS2 scans within each time segment.  
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Figure 36. Comparing Normal Scan Resolution Vs Zoom Scan Resolution. 
The same +3 charged peptide as observed under normal scan (5400 FWHM) and zoom scan (10,100 
FWHM) using an LTQ Velos Pro LIT. The higher resolution permits baseline resolution between the 
isotopically distributed peaks. With baseline resolution, confidence regarding a correct peptide 
assignment and the presence of a contaminant increases. 
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Segment Scan Event m/z Lower bound m/z Upper bound Proteoform m/z 
2 
~4.1 mins 
1 250 1800 
2 393.235 396.735 H3K4me2 2+ 394.735
3 400.243 403.743 H3K4me3 2+ 401.743
4 DDA – Priority Queue 
5 DDA – Priority Queue 
6 DDA – Priority Queue 
7 DDA – Priority Queue 
3 
~3.95 
mins 
1 250 1800 
2 407.233 410.733 H3K4un 2+ 408.733
3 512.799 530.314 
H3K9me2K14ac 2+ 514.299
H3K9me3K14ac 2+ 521.306
H3K9me2K14un 2+ 521.307
H3K9me3K14un 2+ 528.314
4 533.155 545.989 
H3K27me2K36me2 3+ 534.655
H3K27me3K36me2 3+ 539.322
H3K27me3K36me3 3+ 543.989
5 799.979 817.493 
H3K27me2K36me2 2+ 801.479
H3K27me3K36me2 2+ 808.486
H3K27me3K36me3 2+ 815.493
6 814.958 819.458 H3K4un 1+ 816.458
7 DDA – Priority Queue 
4 
~3.8 mins 
1 250 1800 
2 414.241 417.741 H3K4me1 2+ 415.741
3 519.788 537.304 
H3K9acK14ac 2+ 521.288
H3K9acK14un 2+ 528.296
H3K9unK14ac 2+ 528.296
H3K9me1K14ac 2+ 535.304
H3K9unK14un 2+ 535.304
4 542.487 555.33 
H3K27me2K36un 3+ 543.987
H3K27unK36me2 3+ 543.987
H3K27acK36un 3+ 548.646
H3K27me1K36me2 3+ 548.658
H3K27me2K36me1 3+ 548.658
H3K27me3K36un 3+ 548.658
H3K27me1K36me3 3+ 553.33 
H3K27me3K36me1 3+ 553.33 
Table 4. Overview MS Segmentation and Scan Event Scheduling for the Targeted Detection and 
Fragmentation of Human Histone H3 Propionylated and Tryptically Produced Peptide Proteoforms. 
From left to right, the segment number and approximate segment time duration is outlined. Within 
each segment the specific scan number and zoom scan starting and ending m/z range values are 
indicated. For each scan event the expected histone H3 peptide proteoforms that are unmodified (un), 
methylated (me) or acetylated (ac) and their respective charge (2+ or 3+) are listed with their m/z value. 
This method was developed for peptides chromatographically resolved using an Ultimate 3000 RS-LC-
nano System (Dionex), with an Acclaim PepMap100, C18 stationary phase, 2 μm particle size, 100 Å pore 
size, 75 μm internal diameter x 15 cm length column (Thermo Fisher). The nanoLC gradient started at 
1% B (5% H2O, 95% MeCN, and 0.1% formic acid) and 99% A (0.1% formic acid and 100% H2O) and 
increased to 30% B over 35 min followed by an increase to 95% B over 30 mins. Real-time tandem mass 
spectra were acquired on an LTQ Velos Pro linear ion trap (Thermo Scientific) with a 110 min acquisition 
time. 
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Segment Scan Event m/z Lower Bound m/z Upper Bound Proteoform m/z 
4 
~3.8 mins 
(continued) 
5 813.976 832.474 
H3K27me2K36un 2+ 815.476 
H3K27unK36me2 2+ 815.476 
H3K27acK36un 2+ 822.466 
H3K27me1K36me2 2+ 822.484 
H3K27me2K36me1 2+ 822.484 
H3K27me3K36un 2+ 822.484 
H3K27me1K36me3 2+ 829.492 
H3K27me3K36me1 2+ 829.492 
H3K4me1 1+ 830.474 
6 DDA – Priority Queue 
7 DDA – Priority Queue 
5 
~3.15 mins 
1 250 1800 
2 540.812 544.312 H3K9me1K14un 2+ 542.312 
3 551.818 565.833 
H3K27unK36un 3+ 553.318 
H3K27me1K36un 3+ 557.99 
H3K27unK36me1 3+ 557.99 
H3K27me1K36me1 3+ 562.662 
H3K18acK23ac 2+ 563.833 
4 827.973 845.489 
H3K27unK36un 2+ 829.473 
H3K27me1K36un 2+ 836.481 
H3K27unK36me1 2+ 836.481 
H3K27me1K36me1 2+ 843.489 
5 DDA – Priority Queue 
6 DDA – Priority Queue 
7 DDA – Priority Queue 
6 
~4.5 mins 
1 250 1800 
2 569.341 572.841 
H3K18acK23un 2+ 570.841 
H3K18unK23ac 2+ 570.841 
3 576.349 579.849 H3K18unK23un 2+ 577.849 
4 583.357 586.857 
H3K18me1K23un 2+ 584.857 
H3K18unK23me1 2+ 584.857 
5 708.878 712.378 H3K79me2 2+ 710.378 
6 715.886 719.386 H3K79me3 2+ 717.386 
7 DDA 
7 
~7.85 mins 
1 200 1800 
2 722.876 726.376 H3K79un 2+ 724.376 
3 729.883 733.383 H3K79me1 2+ 731.383 
4 DDA – Priority Queue 
5 DDA – Priority Queue 
Table 4. (Continued.) 
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Segment Scan Event m/z Lower Bound m/z Upper Bound Proteoform m/z 
2 
 ~4.1 mins 
1 200 1800     
2 393.235 396.735 H3K4me2 2+ 394.735 
3 400.243 403.743 H3K4me3 2+ 401.743 
4 DDA – Priority Queue 
5 DDA – Priority Queue 
6 DDA – Priority Queue 
7 DDA – Priority Queue 
3 
 ~3.95 
mins 
1 200 1800     
2 407.233 410.733 H3K4un 2+ 408.733 
3 814.958 819.458 H3K4un 1+ 816.458 
4 DDA – Priority Queue 
5 DDA – Priority Queue 
6 DDA – Priority Queue 
7 DDA – Priority Queue 
4  
~1.75 mins 
1 200 1800     
2 414.241 417.741 H3K4me1 2+ 415.741 
3 447.22 450.22 H3T3phK4un 2+ 448.716 
4 519.788 545.5 H3K9acK14ac 2+ 521.288 
H3K9acK14un 2+ 528.296 
H3K9unK14ac 2+ 528.296 
H3K27unK36me2 3+ 543.987 
5 813.976 832.474 H3K27unK36me2 2+ 815.476 
H3K4me1 1+ 830.474 
6 894.92 899.42 H3T3phK4un 1+ 896.424 
7 DDA 
5 
 ~1.9 mins 
1 200 1800     
2 532.8 536.8 H3K9unK14un 2+ 535.304 
3 551.818 565.833 H3K27acK36un 3+ 548.646 
4 566.78 572.14 H3K9acS10phK14un 
2+ 
568.28 
H3K27unS28phK36me2 
3+ 
570.642 
5 820.97 823.97 H3K27acK36un 2+ 822.466 
6 853.96 870.96 H3K27unS28phK36me2 
2+ 
855.459 
7 DDA – Priority Queue 
Table 5. Overview MS Segmentation and Scan Event Scheduling for the Targeted Detection and 
Fragmentation of S. cerevisae Histone H3 Propionylated and Tryptically Produced Peptide Proteoforms. 
From left to right of the table, the segment number and approximate segment time duration is outlined. 
Within each segment the specific scan number and zoom scan starting and ending m/z range values are 
indicated. For each scan event the expected histone H3 peptide proteoforms that are unmodified (un), 
methylated (me), acetylated (ac) or phosphorylated (ph) and their respective charge (2+ or 3+) are listed 
with their m/z value. This method was developed for peptides chromatographically resolved using an 
Ultimate 3000 RS-LC-nano System (Dionex), with an Acclaim PepMap100, C18 stationary phase, 2 μm 
particle size, 100 Å pore size, 75 μm internal diameter x 15 cm length column (Thermo Fisher). The nanoLC 
gradient started at 1% B (5% H2O, 95% MeCN, and 0.1% formic acid) and 99% A (0.1% formic acid and 
100% H2O) and increased to 30% B over 35 min followed by an increase to 95% B over 30 mins. Real-time 
tandem mass spectra were acquired on an LTQ Velos Pro linear ion trap (Thermo Scientific) with a 110 min 
acquisition time. 
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Segment Scan 
Event 
m/z Lower 
Bound 
m/z Upper 
Bound 
Proteoform m/z 
6 
 ~3.55 
mins 
1 200 1800     
2 551.82 559.49 H3K27unK36un 3+ 558.65 
H3K27unK36me1 3+ 563.322 
3 573.79 576.79 H3K9unS10phK14un 
2+ 
575.287 
4 583.8 591.48 H3K27unS28phK36un 
3+ 
585.305 
H3K27unS28phK36me1 
3+ 
589.977 
5 835.971 845.979 H3K27unK36un 2+ 837.471 
H3K27unK36me1 2+ 844.479 
6 875.95 885.96 H3K27unS28phK36un 
2+ 
877.454 
H3K27unS28phK36me1 
2+ 
884.462 
7 DDA – Priority Queue 
7  
~4.25 
mins 
1 200 1800     
2 562.333 572.341 H3K18acK23un 2+ 563.833 
H3K18unK23ac 2+ 563.833 
H3K18unK23un 2+ 570.841 
3 665.38 668.38 H3K56ac 2+ 666.88 
4 708.87 718.89 H3K79me2 2+ 710.378 
H3K79me3 2+ 717.386 
5 1329.75 1335.75 H3K56ac 1+ 1332.75 
6 DDA – Priority Queue 
7 DDA – Priority Queue 
8  
~6.5 
mins 
1 200 1800     
2 672.38 675.39 H3K56un 2+ 673.888 
3 722.88 725.88 H3K79un 2+ 724.376 
H3K79me1 2+ 731.383 
4 1343.77 1349.77 H3K56un 1+ 1346.77 
5 DDA – Priority Queue 
6 DDA – Priority Queue 
7 DDA – Priority Queue 
Table 5 (Continued.) 
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 Materials and Methods 
All chemicals were purchased from Sigma at the highest grade/purity. LC-MS grade solvents and additives 
were purchased from Fisher Scientific. Tissue samples were provided by Rachel Grimley from Pfizer/Neusentis 
and were extracted, propionylated and digested by Peter DiMaggio. HEK293T cells were purchased from 
ATCC. Extracted histones from Saccharomyces cerevisiae were provided by Raul Torres from the Aragón 
group using a yeast optimised histone extraction protocol. 
Cell culturing 
HEK293T cells were grown in Dulbecco's modified Eagle's medium containing l-Glutamine (1× Glutamax, 
Gibco), 10% FBS (New England Biolabs) and antibiotics (100 units/L Pen/Strep, Gibco), and were harvested 
when approximately 90% confluent. For harvesting, cells were scraped with ice cold Dulbecco's phosphate-
buffered saline (no calcium, no magnesium, Gibco), pelleted at 500 xg at 4 °C, and washed and pelleted 
another 2 times, followed by storage at -80 °C. 
Histone extraction 
Histones were acid extracted as previously described (362). Cell pellets were lysed on ice using 0.4% Nonidet 
P-40, 5 µM microcystin, 10 mM sodium butyrate, 300 µM 4-(2-aminoethyl) benzenesulfonyl fluoride 
hydrochloride and 1 mM dithiothreitol. The insoluble chromatin pellet was then extracted with 0.4 N H2SO4 
and the histones were precipitated using 25% (final volume) trichloroacetic acid. The histones were then spun 
at 21,000 xg at 4 °C washed with acetone and spun again. The excess acetone was removed and the pellet air 
dried. 
Histone extraction from tissues 
Histones from Tissues were similarly extracted as previously described (362). Tissues were first treated using a 
motorised pestle on ice in a coctail consisting of 0.4% Nonidet P-40, 5 µM microcystin, 10 mM sodium 
butyrate, 300 µM 4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride and 1 mM dithiothreitol. The 
insoluble chromatin pellet was then extracted with 0.4 N H2SO4 and the histones were precipitated overnight 
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at 4 °C using 25% (final volume) trichloroacetic acid. The histones were then spun at 21,000 xg at 4 °C 
washed with acetone and spun again. The excess acetone was removed and the pellet air dried. 
Chromatographic separation of H3 standards and S. cerevisiae histones 
HEK293T and S. cerevisiae histone pellets were re-solubilised in water containing 0.1% TFA prior to UHPLC 
fractionation to separate the histone families. Chromatography was performed on an Ultimate 3000 HPLC 
(Dionex) with a C18 column, with 3 µm particle size, 250 mm length x 4.6 mm internal diameter (Grace Vydac) 
and peaks were detected using 215 nm absorbance. A linear gradient was used starting at 99.5% A (5%v 
acetonitrile (MeCN), 95% H2O and 0.2%v TFA) and ending at 95% B (95%v MeCN, 5%v H2O 0.2%v TFA) over 
100 minutes. Fractions were collected every 3 minutes and those corresponding to H3 were pooled, dried 
using vacuum centrifugation and stored at -80 °C. 
Histone derivatisation and nanoLC-MS analysis 
After acid extraction or chromatographic separation histones were derivatised and processed for nanoLC-
MS/MS analysis as previously described (323).  Briefly, the histone proteins were propionylated using 
propionic anhydride to label unmodified and monomethylated lysines with a propionyl group (+56 Da), 
which will result in a trypsin digest cleaving only at arginine residues.  This produces the same histone 
peptide sequences regardless of any post-translational modifications present on lysine residues, and thus 
enables relative quantitation between different modifications on the same peptide based on signal intensity 
in the mass spectrometer. Subsequent propionylation of the N-termini of the corresponding histone peptides 
results in enhanced chromatographic resolution of isobaric (i.e. same mass) peptides (e.g. trimethylation 
[42.0469 Da] and acetylation [42.0106 Da] of lysine) based on their degree of hydrophobicity, thereby 
eliminating issues relating to signal interference and increasing confidence in PTM identification. The histone 
peptides were chromatographically resolved using an Ultimate 3000 RS-LC-nano System (Dionex), first 
loaded onto an Acclaim PepMap RSLC Nano-Trap Column, C18 stationary phase, 5 µm particle size, 100 Å 
pore size, 100 μm internal diameter, 20 mm length (Thermo Fisher) using a loading buffer comprised of 0.1% 
TFA, 0.5% acetonitrile and 95.4% H2O running at 3 µL/min, switching after 3 mins onto an Acclaim 
PepMap100, C18 stationary phase, 2 μm particle size, 100 Å pore size, 75 μm internal diameter x 15 cm 
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length column (Thermo Fisher). The nanoLC gradient started at 1% B (5% H2O, 95% MeCN, and 0.1% formic 
acid) and 99% A (0.1% formic acid and 100% H2O) and increased to 30% B over 35 min followed by an 
increase to 95% B over 30 mins. Real-time tandem mass spectra were acquired on an LTQ Velos Pro linear ion 
trap (Thermo Scientific) with a 110 min acquisition time. Targeted zoom scans were performed for m/z values 
corresponding to the modified histone peptides in multiple time segments to mitigate dynamic range issues 
(the zoom scan m/z range values are found in lower and upper bound columns in Table 4, times for each 
segment are listed in the segment column. Tandem mass spectra corresponding to propionylated, 
methylated and acetylated histone peptides were acquired using 35 NCE CID and selected using a priority 
queue (priority queue values are found in the m/z column in Table 4, duplicate values were deleted). Before 
samples were analysed, the HEK293T H3 standard was run and segment times were adjusted accordingly, 
time adjustment was often only required in first segment (segment 1, not shown in the tables, only utilised 
top 7 DDA and was ~10.6 minutes in length) to account for slight early or late elutions that were observed 
proportionately across the chromatogram. 
Data analysis 
Histone PTMs were quantitated manually using Xcalibur (Therno Scientific). Modified histone peptides across 
a number of visible charge states were first manually confirmed using mass, retention time alignment and 
finally by cross comparison of MS/MS spectra (annotations in appendix) with previously generated spectral 
libraries. The extracted ion chromatogram (XIC) peak for each specific histone PTM peptide in its 
corresponding zoom scan was then integrated and the resulting AUC value documented. A normalised 
relative abundance was then calculated for each modified histone peptide by summing the AUC values for all 
visible charge state of the proteoform, and then dividing this value by the sum over all observed AUCs for 
that peptide sequence.  In this chapter, the relative abundances are considered as the ratio with respect to a 
reference sample in an attempt to reduce any effects arising from PTM ionisation bias on the peptide 
sequence.  
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The targeted MS approach for quantitating histone H3 proteoforms was utilised primarily in two applications: 
1. characterising changes in global histone H3 PTMs in a tissue model for studying epigenetic differences 2. 
examining the assumed purity of off-line chromatographic separation between histone variants.  
 Results and Discussion: Limited Starting Material: Tissue 
Models 
Due to the sensitivity of the work that was carried out, a representative illustration will be used to describe 
the way in which tissues samples were mixed and compared. Figure 37 is a representative illustration of the 
tissues that can be obtained from a single individual. Tissue type 1 is derived from one side, whilst type 2 is 
derived from the opposing side. Tissues A and B can be derived from either opposing side. When being used 
for a model, type 1 can be treated independently making type 2 a control tissue within the individual. 
 
 
Figure 37. Illustrative representation of tissue samples. 
This illustration represents how one individual can be used for a model. Tissue type 1 is derived from the 
same side of the individual whilst type 2 is derived from the opposing side. Tissue samples A and B are 
also separate tissue samples and can be obtained from either opposing sides. All tissues can be naïve, i.e. 
no treatment, or type 1 can be used for modelling, whilst type 2 acts as a control for the same individual. 
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We applied the targeted MS method to probe for epigenetic changes in type 1 and type 2 tissues. 
Techniques such as ChIP-Seq and LC-MS are generally used for the study of global histone modifications 
(363) and may require around 106 cells for a single replicate. For cultured cell lines such as HeLa this is not a 
problem, however pooling two tissues from any combination of A and/or B from any type only contains on 
the order of 105 cells, translating to approximately 100 ng of total histone H3 within a single tissue sample 
extraction.  Previous work had determined that up to 8-10 pooled individual tissues were required as starting 
material for a single ChIP-seq replicate. This can be costly and difficult to obtain but more importantly 
epigenetic variance between different individuals may also widen the significance of the results and mask key 
changes or trends that may be occurring. Complimentary or alternative techniques that use as little sample as 
possible would be of great benefit. Therefore efficient and selective recovery of histones is essential for 
obtaining high quality nanoLC-MS/MS readouts. 
Histone H3 PTM patterns from tissues containing 105 cells 
To maximize our available starting material, we iteratively developed an extraction methodology that 
successfully recovers histones to a significant quantity and purity from only 2 pooled tissues (see Figure 38). 
 
Figure 38. SDS-PAGE Following Histone Extraction from Tissue Samples Starting from 105 Cells . 
Tissue samples were first processed using an electronic mechanised pestle to separate the cells. Histones 
were then extracted using a previously reported method, using minimal H2SO4 washes and an overnight 
TCA precipitation before being run on a 8% SDS-PAGE Tris gel. 
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After identifying that sufficient histones were extracted, we then applied the targeted nanoLC-MS/MS 
method described section 4.7, to naïve tissue models, where 2 tissues (A and B) were pooled for types 1 and 
2 (e.g. A1 pooled with A2), respectively, and several technical replicates were measured.  The analysis 
revealed a surprising consistency between the A and B histone PTM patterns; with the exception of one mark 
(H3K9me2K14ac), all relative abundances for the 31 histone H3 PTMs were found to have a standard 
deviation of less than 3% over all A and B replicates. This preliminary data has demonstrated that it is 
possible to robustly quantitate histone PTMs using our customised nanoLC-MS/MS approach starting from 
only 105 cells (1-2 tissues). 
After identifying feasibility of analysis with naïve tissues, we turned our attention to profile semi-
combinatorial epigenetic changes in the designed tissue model. Specifically, the same tissues were pooled 
between two individuals (e.g. A1 from both individuals were pooled) so that a comparison may be made for 
levels A and B from type 1 (treated) against type 2 (control). Before doing so however the individuals were 
confirmed to represent a good model. We then conducted several nanoLC-MS/MS technical replicates and 
the log2 of the fold changes between type 1 and type 2 are presented in Figure 39. 
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Figure 39. Fold changes in histone H3 PTMs from 105 cells in control and treated tissues from the same 
source compared to native control tissues. 
To generate this image, histone H3 PTM peptides were first quantitated using the H3 targeted PTM 
method for control (tissue type 2) and treated (tissue type 1) tissues sourced from a single individual. 
These values were then further compared to the corresponding tissues from another naïve (untreated) 
control individual (i.e. control tissue type 2 from treated individual A was compared to tissue type 2 from a 
naïve individual B and treated tissue type 1 from treated individual A was compared to tissue type 1 from a 
naïve individual B). The results from this experiment show that there is an increase (denoted in red) in 
H3K4me1 and H3K4me2 associated with transcriptional activation. The same PTMs in the control tissues as 
well as K9me2K14ac and K9me3K14ac from the treated individual are lower in intensity (green) compare to 
the native control individual, indicating slight heterogeneity between the individuals.  
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Several interesting findings can be made from this experiment for this model. First, the method shows to be 
quite robust, as not many significant changes in the 31 histone H3 PTMs were observed. In fact, the same 
correlative changes are observed in A and B type 1 when normalising with respect to either type 2 (as 
shown in Figure 39) or independent naive A/B controls from other individuals, thus implying that these 
changes are not the consequence of epigenetic heterogeneity across different individuals.  Second, A and B 
type 1 appear to undergo distinct epigenetic changes. In A tissues we observe trends that are generally 
associated with gene silencing, such as a decrease in H3K4me3 (a promoter-specific mark; Wilcoxon, p = 
1.12E-4) and an increase in H3K27me3K36me2 (Wilcoxon, p = 3.53E-3), potentially due to the silencing of 
existing H3K36me2 substrates (a mark found throughout active gene bodies) via hypermethylation of H3K27 
(a silencing mark bound by Polycomb group proteins).  However, the opposite response is observed in B 
tissues, where activating marks H3K4me2/3 (Wilcoxon, p = 0.01878 and p = 0.06263, respectively) and 
H3K36me2 (Wilcoxon, p = 0.0261) were all found to increase, thus implying additional events of gene 
activation are taking place in the B level.  Other histone variants (e.g. H4, H2A, and H2B) can be analysed 
using an adaption of this targeted nanoLC-MS/MS methodology. 
This new nanoLC-MS/MS methodology resolved the aforementioned issues and resulted in a greater than 
100-fold improvement in sensitivity, thereby allowing us to sample multiple technical replicates (at least 3 
technical replicates from only 2 pooled tissues) to statistically assess quantitative changes. 
 Results and Discussion: Case Study - The Effect of PTMs on 
the Chromatographic Resolution of Histone Variants 
Many studies report the a priori fractionation of histone variants prior to sample preparation for mass 
spectrometry analysis, as this reduces overall sample complexity and effectively improves signal-to-noise. To 
our knowledge no studies have investigated if there is chromatographic resolution between different 
modified states of the same histone variant. Using the targeted approach for sensitive quantitation of histone 
H3 proteoforms, we examined if the modifications present on H3 affected its chromatographic resolution or 
if all modified states co-elute in the same fraction, which is currently supposed. For this purpose, we decided 
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to study histone H3 from S. cerevisiae, as it has fewer proteoforms that higher eukaryotes (largely due its lack 
of H3K9 and H3K27 mono-, di-, and tri-methylation) and thus results in simpler data analysis. 
 
Histones from S. cerevisiae were acid extracted, chromatographically resolved and fractionated in 3 minute 
intervals. The fractions that corresponded to the assumed retention times for histone families H2B/H2A, H4, 
and H3, were then chemically derivatised (respectively) and then were all separately analysed for H3 modified 
histone peptides using a S. cerevisiae variation of the nanoLC-MS/MS as described in section 4.7). 
It is generally assumed that proteoforms from the same histone family have similar chromatographic 
properties, regardless of their modifications, permitting them to be separated from each other with histone 
H3 having the latest retention time. However, using the targeted MS approach we were able to identify 
histone H3 modified states within the fractions assumed to correspond to other purified histone variants (i.e. 
H2A, H2B and H4) (Figure 41.). Additionally, it became apparent that specific modifications do influence the 
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HPLC Fractionation of S. Cerevisae Histones
Figure 40. S. cerevisae Histone Family LC Fractionation Detected Using 215 nm Absorbance. 
Yeast histones were extracted by Raul Torres using a modified histone extraction protocol. 3 minute fractions 
were collected over 140 minutes in order to separately purify H2A, H2B, H4 and H3 fractions. 
Chromatography was performed on an Ultimate 3000 HPLC (Dionex) with a C18 column, with 3 µm particle 
size, 250 mm length x 4.6 mm internal diameter (Grace Vydac) and peaks were detected using 215 nm 
absorbance targeting peptie bonds. A linear gradient was used starting at 99.5% mobile A (5%v acetonitrile 
(MeCN), 95% H2O and 0.2%v TFA) and ending at 95% mobile B (95%v MeCN, 5%v H2O 0.2%v TFA) over 100 
minutes. 
H2B H4 H3 H2A
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chromatographic profile for histone H3 at the protein level. The most striking observation that could be 
made was that the supposed canonical H3 fraction had the largest abundance of acetylated lysines (Figure 
41, red cluster in H3 fractions). In contrast, analysis of earlier fractions previously assumed to only contain the 
H2A/H2B and H4 variants revealed the existence of H3 protein with markedly reduced amounts of 
acetylation, with the notable exception of H3K27ac in the ‘H4’ fractions (Figure 41, strong blue cluster in 
H2A/H2B and H4 fractions). If the chromatographic separation was according to histone PTM modifications 
this would make intuitive sense as acetylation strips the lysine charge making the protein more hydrophobic. 
However the intention here is to separate intact histones, and it is apparent that the supposed ‘H3’ fraction 
holds bias towards hyperacetylated histone species. 
Alongside the hyper acetylation in the H3 fractions, there appears to be a distinct pattern relating to 
transcriptional activation marks, specifically H3K4me3 (364,365) and H3K79me3 methylation (366–368). 
Altogether combined with the histone acetylation indicates active gene transcription in proteoforms from the 
H3 fraction which expected as S. cerevisiae genome can be described as being in a euchromatic state. 
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No targeted acetyl marks were observed in the ‘H2A/H2B’ fraction, however the ‘H3’ fraction contains a 
range of the targeted acetylation marks with exception to H3K27ac whilst the ‘H4’ fraction shows the 
opposite with only H3K27ac being observed. Information on the exact function of H3H27ac is sparse 
however it is known that H3K27ac can be acetylated in S. cerevisiae by Gcn5, and to a lesser extent Rtt109 
which is a H3K56 acetyltransferase linked to transcription activation and responsible for replication-coupled 
Figure 41. Clustal Comparsion of Normalised S. cerevisiae Histone H3 PTM Proteoform Abundances 
Observed in H2A/H2B, H3 and H4 LC Separated Histone Family Fractions. 
Histone H2A/H2B, H3 and H4 LC fractions were separatey propionylated, tryptically digested and analysed 
using the targeted S. cerevisiae histone H3 LC-MS method. The area under the curve (AUC) was obtained 
for m/z intensities over time (mins) corresponding to manully validated histone H3 unmodified (un), 
methylated (me), acetylated (ac) and phosphorylated (ph) PTM peptide proteoforms (labelled on right). 
Red indicates a higher normalised AUC whilst blue indicates a lower normalised AUC. It would be expected 
that only the histone H3 fractions contain meainingful groupings of histone H3 PTM proteoforms, however 
distinct clusters are visible according to histone family (H2A/H2B, H3 and H4) fractions with non histone 
H3 fractions containing higer normalised AUC values for specifc histone H3 peptide proteoforms (e.g. 
H2A/H2B contiaing greater amounts of H3K27unK36me1). 
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nucleosome assembly, however H3K56ac is not a prerequisite to H3K27ac (369). In replication-coupled 
nucleosome assembly H3 histones are predominantly acetylated at H3K56, followed by K9ac and then at 
K27ac (370). Genetic evidence also suggests that the acetylation of five lysine residues (K9, K14, K18, K23, and 
K27), is important for nucleosome assembly (371–373). However, this particular data indicates that K27ac is 
functioning independently and not as part of the replication-coupled nucleosome assembly. 
Furthermore it was noticed that there is also upregulation of H3K36me1 only found in the H2A/H2B fractions. 
It has been reported that H3K36me1 helps to activate early DNA replication origins via Cdc45 binding, whilst 
it’s effect are counteracted by K36me3 encouraging late DNA replication origins in S. cerevisiae (374). 
Unfortunately we were unable to detect H3K36me3 signals and therefore cannot make conclusions regarding 
the relationship between DNA replication in the various histone pools. In addition to this, Set2 on RNAPolII 
replaces H3K36 monomethylation with trimethylation during elongation, although the function for this is 
unknown (375). 
H3K79me2 appears to be upregulated in the H4 fractions. In the literature, K79me2 appears to be 
independent to K79me3, and unlike K79me3 which remains somewhat the same throughout the cell cycle, 
K79me2 increase between the G1 and S phase, and continues to increase towards the G2/M phase (376,377). 
Along with K27ac, these are the only two marks which increase in the H4 fraction possibly indicating some 
kind of potential link, however literature makes no mention of observing these two marks together. 
 Conclusions and Future Work 
By combining the sensitivity of a LIT MS, and increased resolution of zoom scans in an approach similar to 
SRM based acquisition, 100 fold sensitivity was observed for H3 modified histone peptides making them 
distinctly visible above the baseline and even permitted up to three technical replicates from 2 pooled tissues 
only containing ~105 cells. This technique therefore can utilise far less material than traditional approaches 
that require at least 106 cells for a single replicate. Such sensitivity improvements would be greatly beneficial 
with other ChIP-MS based enrichment techniques as less material is required saving time and money when 
generating such samples. Furthermore when applying this method to all histone families fractionated via a 
priori chromatography, H3 modified histone peptides were detected in all family pools. This separation 
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appeared to be resultant of differences in H3 proteoforms. This is a worrying find as this implies that specific 
modifications and combinations can be lost when utilising this approach.  
4.10.1. Further work 
It would be most desirable to observe the absolute limit of detection of histones quantitation from cells by 
carrying analysing serial dilutions of accurately counted cell amounts by a method such as fluorescence-
activated cell sorting (FACS) or alternatively by measuring the histone content after extraction. However, in 
the event of rare tissue types, approximating the amount of sample required would mostly benefit from 
approximate cell counts as a large number of protein assays are either destructive or not sensitive enough. 
Non-destructive spectrophotometry assays using 280 nm absorption would have to be aimed at the less 
absorptive tyrosine residues as histones do not contain tryptophan. Assessing to see if the method can be 
expanded to target other histone family PTMs would also be of great benefit. Furthermore, it would be useful 
to compare the LIT sensitivity to that of a newer Orbitrap based mass spectrometer. It may transpire that too 
many ions are lost during holding and transferring of ions throughout the instrument before the Orbitrap is 
able to make a reading. 
Only a priori chromatography fractions known to contain histone families were studied using the H3 targeted 
method. It may be worth re-investigating all fractions with the targeted methods to make further conclusions 
regarding histone proteoform separation across the chromatogram. It is also important to note that whilst 
blanks were run in between LC-MS samples, blanks were not run inbetween samples queued for offline LC 
fractionation. Furthermore histones may retain structure and interactions even under acidic conditions, which 
may affect their chromatographic separation as structured histones have a smaller surface area with which to 
interact with the stationary phase. To minimise this risk, histones should first be fully denatured using heat or 
chaotropic reagents such as urea before being run on offline LC. Control experiments are then also needed 
to ensure that the modifications based separation observed is not resultant from either offline LC carry over, 
or carry over occurring through the LC-MS blank samples, would be to run the targeted histone method on 
offline LC blanks and the LC-MS blanks in between histone samples followed by an attempt to detect or 
quantitate histone H3 modifications. Should the proper controls be clear of any histone H3 PTMs it would be 
158 
 
concerning as it suggests that offline fractionation is selectively removing specific histone H3 proteoforms 
thereby affecting any quantitative conclusions. It would then mean that any analysis should be conducted on 
the one pot methods that were utilised for the tissue based histone H3 methods in order to capture all PTM 
information.   
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 General introduction: Identifying Protein-ligand binding 
sites 
Identifying the site at which a ligand binds a protein is highly useful in drug development. This information 
can be used to understand a compound’s mechanism of action thereby permitting development of 
analogues with more potency, efficacy, and specificity. Ultimately, a high resolution structure of a protein-
ligand system obtained using X-ray crystallography and 3D-EM techniques (as discussed in Ch3 section 1.3) 
are most desirable. With high resolution information, drug series development becomes a more informed 
process whereby chemical alterations can be made logically for better compound properties. This informed 
process has the potential to reduce the number of ineffective candidates synthesised in a chemical series. 
However, often such high resolution techniques are not possible as not only is crystallising a protein difficult, 
adding something as simple as a small molecule can perturb the formation of even previously crystallisable 
proteins. As a result of this, alternative techniques are required.  
In the event a small molecule probe is able to covalently bind, it may be analysed directly using traditional 
bottom up proteomics as long as the bond is able to survive the sample preparation procedures and 
ionisation. In this way they may be searched as a larger version of a PTM and an expected mass shift may be 
used in traditional proteomic software. The majority of small molecules however will not covalently bind to 
target proteins. In order to identify binding domains for small molecules, a small molecule analogue can be 
synthesised with a photoreactive group in order to covalently attach it to the proteins that use it. In this way 
we can identify what part of the protein sequence is interacting with the probe when X-ray crystallography or 
3D-EM is unavailable. However, this technique may not always be straightforward if ESI proves mildly 
damaging to the probes, as unrecognisable peptide masses may be produced making database searching 
difficult. Furthermore, due to the random insertion nature of photreactive probes, the search space of 
peptide PTM would have to be greatly widened as virtually any amino acid residue may become modified. 
This in turn however may result in a large degree of false positives requiring a great deal of further validation. 
Native mass spectrometry is also emerging as a technique to analyse protein-ligand complexes as it 
preserves the integrity of a protein even upon entry into the MS allowing small molecules to be 
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simultaneously analysed (97–99). Combining this with the development of new fragmentation techniques 
such as UVPD, the regions were protein-ligand interactions are occurring can be predicted based on the 
fragmentation stage at which a ligand is released (378,379). 
5.1.1. G9a 
G9a is a HKMT and part of the SU(VAR)3-9 family proteins that catalyse mono- and dimethylation on histone 
H3 lysine 9 through it's SET domain. This results in Heterochromatin protein 1 (HP1) recruitment and 
subsequent gene silencing through the prevention of transcription (380). Following this, DNA 
methyltransferase 1 (DNMT1) is then recruited to methylate DNA on nearby sites further reinforcing gene 
silencing (381).  In addition to the catalytic SET domain G9a also contains an ankyrin repeat binding domain 
responsible for protein interactions as well as binding to H3K9me1 and me2 and acting as a recruitment 
protein (366). Lastly the N-terminus is implicated in nuclear localisation. G9a methyltransferase activity is 
predominantly carried out when in complex as a heterodimer with G9a-Like Protein (GLP) (25). G9a 
overexpression has been linked to a number of cancers with higher expression being linked to poor 
prognosis (382–384). 
 Motivation and importance 
The reversible nature of epigenetics is in general becoming a growing area of therapeutic interest and with 
the success of drugs such as vorinostat (discussed in section 2.2) attention is being drawn to alternative PTM 
modifying proteins such as HKMT targets (37,385,386). In this work we focus our attention on studying a 
protein-ligand system comprised of the HKMT, G9a, and a known inhibitor, chaetocin, in an attempt to better 
understand the mechanism of inhibition so that alternative analogues with improved inhibitive properties 
may be developed.  
 Previous Work: G9a-Chaetocin 
Chaetocin (Figure 42) is an epipolythiodioxopiperazine (ETP) containing fungal toxin that can be isolated 
from chaetomium minutum fermentation and was reported as the first inhibitor of the SU(VAR)3-9 HKMTs 
(387). Chaetocin showed far less activity to non SU(VAR)3-9 family proteins such as PRSET7 or SET7/9 
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resulting in the suggestion that it is specific to the SU(VAR)3-9 enzymes class. It was later found that 
chaetocin is also able to inhibit other SU(VAR)3-9 family proteins including the human analogue SUV39H1 
and mouse G9a. As human G9a is closely related to SUV39H1, it can also be inhibited by chaetocin (388). It 
had previously been assumed that the disulphide component (Figure 42 A in red) was not considered 
essential to chaetocin’s functionality (387) however analogues without the disulphide functionality had very 
little effectiveness (389,390)(examined further by (391), see Figure 43). 
 
Figure 42. Structure of Chaetocin. 
The disulphide component is considered important in function (A, red) as removing it decreases the
effectiveness of inhibition (389,390). Reducing the disulphide bond (B, blue) also decreseases the
effectiveness of function (392). 
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Figure 43. G9a Concentration-Inhibition Curves for ETP Analogues. 
ETP analogues containing a disulphide bond (analogues a and d corresponding to inhibitions graphs a 
and d respectively) reduce activity more effectively compared to non-disulphide containing analogues (b
and c corresponding to inhibition graphs b and c respectively). Figure adapted from Cherblanc et al. 2013 
(391). 
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 Technical Challenges and Opportunities 
From detailed collaborator’s work with SU(VAR)3-9 family proteins we were confident that chaetocin was 
covalently binding via disulphide bonding with cysteine residues (Figure 43, Figure 44) (392). However due to 
potential ESI instability issues of chaetocin or chaetocin-cysteine bonding, identifying the correctly modified 
G9a region or peptide was challenging. Identifying how and where chaetocin binds to G9a would result in 
important understanding into the mechanisms of action of these inhibitors. More specific analogues with 
better specificity and efficacy may then be later developed based on this information potentially resulting in 
an effective new class of drugs specific to G9a HKMT activity.  
Figure 44. G9a inhibition by chaetocin and SAH in the presence and absence of DTT. 
(a, b) Effect on the potency of chaetocin with or without 30 min preincubation time before measuring G9a 
activity inclusive and exclusive of DTT (1 mM in the buffer), and (c) effect of preincubation of SAH with 
G9a, also at 0 or 30 min preincubation, as a negative control for time dependency. The differences 
between a and b indicate that in the presence of DTT chaetocin’s inhibitory effects are reduced below the
Log.[Conc] M of -5 after 30 mins of incubation. Figure adapted from Cherblanc et al. 2013 (391). 
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 Proposed Methodology 
As cysteine bonding was highlighted as a highly probable mechanism for chaetocin function by collaborators 
(391,392). Its efficiency of inhibition on SU(VAR)3-9 proteins and G9a compared to SETD7/8 based complexes 
prompted a clustal amino acid sequence alignment of these proteins (Figure 45). It was found that there was 
a very high level of cysteine conservation in the sequences surrounding the SET domain between SUV39H1, 
SUV39H2 and G9a when compared to SETD7 further strengthening the hypothesis of a cysteine based mode 
of action. MS method analysis from previous work had indicated difficulty with identifying the cysteine-
peptide interaction either as a result of chaetocin ESI instability or instability of the chaetocin-cysteine 
disulphide bond. Cysteine labelling has been previously proposed for fluorescence based quantitative 
analysis of changes in free or occupied thiol groups (393,394). We therefore proposed an indirect cysteine 
labelling approach for identifying the sites most likely bound by chaetocin to narrow the number of peptide 
targets and then further develop methods to directly identify the exact peptides bound by chaetocin. 
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Dual Labelling 
A dual labelling approach was considered the best alternative in indirectly indicating sites that were most 
likely bound by chaetocin (Figure 46). In order for this method to function, two comparative samples were 
required. A G9a control without any chaetocin treatment resulted in baseline values of differential chemical 
labelling to which values for a chaetocin treated G9a sample were compared. However, in order for this 
method to function successfully a number of considerations were needed. Firstly due to the abundance of 
cysteines found in G9a in, care needed to be taken to ensure that a redox potential was maintained so that 
disulphide bonds would not dissociate and re-form unnaturally during sample handling, but also not 
Figure 45.  Clustal Comparison of Related Histone Lysine Methyl Transferases. 
Clustal comparison showing the large amount of cysteine conservation between the amino acid sequences of 
G9a (EHMT2) and the SU(VAR)3-9 proteins SUV39H1 (SUV91) and SUV39H2 (SUV92) compared to SETD7 and
SETD8. 
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interfere with the addition of chaetocin. Commonly used redox miming reagents are DTT, TCEP and GSH-
GSSG, added at specific concentrations. However, collaborators had shown that DTT had a direct impact on 
chaetocin binding, and the free thiol of GSH would also sequester chaetocin. We were informed that TCEP 
was observed to not be as detrimental to the inhibition of chaetocin and was therefore used as a substitute. 
Secondly, whist care was needed to not dissociate already formed disulphide bonds, it was necessary that all 
free thiols were equally accessible to modification. Denaturing agents were required to expose all non-
bonded cysteines without disrupting already formed disulphide bridges. Chaotropic agents such as 
Guanidine HCl or urea will destabilise hydrogen bonding interactions between the structurally important 
amino acid residues whilst not acting as reducing agents. Urea is a milder chaotrope compared to guanidine 
HCl and can also undergo degradation into isocyanic acid which can result in carbamylation of peptides and 
therefore guanidine HCl was preferred. Other treatments such as heat were decided against as they may have 
resulted in chaetocin to dissociate by overcoming the required energy barriers, whilst detergents are not MS 
friendly. Lastly, a N-ethylmaleimide (NEM)/Iodoacetamide dual labelling approach had been decdided upon. 
NEM was chosen as the first label based on its more efficient alkylation of free thiols at a lower concentration 
and faster rate of reaction at low to neutral pHs (Rogers 2006). However after use, NEM needed to be 
removed from the sample using C18 SPE before continuing, as further cysteine bonds were to be later 
exposed. The rest of the protocol is a typical is solution trypsin digest carried out in ammonium bicarbonate 
pH 8. The remaining cysteine bonds, including bound chaetocin, are reduced using DTT and the newly 
exposed thiols are alkylated using iodoacetamide leaving behind a carbamidomethyl group that has a 
different molecular weight when compared to the maleimide. 
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Data anaylsis 
Samples were analysed by LC-MS and pre-prosessed on a Sequest proteomics database searching for 
carbamidomethyl and NEM thioether modifications of cysteine residues with the addition of a commonly 
observed sulphoxide on the NEM thioether. Full sequence coverage for a single MS analysis is uncommon as 
a decent fragmentation spectra for every peptide is difficult to obtain. A commonly occurring reason for this 
is when peptides are too small or too large they produce a poor or overwhelming number of CID fragments 
(respectively) as observed for the NCK, GYENVPIPCVNGVDGEPCPEDYK and 
NITHLQHCTCVDDCSSSNCLCGQLSIR peptides. Furthermore the software often struggles to identify the exact 
Figure 46. Overview of Dual Cysteine Labelling Workflow. 
The workflow indirectly identifies peptides originally bound to chaetocin (orange square) by quantitatively 
comparing NEM (blue triangle)/Iodoacetamide (purple trapezoid) labelled cysteine residues (red ellipsoid). 
An increase in iodoacetamide labelling in the treated sample (+chaetocin) compared to NEM labelling in the 
control sample (-chaetocin) is indicative of chaetocin binding. To achieve this difference in labelling, two G9a
samples are prepared, one chaetocin treated and the other untreated. The samples are denatured using 
Guanidine HCl to unravel the proteins and expose all naturally reduced cysteine residues. The samples are 
then desalted into NEM to label these naturally reduced cysteine residues. DTT is then used to reduce any
remaining natural di-sulphide bonds, which are then labelled with iodoacetamide. The proteins are
proteolytically cleaved using trypsin, analysed using LC-MS, quantitated and normalised to compare NEM to 
iodoacatamide labelling. 
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location of variable modifications when more than one modifiable site exists. To accommodate for the non-
comprehensive detection of all cysteine containing peptides and modification combinations, manual 
assessment of each potential modified peptide was required. To aid in manual assignment of these peaks a 
combination of methods were used including the aid of an observed elution pattern for modified peptides 
following the elution order: carbamidomethyl < NEM thioether sulfoxide < NEM thioether in addition to 
multiple charge states of the same peptide. The majority of peptides analysed had at least two charge states 
available for integration with exception to smaller peptides. Larger peptides containing a number of 
combinatorial modifications had very wide retention times and also contained a number of maximal peak 
heights as would be expected due differences in chromatographic properties and were integrated as one 
peak. 
 Materials and Methods 
All chemicals were purchased from Sigma at the highest grade/purity unless otherwise stated. All LC-MS 
solvents were purchased at LC-MS grade from Fisher Scientific. Amino acid residues 913-1193 of G9a 
containing the pre-SET, SET and post-SET domains with the addition of a histidine TAG at the N-terminal 
region was supplied at 2.67 g/L in 20mM Tris pH 8, 150mM NaCl by Domainex (Cambridge, UK). Chaetocin 
was supplied by Fanny Cherblanc from the Fuchter group. Thomas Chavas from the DiMaggio group carried 
out the sample preparation and data analysis for the direct chaetocin binding analysis. 
5.6.1. Dual Labelling 
Cysteine labelling and in solution digestion 
450 µg G9a SET domain was dialysed into 100 mM NaCl, 1 mM tris(2-carboxyethyl)phosphine (TCEP) and 50 
mM Hepes pH 7.3 at 4 °C. From this dialysed G9a SET, 2 samples were prepared: a control sample to which 
no Chaetocin was added, and a treated sample where chaetocin was added to the G9a SET at a molar ratio of 
2:1 and left to react at 25 °C for 30 mins. To both the control and the treated samples, a final concentration 
of 6 M Guanidine HCl (Promega) was added followed by addition, n-ethylmaleimide (NEM), at a final 
concentration of 14 mM to label cysteines not engaged in disulphide bonding nor interacting with chaetocin. 
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The reaction took place over 30 mins at room temperature (~23 °C). A buffer exchange to remove guanidine 
HCl and excess NEM was done using Zip Tips with multiple elution steps to ensure the proteins were fully 
eluted, followed by volume reduction via vacuum centrifugation. Both samples were reconstituted in 100 mM 
ammonium bicarbonate, pH 8.5, and reduced in a final concentration of 5 mM DTT for 1 hour at 51 °C. 
Iodoacetamide was dissolved in 50 mM ammonium bicarbonate and added at a final concentration of 14 
mM to label reduced cysteines. The reaction proceeded at room temperature for 45 mins in the dark and was 
quenched by returning the DTT concentration back to 5 mM. Digestion was carried out with proteomics 
grade trypsin (Promega) at a 1:20 ratio for 6 hours at 37 °C. Solvent exchange using ZipTips (Merck Millipore) 
was used to reconstitute both samples into the correct loading solvent for nanoLC-MS. 
LC-MS analysis 
Chromatography was carried out using an Ultimate 3000 RSLCnano System (Dionex), first loaded onto an 
Acclaim PepMap RSLC Nano-Trap Column, C18 stationary phase, 5 µm particle size, 100 Å pore size, 100 μm 
internal diameter, 20 mm length (Thermo Fisher) using a loading buffer comprised of 0.1% TFA, 0.5% 
acetonitrile and 95.4% H2O running at 3 µL/min, switching after 3 mins onto with an Acclaim PepMap100, 
C18 stationary phase, 3 μm particle size, 100 Å pore size, 75 μm internal diameter × 15 cm length separation 
column (Thermo Fisher). The LC conditions comprised of a flow rate of 0.3 µL/min and a linear gradient 
starting at 1% B (5% H2O, 95% MeCN, 0.1% Formic Acid and 99% A (0.1% FA, 100% H2O) and increased to 
95% B over 70 mins. Mass Spectrometry (MS) was carried out using a LTQ Velos Pro linear ion with an trap 
(Thermo Scientific) 80 minute acquisition time over a 240-1800 m/z scan range, with collision energy of 35. 
The top 5 most intense ions from the first scan were then further fragmented to produce the ions needed for 
peptide identification. A dynamic exclusion list with a repeat count of 2, repeat duration of 10 secs, exclusion 
list size 100 and exclusion duration of 100 secs was employed to prevent repeat sampling of a previously 
fragmented peptide. 
Data analysis 
Preliminary peptide identification from MS data was conducted using a Sequest search in Proteome 
discoverer 1.3 (Thermo Fisher) against the Uniprot database with added G9a. Settings used included a mass 
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threshold of 240-1800 Da, CID activation type, Arg and Lys trypsin cleavage, 2 missed cleavage allowance, 2 
Da precursor mass tolerance and reverse decoy target false discovery rate values of 0.01/0.05 for 
strict/relaxed (respectively). Dynamic side chain modifications searched for were carbamidomethyl (+57.021) 
from the iodoacetamide treatment, NEM thioester (+125.048 Da) and NEM thioester in sulfoxide form 
(143.058 Da) on cysteine residues and oxidation (+15.995 Da) on methionine residues. The two most 
abundant charge states on all cysteine containing peptides were compared to assess the validity of 
identifications and were then quantitated manually through peak area integration of the extracted ion 
chromatogram of the monoisotopic peak. This was done for all possible peptide modification combinations 
on both cysteine and methionine residues and both charged state areas were summed for each peptide 
modification combination. The ratio of total NEM to cabamidomethyl for each peptide was calculated and 
the treated samples were compared with respect to the control. 
5.6.2. Direct G9a-chaetocin: 
Coupling and in solution digestion 
After narrowing down the number of potential sites of chaetocin binding, a more targeted approach was 
taken to directly observe chaetocin bound to G9a peptides. To do this 200 µL G9a (5 mM Tris, 250 mM NaCl, 
2 mM TCEP, 0.26 mg/mL), 0.2 µL of 20 mM chaetocin in DMSO was added for final concentration of 20 µM. 
This was incubated for 1 hour at 37 ˚C. The sample was then concentrated to 100 µL using Amicon spin 
columns (Merck, Millipore) to which 300 µL of 8 M Guanidine HCl was added for a final concentration of 6 M.  
Unlike traditional in solution digestion, reduction was avoided to prevent removal of chaetocin adducts. 
Therefore after denaturation alkylation was directly performed via the addition of iodoacetamide at a final 
concentration of 14 mM and incubated in the dark for 45 mins. A further 420 µL of 100 mM ammonium 
bicarbonate was added and the solution was left in the dark for another 30 mins. The volume was 
concentrated to 100 µL using amicon spin columns, to which another 400 µL of 100 mM ammonium 
bicarbonate was added. The sample was re-concentrated a final time to a volume of 100 µL. Trypsin was 
added at a 1:20 ratio and left incubating overnight at 37 ˚C. The solution was acidified by adding 2% v/v FA 
to quench the reaction and desalted by using Zip Tips. LC-MS was then conducted as described above. 
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Data analysis 
Data analysis was carried out using an in-house built targeted peptide sequencing algorithm that is capable 
of searching spectra using a given peptide sequence regardless of precursor mass followed by careful 
manual assessment of the fragments produced. As cysteine 994 (CWYDKDGR, and CWYDKDGRLLQEFNK) 
from dual labelling experiments was highlighted as the most likely target and emphasis was placed on this 
peptide. 
 Results and Discussion: Dual cysteine labelling MS data 
analysis 
Raw and processed data from the extracted ion chromatograms using a minimum of two charge states where 
possible can be seen in Table 6. Of the 280 amino acid residues contained within the G9A SET domain, 249 
were identified from the LC-MS/MS data resulting in 89% sequence coverage (see underlined residues in 
Figure 47). The G9a SET domain contains a total of 20 cysteines distributed on 12 peptides, and the fold 
change of 12 cysteines in response to chaetocin treatment were quantitated on 9 of these peptides (see 
doubly underlined residues in Figure 47). The 3 remaining cysteine-containing peptides could not be 
accurately quantitated, as two peptides were unusually large in size and thus exhibited poor ionization 
efficiencies (i.e. a 23 amino acid peptide containing cysteines 937 and 946, and a 27 amino acid peptide 
containing cysteines 974, 976, 980, 985 and 987), and one peptide containing cysteine 1027 was only 3 amino 
acids in length and could not be fragmented efficiently for identification. Although these 3 peptides could 
not be accurately quantitated using chromatographic peak areas, manual inspection of the available MS/MS 
data did not reveal significant evidence of carbamidomethyl labelling (i.e. chaetocin binding).  Out of the 12 
quantitated cysteines, 5 exhibited a greater than 2 fold change in carbamidomethyl labeling upon chaetocin 
treatment (see Figure 47). These corresponded to Cys994 (4.8 fold increase), Cys1017, 1021 and 1023 (3.1 
fold increase) and Cys1115 (2.1 fold increase). 
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Table 6. G9a Peptide Labelling Ratios. 
Areas were computed from extracted ion chromatograms (XICs) for the two most abundant charge-states 
('Charge State 1' and 'Charge State 2'), for both chaetocin treated and control samples. 
'Sequence' specifies the peptide that was quantitated from the LC-MS data; 'Location' denotes the position 
of the N-terminal amino acid of the peptide in the full-length G9a sequence; 'Cys Location' is the 
corresponding location of the cysteine residues. The cysteine residues are either labelled with iodoacetamide 
('IA'), N-ethylmaleimide ('NEM'), or an oxidated form of NEM ('NEMox'). The 'Ratio (Treated/Control)' 
between treated and control represents the fold increase in relative iodoacetamide labelling upon chaetocin 
treatment, thus representing the fold change in disulfide bonding. 
Sequence Location Cys Locations Modification
Treated 
Charge 
State 1
Treated 
Charge 
State 2
Total 
Area 
Treated
Ratio 
Treated 
(NEM/IA)
Control 
Charge 
State 1
Control 
Charge 
State 2
Total Area 
Control
Ratio 
Control 
(NEM/IA)
Ratio log 
(Treated/Control)
IICR 921 923 IA 3.17E+08 3.82E+08 6.99E+08 4.06 2.48E+07 3.84E+07 6.33E+07 2.71 0.67
IICR 921 923 NEM 1.01E+08 2.74E+09 2.84E+09 4.93E+07 1.22E+08 1.72E+08
IICR 921 923 NEMox 0.00E+00 0.00E+00
YISENCETSTMNIDR 952 957 IA 2.11E+08 1.24E+06 2.12E+08 3.53 2.59E+08 1.58E+07 2.74E+08 2.18 0.62
YISENCETSTMNIDR 952 957 NEM 2.80E+08 7.29E+06 2.87E+08 1.13E+08 1.38E+07 1.27E+08
YISENCETSTMNIDR 952 957 NEMox 4.41E+08 2.07E+07 4.61E+08 4.22E+08 4.90E+07 4.71E+08
CWYDKDGR 994 994 IA 2.47E+07 1.31E+07 3.78E+07 4.59 1.93E+07 1.60E+07 3.53E+07 22.16 4.82
CWYDKDGR 994 994 NEM 5.60E+07 6.40E+07 1.20E+08 6.92E+08 4.08E+07 7.32E+08
CWYDKDGR 994 994 NEMox 3.84E+07 1.51E+07 5.35E+07 3.24E+07 1.69E+07 4.93E+07
IEPPLIFECNQACSCWR 1009 1017, 1021, 1023 3IA 1.47E+08 1.22E+07 1.59E+08 1.43 9.12E+07 9.74E+06 1.01E+08 4.48 3.14
IEPPLIFECNQACSCWR 1009 1017, 1021, 1023 3NEM 2.57E+07 6.02E+06 3.17E+07 6.33E+07 1.27E+07 7.59E+07
IEPPLIFECNQACSCWR 1009 1017, 1021, 1023 3NEMox 4.08E+07 2.14E+07 6.22E+07 5.29E+07 2.06E+07 7.35E+07
IEPPLIFECNQACSCWR 1009 1017, 1021, 1023 2NEM1NEMox 2.82E+07 1.66E+07 4.48E+07 1.04E+08 4.31E+07 1.47E+08
IEPPLIFECNQACSCWR 1009 1017, 1021, 1023 1NEM2NEMox 4.98E+07 3.87E+07 8.85E+07 9.68E+07 5.83E+07 1.55E+08
ALQTIPQGTFICEYVGELISDAEADVR 1054 1064 IA 7.78E+07 2.95E+08 3.73E+08 0.90 1.26E+08 3.03E+08 4.29E+08 1.25 1.39
ALQTIPQGTFICEYVGELISDAEADVR 1054 1064 NEM 2.40E+07 1.01E+08 1.25E+08 8.08E+07 2.50E+08 3.31E+08
ALQTIPQGTFICEYVGELISDAEADVR 1054 1064 NEMox 1.52E+08 5.92E+07 2.11E+08 1.39E+08 6.66E+07 2.06E+08
DGEVYCIDAR 1093 1098 IA 1.26E+08 1.45E+08 2.71E+08 1.32 2.08E+08 6.96E+07 2.78E+08 0.79 0.60
DGEVYCIDAR 1093 1098 NEM 1.28E+08 3.34E+07 1.61E+08 4.68E+07 2.31E+07 6.98E+07
DGEVYCIDAR 1093 1098 NEMox 1.68E+08 2.93E+07 1.98E+08 1.30E+08 2.02E+07 1.50E+08
FINHLCDPNIIPVR 1110 1115 IA 3.35E+08 9.00E+08 1.24E+09 1.94 1.53E+08 2.93E+08 4.46E+08 4.01 2.07
FINHLCDPNIIPVR 1110 1115 NEM 2.56E+08 2.69E+08 5.26E+08 1.90E+08 1.84E+08 3.75E+08
FINHLCDPNIIPVR 1110 1115 NEMox 1.05E+09 8.16E+08 1.87E+09 7.40E+08 6.74E+08 1.41E+09
SKYFTCQCGSEK 1163 1168 2 IA 2.80E+06 1.50E+06 4.30E+06 3.63 4.16E+06 4.01E+06 8.17E+06 2.51 0.69
SKYFTCQCGSEK 1163 1168 2 NEM 7.16E+06 8.48E+06 1.56E+07 7.36E+06 1.32E+07 2.05E+07
SKYFTCQCGSEK 1163 1168 2 NEMox 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
SKYFTCQCGSEK 1163 1168 1NEM 1NEMox 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
CKHSAEAIALEQSR 1175 1175 IA 5.46E+07 5.35E+07 1.08E+08 0.94 1.10E+08 1.40E+08 2.50E+08 1.17 1.24
CKHSAEAIALEQSR 1175 1175 NEM 0.00E+00 0.00E+00
CKHSAEAIALEQSR 1175 1175 NEMox 5.21E+07 4.99E+07 1.02E+08 1.42E+08 1.50E+08 2.93E+08
NCK 1026 1027 IA 1.20E+08 1.20E+08 0.53 9.00E+07 9.00E+07 0.55 1.04
NCK 1026 1027 NEM 6.31E+07 6.31E+07 4.92E+07 4.92E+07
NCK 1026 1027 NEMox 0.00E+00 0.00E+00
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Figure 47. G9a SET Domain Sequence Highlighting Cysteines Involved in Chaetocin Binding. 
All 20 cysteine residues are highlighted in boldface, and those cysteines involved in the formation of disulfide 
bonds with chaetocin are scaled according to their fold increase in carbamidomethyl labeling upon chaetocin
treatment (the numbers above these residues represent the fold change observed). Singly and doubly 
underlined sequences indicate identified and quantitated peptides from the LC-MS/MS data, respectively. 
Shaded sequences highlight the SET domain, which is flanked on the left by the pre-SET domain and on the 
right by the post-SET domain. The arrows and twists represent β sheet and α helical secondary structural
elements, respectively, as identified by RSCB PDB accession number 2O8J. 
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Due to the multitude of cysteine residues that engaged in disulfide bond formation upon chaetocin 
treatment, it appears that chaetocin does not exhibit specificity towards a single cysteine residue, nor does it 
bind in an entirely random fashion to the G9a SET domain.  It should be noted that all of the cysteines 
observed in disulfide bond formation with chaetocin are located in unstructured regions of the SET domain, 
as determined by available structural data for G9a (395). Cysteines 994, 1017, 1021 and 1023 exhibited the 
largest fold increase and are all located in the C-terminal region of the pre-SET domain of G9a. These 
cysteines are implicated in the binding of zinc atoms, which is thought to have a structural function in linking 
random coils of the protein and stabilising the SET domain (396). There was no observed specificity for 
chaetocin with any of the 3 cysteine residues in the post-SET domain.  Interestingly, we observed some 
labelling of Cys1115, which is part of the highly conserved NHS/CxxPN region in the pseudo-knot motif of 
the SET domain and is involved in hydrogen binding interactions with the adenine ring of S-adenosyl 
methionine (SAM) and S-adenosyl homocysteine (SAH) making it plausible that adduct formation with this 
cysteine may have some direct inhibitory role (396). Analysis using the previously published crystal structure 
for G9a (208J) shows the location of all potential binding regions are localised into 3 specific clusters that are 
on the periphery of the SET binding groove (Figure 48). 
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 Results and Discussion: Direct sequencing of chaetocin 
binding on targeted peptides 
After the peptides most likely to contain the chaetocin modification were identified, they were targeted for 
further examination so that direct chaetocin binding could be observed. With the help of an in-house 
targeted peptide sequencing software, sequence matches were found to the CWYDKDGR and 
CWYDKDGRLLQEFNK peptides originally containing a 4.8 fold increase in iodoacetamide. The peptides were 
found with large mass additions (Figure 49). For the CWYDKDGRLLQEFNK peptide a mass addition of 731.18 
Da was found, which roughly equates to the mass of chaetocin (696.1 Da) and two OH additions. However, 
the spectral annotation for this peptide alone did not provide sufficient annotation of product fragments. By 
combining the annotation from the loss of one OH group and two OH groups, the spectra becomes a lot 
better annotated (Figure 49, A). A match for CWYDKDGR was also found, this time with a mass addition of 
712.18 Da roughly equating to the mass of chaetocin with a mass shift of one OH addition. Again, annotating 
the spectra without any water losses did not account for the majority of peaks. By adding the loss of one OH 
group, a much better number of annotations can be made (Figure 49, B). 
Figure 48. Crystal Structure of G9a with Highlighted SET Domain and Possible Chaetocin Binding Sites. 
The most intensely labelled cysteine residues (marked in red) from the NEM/iodoacetamide labelling are
all located on the periphery and away from the SET domain (marked in purple). The image was 
generated using PyMol displating G9a crysatllogrpaphy data accessed from the  RCSB Protein Data Bank
PDB accession number 2O8J (395). 
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Figure 49. CID Fragmentation Spectra Confirming the Presence of Chaetocin Adducts. 
G9a was treated with chaetocin, denatured using guanidine HCl, alkylated using iodoacatmide without
reduction and digested using trypsin. Peptides were analysed using LC-M and data was searched using an 
in house developed peptide specific search tool permitting large precursor mass tolerances. (a)
CWYDKDGRLLQEFNK (charge +3, m/z 882.7) and (b) CWYDKDGR (charge +3, m/z 585.4) peptides were 
identified with a mass shift corresponding to a chaetocin adduct with up to two losses of OH groups, 
resulting in a near comprehensive annotation of the spectra. 
A 
B 
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 Conclusions 
The dual cysteine labelling approach was able to indirectly back up collaborator findings that cysteine 
residues where being directly bound by chaetocin. In addition we were able to identify the most likely sites of 
binding, also showing that they were located outside of the set domain, further supporting their claim that 
inhibition was non-competitive.  This was extremely useful as previous attempts to directly detect chaetocin 
using LC-MS had proved difficult, potentially due to unforeseen mass shifts and loss of the chaetocin adduct 
due to weak bonds. The number of peptides that then needed targeting for an attempt at detecting direct 
chaetocin binding was reduced substantially. This focused our efforts and confidence, and with the aid of an 
in-house tageted peptide sequencing tool we were able to confirm chaetocin was in fact binding at the site 
most indicated through the dual labelling approach. It also transpired that the mass needed for observation 
was not that of chaetocin alone but with the addition of one or more OH groups. In addition to this OH 
groups were highly labile from the chaetocin adduct itself and needed to be taken into consideration for 
better annotation of peptides.Further work 
Further work may need to be carried out to examine if the other locations on G9a that were highlighted by 
the dual labelling approach also contain chaetocin adducts with similar observed mass shifts. If it is identified 
that chaetocin is also binding to these sites it may also be worth further investigating if all sites lead to 
inhibition by carrying out by mutation studies and inhibition assays. This approach could than also be used 
with other members of the SU(VAR)3-9 family proteins, either by directly searching for the observed 
chaetocin mass shifts already characterised, or by again using the dual labelling approach and narrowing 
down the number of peptides that require targeting. It would be interesting to also find out if chaetocin 
binds away from SET domains for these proteins also. Both of these studies could prove useful in the 
development of more specific analogues. A proposed improvement to the method could be to utilise heavy 
labelled iodoacetmide and NEM for one condition and light labels for the other. This permits sample mixing 
and analysis within a single LC-MS run whereby the respective light and heavy peptide intensities can be 
directly compared, simplifying the method by removing the need for data normalisation. 
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  Conclusive Remarks 
LC-MS is continuing to be a useful tool for addressing a great deal of many biological questions, and has 
greatly contributed to two preliminary drafts of the human proteome (83,84). Even upon completion of such 
an ambitious project, mass spectrometry will still be required alongside many other biochemical and 
biological methods to address further questions raised, such as identifying or better charactersing PPIs, 
protein structures and PTMs (397). Owing to its femtomolar sensitivity and ability for large scale high-
throughput proteomic analysis is almost commonplace for a number of experiments, thanks to the great 
improvements in instrumentation and methodology (397,398). 
CXMS 
CXMS is maturing as a technology, and whilst over recent years great interest has been placed in irreversible 
cross-linkers (209) attention is now shifting towards low-energy MS cleavable linkers that can be utilised in 
an MS3 approach (185,399) (6,400), as demonstrated by the integration of DSSO developed by Kao et al. 
(257) and Thermo Scientific. At the beginning of this work, a range of low-energy cleavable cross-linkers had 
already been published, although ambiguity surrounded those designed for a MS3 based approach and 
those to be utilised in the MS2 approach with signature m/z peaks identifying the presence of a cross-link. 
This ambiguity delayed progress in our work requiring the synthesis and testing of a range of proposed MS3 
cleavable cross-linkers suitable for our needs. T2 enrichment is also a key issue and is currently addressed by 
using non-specific techniques such as SCX and SEC. We attempted to overcome this problem by using 
biotin-avidin capture systems for cross-links, with the aim of engineering a simpler release from avidin by 
utilising previously reported biologically orthogonal cleavable linkers. We attempted synthesising and using a 
number of proposed cleavable linkers, although none of those trialled were effective in conjunction with our 
cross-linking workflow. However, through ongoing research, a wide variety of biorthogonal enrichment 
strategies are being developed and applied in CXMS (253,267–269) and it will not be long before specific 
enrichment strategies also become standard in CXMS workflows. Although we were unsuccessful in creating 
a complete workflow to maximise enrichment and prioritise MS sampling of T2, the removal of T0 was clearly 
able to contribute a great deal of simplification in the number of chromatographic peaks that were 
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observable. As the process of capturing T0 is relatively straightforward, it can be easily incorporated into 
most CXMS workflows.Histone PTMs 
Previous bottom up histone PTM methods have largely focussed on throughput and maximising the number 
of histone PTMs for quantitation (176), or maximising the sensitivity of specific PTMs. We have been able to 
utilise the speed and sensitivity of a LIT mass analyser in an approach similar to SIM and PRM acquisition for 
31 abundant histone H3 lysine methylation and acetylation PTM combinations from a single sample, 
previously thought to not be possible (358). At present the method utilises a normalisation based approach 
which may not take into consideration large shifts in less commonly observed histone PTMs. However, this 
can be remedied with very little modification to the method. A heavy labelled synthetic histone peptide 
library is available which can be added to the sample and used as a quantitative marker to compare against 
(348). Additionally zoom scan windows can easily be widened with little consequence to the method to 
accommodate the larger mass ranges. Should the need arise, new masses can be incorporated and re-
processed using the MILP algorithm so that the m/z and time scheduling can be recalculated. This method 
could also be easily transferred onto orbitrap instruments such as the Fusion Lumos (Thermo Scientific) which 
permits a larger degree of freedom when programming methods and allows for the parallel use of mass 
analysers.  
Dual cysteine labelling 
Through indirect cysteine labelling, collaborator findings showing that chaetocin was directly bound to 
cysteine through disulphide bonds was verified (391,392), and in addition the most likely residues to be 
bound were also indicated. Although previous LC-MS attempts to show chaetocin directly bound to cysteine 
containing peptides had proved difficult, by targeting the indirectly identified peptides we were able to 
confirm direct binding. Additionally, it was identified that the difficulty surrounding the identification was a 
result of OH group losses from the chaetocin molecule itself, altering the observed mass and thereby 
preventing conventional database peptide sequencing. Additional work is required to characterise the other 
labelled G9a peptides, perhaps through targeted SIM and PRM based approaches for the expected shifts in 
chaetocin mass. If other sites are identified a non-specific mechanism of chaetocin may be revealed, although 
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it could also be resultant from high concentrations of chaetocin being used in the in vitro assay and would 
not be reproducible in vivo. Controls to confirm this could be done by measuring the amount of observed 
G9a-chaetocin interaction across a range of chaetocin concentrations as well as by assessment of in vivo 
G9a-chetocin binding of these sites. To simplify the retrieval of G9a, an enrichment tag may need to be 
incorporated into G9a. Once all the G9a-chaetocin binding sites have been identified, mutation studies and 
inhibition assays should be carried out to confirm the effectiveness of G9a inhibition at each site. 
 Further Applications of the Targeted Global Histone 
Method 
CRISPR as an Alternative to ChIP-MS 
Due to the increasing interest in characterising the function of suspected histone writers/erasers, the 
previously described targeted histone PTM method (discussed in section 4.6) could be coupled to CRISPR 
based approaches as an alternative to ChIP-MS. Histone PTMs specific to writers/erasers can be studied by 
applying the targeted method to histone modifiers attached to Cas9 (343). It is important to note that PTMs 
altered in this way may be unnaturally forced and not endogenously authentic. Additionally, a non-result may 
not be reflective of enzyme function, but resultant from missing regulatory mechanisms. 
Cas9 can also be used to specifically target gene loci for the pull down of bound proteins in a technique 
referred to as enChIP (344), thereby permitting MS histone PTM profiling of attached nucleosomes. By 
targeting gene loci nearby to sites of interest (e.g. transcription start sites), a nucleosome-focussed view may 
begin to describe the epigenetics occurring during a specific event of interest. 
High Throughput Histone PTM profiling in Drug Discovery 
An alternative usage of the targeted histone method may be for higher throughput screening of PTM profiles 
altered by therapeutic molecules designed to have epigenetic targets. Therapeutics that have epigenetic 
targets are a growing area of interest (37,385,386,401) and such assays may be highly sought after. Provided 
that histone propionylation is performed using reagents more amenable to automation (e.g. NHS based 
chemistry), a large portion of the preparation for histone PTM profiles can be automated for higher 
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throughput (e.g. propionylation, digestion and LC-MS). To aid in throughput, histones from control and drug 
treated cell models could be SILAC labelled and pooled so that they may be analysed within the same LC-MS 
run (346,349). Alternatively, different drug concentrations could also be multiplexed with TMT reagents (352) 
to create a dose response curve, although TMT reagents have yet to be used in conjunction with histone PTM 
analysis. 
 Further Applications of CXMS 
In vitro nucleosome CXMS 
Individual nucleosomes (mononucleosomes) can be recombinantly synthesised and then assembled in vitro 
(402,403) and desired PTMs can also be attached onto histones using a number of different techniques (404). 
Mononucleosomes have been used as a simplified in vitro way to study a wide range of chromatin related 
intra-nuclear functions including regulatory protein binding (405), function of histone PTMs (406,407) and 
structure (408,409). In a similar approach to attempting to crystallise nucleosomes with interacting protein 
partners for X-ray crystallography, recombinant proteins may be added to mononucleosomes and then 
CXMS can be used as a quicker and easier alternative to identify which protein regions may be interacting, 
especially for protein complexes that are difficult to obtain a crystal structure for. 
In vivo nucleosome CXMS 
As further developments are made to the cross-linking procedure, specifically the enrichment of T2 links, 
cross-linking can be carried out more easily in vivo for the study of the chromatin environment. To our 
knowledge, this technique has only been applied to cell lysates (6,410,411). Although a number of cross-
linkers such as DSS are marketed as cell membrane permeable, attempting to traverse the cell membrane 
may be difficult. In order to study the PPIs within nuclei a simpler alternative exists. Nuclear pores are 
permeable to smaller molecules such as a cross-linkers and nuclear isolation protocols exist for harvesting 
live nuclei (412) therefore permitting cross-linking within the native nuclear environment. 
Alternatively if T2 from an interaction of interest are not abundant enough in signal intensity for adequate 
detection as a result of competition from other cross-linked peptides, a desired chromatin binder of interest 
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may be transfected with an attached tag, in a similar approach used for PP2A (discussed in section 3.1), prior 
to nuclear isolation. The nuclei may then be cross-linked and then the protein tags enriched for, thus 
resulting in a cleaner background for the study of in nucleo systems thereby reducing the level of data 
analysis complexity. It is important that any enrichment or epitope tags chosen do not contain primary 
amines or lysine residues, e.g. HA (YPYDVPDYA) or histidine (HHHHHH), as tags that do contain lysine, e.g. 
Myc (EQKLISEEDL) and Flag (DYKDDDDK), may be cross-linked preventing their enrichment. 
Examining PPIs and structure under different conditions using cross-linking 
A potential method to study conformational changes as a result of changes in conditions may be achieved 
using heavy and light cross-linkers for each condition. The heavy and light samples would be mixed, analysed 
in the same LC-MS run and the differences compared. A reverse labelling experiment could also be used to 
provide a replicate. Changes in conformation would result in differences in heavy to light ratios to be 
observed. A similar approach could also be used to study histone binding proteins in the presence and 
absence of various histone PTMs. 
6.3.1. Combining In Nucleo CXMS with Histone PTM analysis. 
In a similar way to analysing histone PTMs after a ChIP-MS approach, CX-ChIP-MS histone PTM analysis 
could also become an available technique. Tagged proteins known to interact with nucleosomes would first 
be cross-linked and then enriched for in a similar approach to X-ChIP (413). They would then analysed by LC-
MS using the previously described MS3 approach (outlined in section 3.8). Following the identification of T2 
peptides, the data can then be searched for further PTMs by specifying precursor mass within the MS2 level 
and product spectra in the MS3 level, by utilising software such as PEAKS or PepNovo, with cross-linker 
spacer fragments included as a variable modification. It may transpire that certain PPIs will only occur in the 
event that specific PTM combinations are observed on histones. 
 Further Applications: Dual Cysteine Labelling 
A proposed improvement to the method could be to utilise heavy labelled iodoacetamide and NEM for one 
condition and light labels for the other. This permits sample mixing and analysis within a single LC-MS run 
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whereby the respective light and heavy peptide intensities can be directly compared, simplifying the method 
by removing the need for data normalisation and improving the throughput of the method. 
This improved dual labelling method could then be applied as a screening method for the discovery of other 
effective ETP containing inhibitors against G9a as well as other members of the SU(VAR)3-9 family proteins.  
A variation of this dual labelling approach could also be used to study which cysteine residues in a protein 
are occupied in disulphide bridges. An applied use for this could be to ensure that proteins are folded 
correctly upon synthesis in different recombinant conditions (e.g. synthesis rom insect cells and bacterial) 
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Appendix 
Human H3K4un 2+ m/z: 408.733 observed m/z: 408.7161 
R.prTKprQTAR.K 
Monoisotopic mass of neutral peptide Mr(calc): 815.4501 
Variable modifications:  
N-term : Propionyl (N-term) 
K2     : Propionyl (K) 
 
 
 
  
210 
 
Human H3K4un 1+ m/z: 816.458 observed m/z: 816.4600 
Monoisotopic mass of neutral peptide Mr(calc): 815.4501 
Variable modifications:  
N-term : Propionyl (N-term) 
K2     : Propionyl (K) 
 
R.prTKprQTAR.K 
 
 
 
 
211 
 
Human H3K4me1 2+ m/z: 415.741 observed m/z: 415.7400 
R.prTKme-prQTAR.K 
Monoisotopic mass of neutral peptide Mr(calc): 829.4658 
Variable modifications:  
N-term : Propionyl (N-term) 
K2     : Methyl-Propionyl (K) 
 
 
212 
 
Human H3K4me2 2+ m/z: 394.735 observed m/z: 394.7285 
R.prTKme2QTAR.K 
Monoisotopic mass of neutral peptide Mr(calc): 787.4552 
Variable modifications:  
N-term : Propionyl (N-term) 
K2     : Dimethyl (K) 
 
 
 
  
213 
 
Human H3K4me3 2+ m/z: 401.743 observed m/z: 401.7400 
R.prTKme3QTAR.K 
Monoisotopic mass of neutral peptide Mr(calc): 801.4708 
Variable modifications:  
N-term : Propionyl (N-term) 
K2     : Trimethyl (K), with neutral losses 0.0000(shown in table), 59.0735 
 
 
 
  
214 
 
Human H3K9unK14un 2+ m/z: 535.304 observed m/z: 535.3000 
R.prKprSTGGKprAPR.K 
onoisotopic mass of neutral peptide Mr(calc): 1068.5927 
Variable modifications:  
N-term : Propionyl (N-term) 
K1     : Propionyl (K) 
K6     : Propionyl (K) 
 
 
 
  
215 
 
Human H3K9me1K14un 2+ m/z: 542.312 observed m/z: 542.3100 
R.prKme-prSTGGKprAPR.K 
Monoisotopic mass of neutral peptide Mr(calc): 1082.6084 
Variable modifications:  
N-term : Propionyl (N-term) 
K1     : Methyl-Propionyl (K) 
K6     : Propionyl (K) 
 
 
 
 
 
  
216 
 
Human H3K9me1K14ac 2+ m/z: 535.304 observed m/z:  
R.prKme-prSTGGKacAPR.K 
Monoisotopic mass of neutral peptide Mr(calc): 1068.5927 
Variable modifications:  
N-term : Propionyl (N-term) 
K1     : Methyl-Propionyl (K) 
K6     : Acetyl (K) 
 
 
 
217 
 
Human H3K9me2K14un 2+ m/z: 521.307 observed m/z: 521.2751 
R.prKme2STGGKprAPR.K 
Monoisotopic mass of neutral peptide Mr(calc): 1040.5978 
Variable modifications:  
N-term : Propionyl (N-term) 
K1     : Dimethyl (K) 
K6     : Propionyl (K) 
 
 
 
  
218 
 
Human H3K9me2K14ac 2+ m/z: 514.299 observed m/z: 514.3000 
R.prKme2STGGKacAPR.K 
Monoisotopic mass of neutral peptide Mr(calc): 1026.5822 
Variable modifications:  
N-term : Propionyl (N-term) 
K1     : Dimethyl (K) 
K6     : Acetyl (K) 
 
 
 
  
219 
 
Human H3K9me3K14un 2+ m/z: 528.314 observed m/z: 528.2398 
R.prKme3STGGKprAPR.K 
Monoisotopic mass of neutral peptide Mr(calc): 1054.6135 
Variable modifications:  
N-term : Propionyl (N-term) 
K1     : Trimethyl (K), with neutral losses 0.0000(shown in table), 59.0735 
K6     : Propionyl (K) 
 
 
 
  
220 
 
Human H3K9me3K14ac 2+ m/z: 521.306 observed m/z: 521.3100 
R.prKme3STGGKacAPR.K 
Monoisotopic mass of neutral peptide Mr(calc): 1040.5978 
Variable modifications:  
N-term : Propionyl (N-term) 
K1     : Trimethyl (K), with neutral losses 0.0000(shown in table), 59.0735 
K6     : Acetyl (K) 
 
 
 
  
221 
 
Human H3K9unK14ac 2+ m/z: 528.296 observed m/z: 528.2330 
R.prKacSTGGKprAPR.K / R.prKprSTGGKacAPR.K 
Monoisotopic mass of neutral peptide Mr(calc): 1054.5771 
Variable modifications:  
N-term : Propionyl (N-term) 
K1     : Propionyl (K) 
K6     : Acetyl (K) 
 
 
 
  
222 
 
Human H3K9acK14un 2+ m/z: 528.296 observed m/z: 528.2330 
R.prKacSTGGKprAPR.K 
Monoisotopic mass of neutral peptide Mr(calc): 1054.5771 
Variable modifications:  
N-term : Propionyl (N-term) 
K1     : Acetyl (K) 
K6     : Propionyl (K) 
 
 
 
 
  
223 
 
Human H3K9acK14ac 2+ m/z: 521.288  observed m/z: 521.2339 
R.prKacSTGGKacAPR.K 
Monoisotopic mass of neutral peptide Mr(calc): 1040.5614 
Variable modifications:  
N-term : Propionyl (N-term) 
K1     : Acetyl (K) 
K6     : Acetyl (K) 
 
 
 
  
224 
 
Human H3K18unK23un 2+ m/z: 577.849 observed m/z: 577.8500 
R.prKprQLATKprAAR.K 
Monoisotopic mass of neutral peptide Mr(calc): 1153.6819 
Variable modifications:  
N-term : Propionyl (N-term) 
K1     : Propionyl (K) 
K6     : Propionyl (K) 
 
 
 
  
225 
 
Human H3K18unK23ac 2+/ H3K18acK23un 2+ m/z: 570.841  observed m/z: 570.7826 
R.prKprQLATKacAAR.K / R.prKacQLATKunAAR.K 
Monoisotopic mass of neutral peptide Mr(calc): 1139.6662 
Variable modifications:  
N-term : Propionyl (N-term) 
K1     : Propionyl (K) 
K6     : Acetyl (K) 
 
 
 
  
226 
 
Human H3K27unK36un 2+ m/z: 829.473 observed m/z: 829.4350 
R.prKprSAPATGGVKprKprPHR 
Monoisotopic mass of neutral peptide Mr(calc): 1656.9311 
Variable modifications:  
N-term : Propionyl (N-term) 
K1     : Propionyl (K) 
K10    : Propionyl (K) 
K11    : Propionyl (K) 
 
 
 
  
227 
 
Human H3K27unK36un 3+ m/z: 553.318 observed m/z: 829.4350 
R.prKprSAPATGGVKprKprPHR 
Monoisotopic mass of neutral peptide Mr(calc): 1656.9311 
Variable modifications:  
N-term : Propionyl (N-term) 
K1     : Propionyl (K) 
K10    : Propionyl (K) 
K11    : Propionyl (K) 
 
 
 
 
 
228 
 
229 
 
Human H3K27me1K36un 2+ m/z: 836.481 observed m/z: 836.4800 
R.prKme-prSAPATGGVKprKprPHR 
Monoisotopic mass of neutral peptide Mr(calc): 1670.9468 
Variable modifications:  
N-term : Propionyl (N-term) 
K1     : Methyl-Propionyl (K) 
K10    : Propionyl (K) 
K11    : Propionyl (K) 
 
 
 
 
  
230 
 
Human H3K27me1K36me1 2+ m/z: 843.489 observed m/z: 843.4900 
R.prKme-prSAPATGGVKmr-prKprPHR.Y 
Monoisotopic mass of neutral peptide Mr(calc): 1684.9624 
Variable modifications:  
N-term : Propionyl (N-term) 
K1     : Methyl-Propionyl (K) 
K10    : Methyl-Propionyl (K) 
K11    : Propionyl (K) 
 
 
 
  
231 
 
Human H3K27me2K36me1 3+ m/z: 822.484 observed m/z: 822.4700 
R.prKme2SAPSTGGVKme-prKprPHR.Y 
Monoisotopic mass of neutral peptide Mr(calc): 1658.9468 
Variable modifications:  
N-term : Propionyl (N-term) 
K1     : Dimethyl (K) 
K10    : Methyl-Propionyl (K) 
K11    : Propionyl (K) 
 
 
 
 
  
232 
 
Human H3K27me2K36me1 2+ m/z: 548.658 observed m/z: 548.6500 
R.prKme2SAPSTGGVKme-prKprPHR.Y 
Monoisotopic mass of neutral peptide Mr(calc): 1642.9519 
Variable modifications:  
N-term : Propionyl (N-term) 
K1     : Dimethyl (K) 
K10    : Methyl-Propionyl (K) 
K11    : Propionyl (K) 
 
 
 
 
 
233 
 
H3K27me1K36me2 2+ m/z: 822.484 observed m/z: 822.46 
R.prKme-prSAPSTGGVKme2KprPHR.Y 
Monoisotopic mass of neutral peptide Mr(calc): 1642.9519 
Variable modifications:  
N-term : Propionyl (N-term) 
K1     : Methyl-Propionyl (K) 
K10    : Dimethyl (K) 
K11    : Propionyl (K) 
 
 
 
 
 
234 
 
Human H3K27me2K36un 3+ m/z: 543.987 observed m/z: 543.9000 
R.prKprSAPATGGVKprKprPHR.Y 
Monoisotopic mass of neutral peptide Mr(calc): 1628.9362 
Variable modifications:  
N-term : Propionyl (N-term) 
K1     : Dimethyl (K) 
K10    : Propionyl (K) 
K11    : Propionyl (K) 
 
 
 
 
  
235 
 
Human H3K27me2K36un 2+ m/z: 815.476  observed m/z: 815.4573 
R.prKme2SAPATGGVKprKprPHR.Y 
Monoisotopic mass of neutral peptide Mr(calc): 1628.9362 
Variable modifications:  
N-term : Propionyl (N-term) 
K1     : Dimethyl (K) 
K10    : Propionyl (K) 
K11    : Propionyl (K) 
 
 
 
  
236 
 
Human H3K27unK36me2 2+ m/z: 815.476  observed m/z: 815.4500 
R.prKprSAPATGGVKme2KprPHR.Y 
Monoisotopic mass of neutral peptide Mr(calc): 1628.9362 
Variable modifications:  
N-term : Propionyl (N-term) 
K1     : Propionyl (K) 
K10    : Dimethyl (K) 
K11    : Propionyl (K) 
 
 
 
  
237 
 
Human H3K27me3K36un 2+ m/z: 822.484 observed m/z: 822.4700 
R.prKme3SAPATGGVKprKprPHR.Y 
Monoisotopic mass of neutral peptide Mr(calc): 1642.9519 
Variable modifications:  
N-term : Propionyl (N-term) 
K1     : Trimethyl (K), with neutral losses 0.0000(shown in table), 59.0735 
K10    : Propionyl (K) 
K11    : Propionyl (K) 
 
 
 
  
238 
 
Human H3K27me3K36un 3+ m/z: 548.658 observed m/z: 548.6500 
R.prKme3SAPATGGVKprKprPHR.Y 
Monoisotopic mass of neutral peptide Mr(calc): 1642.9519 
Variable modifications:  
N-term : Propionyl (N-term) 
K1     : Trimethyl (K), with neutral losses 0.0000(shown in table), 59.0735 
K10    : Propionyl (K) 
K11    : Propionyl (K) 
 
 
 
 
 
239 
 
Human H3K27me3K36me1 3+ m/z: 553.33 observed m/z: 553.3300 
R.prKme3SAPATGGVKme-prKprPHR.Y 
Monoisotopic mass of neutral peptide Mr(calc): 1656.9675 
Variable modifications:  
N-term : Propionyl (N-term) 
K1     : Trimethyl (K), with neutral losses 0.0000(shown in table), 59.0735 
K10    : Methyl-Propionyl (K) 
K11    : Propionyl (K) 
 
 
 
 
  
240 
 
Human H3K27me2K36me2 2+ m/z: 808.486 observed m/z: 801.4564 
R.prKme2SAPATGGVKme2KprPHR.Y 
Monoisotopic mass of neutral peptide Mr(calc): 1600.9413 
Variable modifications:  
N-term : Propionyl (N-term) 
K1     : Dimethyl (K) 
K10    : Dimethyl (K) 
K11    : Propionyl (K) 
 
 
 
 
 
241 
 
Human H3K27me2K36me2 3+ m/z: 534.655 observed m/z: 534.6453 
R.prKme2SAPATGGVKme2KprPHR.Y 
Monoisotopic mass of neutral peptide Mr(calc): 1600.9413 
Variable modifications:  
N-term : Propionyl (N-term) 
K1     : Dimethyl (K) 
K10    : Dimethyl (K) 
K11    : Propionyl (K) 
 
  
  
  
242 
 
 
Human H3K27me3K36me2 2+ m/z: 808.486 observed m/z: 808.4900 
R.prKme3SAPATGGVKme2KprPHR.Y 
Monoisotopic mass of neutral peptide Mr(calc): 1614.9569 
Variable modifications:  
N-term : Propionyl (N-term) 
K1     : Trimethyl (K), with neutral losses 0.0000(shown in table), 59.0735 
K10    : Dimethyl (K) 
K11    : Propionyl (K) 
 
 
 
 
243 
 
Human H3K27me3K36me2 3+ m/z: 539.322 observed m/z: 539.3200  
R.prKme3SAPATGGVKme2KprPHR.Y 
Monoisotopic mass of neutral peptide Mr(calc): 1614.9569 
Variable modifications:  
N-term : Propionyl (N-term) 
K1     : Trimethyl (K), with neutral losses 0.0000(shown in table), 59.0735 
K10    : Dimethyl (K) 
K11    : Propionyl (K) 
 
 
 
 
 
244 
 
245 
 
Human H3K79un 2+ m/z: 724.376 observed m/z: 724.3800 
R.prEIAQDFKunTDLR.F 
Monoisotopic mass of neutral peptide Mr(calc): 1446.7354 
Variable modifications:  
N-term : Propionyl (N-term) 
K7     : Propionyl (K) 
 
 
 
  
246 
 
H3K79me1 2+ m/z: 731.383 observed m/z: 731.3800 
R.prEIAQDFKme1TDLR.F 
Monoisotopic mass of neutral peptide Mr(calc): 1460.7511 
Variable modifications:  
N-term : Propionyl (N-term) 
K7     : Methyl-Propionyl (K) 
 
 
 
 
  
247 
 
Human H3K79me2 2+ m/z: 710.378 observed m/z:  710.3599 
R.prEIAQDFKme2TDLR.F 
Monoisotopic mass of neutral peptide Mr(calc): 1418.7405 
Variable modifications:  
N-term : Propionyl (N-term) 
K7     : Dimethyl (K) 
 
 
 
 
 
  
248 
 
Yeast Specific Peptides 
Yeast H3K27acK36un / H3K27unK36ac 3+ m/z: 553.978 observed m/z: 553.9596 
R.prKacSAPATGGVKprKprPHR.Y / R.prKprSAPATGGVKacKprPHR.Y 
Monoisotopic mass of neutral peptide Mr(calc): 1658.9104 
Variable modifications:  
N-term : Propionyl (N-term) 
K1     : Propionyl (K) 
K10    : Propionyl (K) 
K11    : Acetyl (K) 
 
 
 
 
249 
 
Yeast H3K27acK36un / H3K27unK36ac 3+ m/z: 830.463 observed m/z:  
R.prKacSAPATGGVKprKprPHR.Y / R.prKprSAPATGGVKacKprPHR.Y 
Monoisotopic mass of neutral peptide Mr(calc): 1658.9104 
Variable modifications:  
N-term : Propionyl (N-term) 
K1     : Acetyl (K) 
K10    : Propionyl (K) 
K11    : Propionyl (K) 
 
 
 
 
 
250 
 
Yeast H3K27unK36un 3+ m/z: 558.65 observed m/z: 558.6357 
R.prKprSAPATGGVKprKprPHR.Y 
Monoisotopic mass of neutral peptide Mr(calc): 1672.9260 
Variable modifications:  
N-term : Propionyl (N-term) 
K1     : Propionyl (K) 
K10    : Propionyl (K) 
K11    : Propionyl (K) 
 
 
 
 
 
251 
 
Yeast H3K27unK36un 2+ m/z: 837.471 observed m/z: 837.4658 
R.prKprSAPATGGVKprKprPHR.Y 
Monoisotopic mass of neutral peptide Mr(calc): 1672.9260 
Variable modifications:  
N-term : Propionyl (N-term) 
K1     : Propionyl (K) 
K10    : Propionyl (K) 
K11    : Propionyl (K) 
 
 
 
 
 
252 
 
Yeast H3K27unK36me1 2+ m/z: 844.479 observed m/z: 844.4767  
R.prKprSAPATGGVKme1KprPHR.Y 
Monoisotopic mass of neutral peptide Mr(calc): 1686.9417 
Variable modifications:  
N-term : Propionyl (N-term) 
K1     : Propionyl (K) 
K10    : Methyl-Propionyl (K) 
K11    : Propionyl (K) 
 
 
 
 
  
253 
 
Yeast H3K27unK36me1 2+ m/z: 563.322 observed m/z: 563.2873  
R.prKprSAPATGGVKme1KprPHR.Y 
Monoisotopic mass of neutral peptide Mr(calc): 1686.9417 
Variable modifications:  
N-term : Propionyl (N-term) 
K1     : Propionyl (K) 
K10    : Methyl-Propionyl (K) 
K11    : Propionyl (K) 
 
 
 
 
 
254 
 
Yeast H3K18acK23un / H3K18unK23ac 2+ m/z: 563.833 observed m/z: 563.8300 
R.prKacQLASKprAAR.K / R.prKprQLASKacAAR.K 
Monoisotopic mass of neutral peptide Mr(calc): 1125.6506 
Variable modifications:  
N-term : Propionyl (N-term) 
K1     : Propionyl (K) 
K6     : Acetyl (K) 
 
 
 
 
  
255 
 
Yeast H3K18unK23un 2+ m/z: 570.841 observed m/z: 570.8042 
R.prKprQLASKprAAR.K 
Monoisotopic mass of neutral peptide Mr(calc): 1139.6662 
Variable modifications:  
N-term : Propionyl (N-term) 
K1     : Propionyl (K) 
K6     : Propionyl (K) 
 
 
 
 
 
 
256 
 
Yeast H3 K56ac 1+ m/z: 1332.75  observed m/z: 1332.7500 
R.prFQKacSTELLIR.K 
Monoisotopic mass of neutral peptide Mr(calc): 1331.7449 
Variable modifications:  
N-term : Propionyl (N-term) 
K3     : Acetyl (K) 
 
 
 
  
257 
 
Yeast H3 K56ac 2+ m/z: 666.88  observed m/z: 666.8800 
R.prFQKacSTELLIR.K 
Monoisotopic mass of neutral peptide Mr(calc): 1331.7449 
Variable modifications:  
N-term : Propionyl (N-term) 
K3     : Acetyl (K) 
 
 
 
 
  
258 
 
Yeast H3 K56un 2+ m/z: 673.888  observed m/z: 673.8550 
R.prFQKprSTELLIR.K 
Monoisotopic mass of neutral peptide Mr(calc): 1345.7605 
Variable modifications:  
N-term : Propionyl (N-term) 
K3     : Propionyl (K) 
 
 
 
 
  
259 
 
Yeast H3 K56un 1+ m/z: 1346.77  observed m/z: 1346.7596 
R.prFQKprSTELLIR.K 
Monoisotopic mass of neutral peptide Mr(calc): 1345.7605 
Variable modifications:  
N-term : Propionyl (N-term) 
K3     : Propionyl (K) 
 
 
 
